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ABSTRACT 
Sildenafil citrate (SC) is a phosphodiesterase-5 inhibitor that is used to treat pulmonary hypertension 
(PH) in paediatric patients. The purpose of these studies was to develop a formulation and 
manufacture an orodispersible tablet (ODT) that can be easily administered to neonates and children 
with PH. The advantages of ODT dosage forms include ease of administration, rapid dissolution of 
the API, SC. Furthermore the dosage form can be taken without water which is beneficial to patients 
without immediate access to potable fluids.  
A simple, rapid, accurate, precise and selective reversed-phase HPLC method was developed and 
validated in accordance with International Conference on Harmonization (ICH) guidelines and was  
successfully used for the analysis  of SC as raw material and in SC containing pharmaceutical dosage 
forms. 
Preformulation studies were performed on SC, alone and in combination with potential excipients that 
could be used to make tablets. Investigations into potential interactions between SC and the excipients 
were performed using Differential Scanning Calorimetry (DSC) and Infrared Spectroscopy (IR). DSC 
results revealed that SC was compatible with all potential excipients except mannitol and magnesium 
stearate. However these interactions were not observed with IR and therefore it was concluded that 
the interactions were induced by the high temperatures that DSC operates at. Particle size and shape 
was also established by use of Scanning Electron Microscopy (SEM) and flow properties were 
monitored by calculating Carr’s Index (CI) and the Hausner Ratio (HR). 
Direct compression was used as the method of manufacture for SC tablets as this approach is simple 
and the most economic production approach. The powder blends were assessed for bulk and tapped 
density and the CI and HR were used to determine the flowability of the blends. The quality attributes 
of the resultant tablets that were monitored included uniformity of weight, friability, crushing 
strength, tensile strength, disintegration, wetting and in vitro dispersion times. 
Design of Experiments is an efficient statistical approach that has become a popular tool used in the  
pharmaceutical industry to optimize formulation compositions, as it allows for the investigation of 
several input factors at the same time whilst not using the tedious and traditional “ modification of one 
variable at a time” approach. 
A Central composite experimental design was chosen as the most appropriate means to optimize the 
formulation as it produces more accurate results as opposed to other experimental designs approaches 
as input factors are investigated at five different levels. 
ii | P a g e  
 
Through the use of mathematical modelling, optimum concentrations of disintegrant(s) and an 
appropriate blending time were established. Analysis of the data from the experimental design and 
mathematical modelling studies reveal that no changes in disintegrant concentration or blending time 
altered the disintegration time of the formulation to any significant extent. This result is most likely 
due to the fact that the critical disintegrant concentration has been reached and increasing the 
disintegrant concentration further has no effect on disintegration time. It was also established that a 
change in the concentration of CMS and CRP altered the wetting time of the tablet significantly. 
Finally it was noted that there was a linear relationship between blending time and the uniformity of 
content of the tablets produced in these studies.   
 
The optimized product was a white tablet with a diameter of 7.31 mm with a thickness of 2.80mm. 
The dosage form had no visible cracks or evidence of picking or sticking. The tablet exhibits suitable 
friability and tensile strength while exhibiting a disintegration time of only 8s. Therefore an 
orodispersible tablet containing SC intended for paediatric use has been successfully developed, 
manufactured and optimized through the use of preformulation studies, appropriate quality control 
monitoring and mathematical modelling. These formulations require further optimization in respect of 
addition of flavours and or additional sweetening agents. 
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STUDY OBJECTIVES 
Sildenafil citrate (SC) is used as an alternative to other treatments such as inhaled nitrous oxide, 
which is not always effective in the treatment of Pulmonary Hypertension in paediatric patients. The 
prescribing of SC in paediatric patients is becoming common practice. However since the API is only 
available in tablet form the only option for the pharmacist is of preparation of extemporaneous 
preparations. Potential problems may arise with the use of extemporaneous formulations as the 
stability of SC in these formulations has not been monitored.  
Orodispersible tablets (ODT) is a drug delivery technology that has been identified as a potential 
dosage form for paediatric patients in addition to patients that have difficulty in swallowing. 
Therefore the development of an ODT of SC may ensure the successful administration of SC to 
patients for which an age appropriate dosage form is not available. 
The objectives of this study were: 
i. To develop and validate a high performance liquid chromatographic method for the analysis 
of SC as raw material and in pharmaceutical dosage forms. 
ii. To conduct preformulation studies to ensure the selection of appropriate excipients to produce 
a SC ODT and establish if any interactions may occur between SC and these  excipients. 
iii. To develop and optimize a suitable method of manufacture for an SC containing ODT. 
iv. To use Response Surface Methodology (RSM) and experimental design to establish  
relationships between identified independent variables and selected responses  
v. To use RSM and experimental design to optimize an ODT for SC.  
vi. To evaluate and ensure the quality of the SC ODT by evaluation of the in vitro release 
profiles, as well as friability, crushing and tensile strength, disintegration time, wetting time, 
in vitro dispersion time and  the water absorption ratio of the tablets.  
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The definition of insanity is doing the same thing over and over again and expecting different 
results 
        -Albert Einstein  
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CHAPTER ONE 
SILDENAFIL CITRATE 
 
1.1 INTRODUCTION 
Sildenafil citrate (SC), a selective phosphodiesterase 5(PDE5) inhibitor, is the drug of choice for  the 
treatment of erectile dysfunction (ED) (1; 2).  It has recently also been shown to be effective in the 
treatment of Pulmonary Hypertension (PH) in adult and paediatric patients (3-7). In the latter group, 
PH is regarded as a disease that is characterized by pulmonary vascular resistance (7) and has a 
mortality rate of approximately 10–20% (8).   
Medicines for use in neonates and children are not typically evaluated and doctors have to prescribe 
medication off-licence and/or off-label for paediatric patients (9-11). This is the case for SC, which is 
licensed for the treatment of PH in adult patients only.  
Because SC is not licensed for paediatric use, it is important to ensure that paediatric patients are not 
exposed to avoidable risk. Conducting controlled clinical trials (9) in this patient subgroup is therefore 
a matter of utmost importance. Published reports of SC use in adult patients and in animal models 
(12-14), prior to its use in newborns, have been documented. More recently, some limited randomized 
trials on the use of SC, as a treatment for paediatric patients suffering from PH have been undertaken.  
There is no cure for pulmonary hypertension of the neonate (PPHN) and treatment is therefore aimed 
at relieving the symptoms of the disease (5). In the past, the treatment for PPHN included inhalation 
of nitrous oxide, the use of calcium channel blockers,  and extracorporeal membrane oxygenation 
(ECMO) (5; 8). The disadvantage of this treatment is that it is expensive and, in the case of ECMO, is 
not readily available, particularly in developing countries (8). The advantage of treating PH with SC 
relates to the availability of the compound and the lower cost compared to other modes of PH 
treatment. An additional  benefit of SC is that its use in paediatric patients is safe, with only a few side 
effects having been reported (3).   
Although there are many published reports on  the benefits of using SC in paediatric patients, there 
have not been many clinical trials conducted  and the few that have been undertaken have used very 
small cohort sizes (3; 6). This clearly highlights the need for more research on the use of SC in 
paediatric patients. Available research is however promising and results so far suggest that SC is an 
acceptable alternative to ECMO for the treatment of PH in paediatric patients.  
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1.2. PHYSICOCHEMICAL PROPERTIES 
1.2.1. Description 
SC is an odourless white to off-white crystalline powder (15). The chemical name for SC is 1-[[3-
(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-
ethoxyphenyl]sulphonyl]-4-methylpiperazine citrate. The empirical formula for SC is 
C22H30N6O4S·C6H8O7 and the molecular weight of SC is 666.71. The chemical structure of SC is 
depicted in Figure 1.1. 
 
Figure 1.1 The chemical structure of sildenafil citrate (15) 
1.2.2. Dissociation Constant (pKa) 
Sildenafil has two pKa values, viz.  pKa1=6.78 and pKa2=9.12. This indicates that sildenafil is an 
ordinary ampholyte with mild basicity and weak acidity. The compound  is therefore typically neutral 
at physiological pH (16). A depiction of the different ionization states of SC is given in Figure 1.2. 
    
Figure 1.2 Ionization equilibria of sildenafil (16) 
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1.2.3. Solubility 
The solubility of SC, determined in different solvents, is summarized in Table 1.1 (15). 
Table 1.1 Solubility of SC in various solvents (15) 
Solvent Solubility (mM) 
Methanol 1.2  
Water 0.6 
Ethanol 0.17 
Dichloromethane 0.005 
Diethyl ether 0.005 
n-Hexane 0.0001 
 
1.2.4 Partition coefficient 
The partition coefficient is the equilibrium distribution of a molecule between a hydrophilic phase 
(aqueous) and a hydrophobic phase (oil).  The hydrophilic solvent used is usually water while the 
hydrophobic solvent in these experiments is usually octanol as this solvent has the ability to mimic the 
aqueous/membrane interface, due to its chemical characteristics (17).  
The partition coefficient is an important physicochemical property of a compound since it provides an 
indication of the hydrophobicity of a drug molecule and hence the ability of the molecule to cross 
membranes. Hydrophobic drugs are preferentially concentrated in the hyprophobic compartments of 
membranes, viz. the lipid bilayers, whereas  hydrophilic drugs favour hydrophilic compartments such 
as blood serum (18).  
 The value of the partition coefficient (log P ) of SC is 2.7–3.18 (16; 19) indicating  a relatively 
lipophilic molecule.   
1.2.5. Melting range 
SC melts within a range of 194-199°C (15) . Lower melting points within the range 182°C –186°C 
have however been reported with regard to SC however this is attributed to the incomplete extraction 
process of the API from the dosage form (20). 
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1.2.6 Ultraviolet absorption spectrum 
An ultraviolet scan, generated using a Lamba 25 UV/VIS Spectrometer (Perkin Elmer® Ltd, 
Beaconsfield, England) at a scan speed of 480 nm.min-1, is depicted in Figure 1.3 
 
 
Figure1.3 Ultraviolet absorption spectrum of SC 
1.2.7 Infra-red spectrum 
The Infrared (IR) absorption spectrum of SC powder was generated using a Spectrum 100 Fourier 
transform-infrared attenuated total reflectance spectrometer (Perkin Elmer® Ltd Beaconsfied, 
England). The spectrum, obtained at a wave-number range of 4000–650cm-1  and a resolution of            
4cm-1, is depicted in Figure 1.4.. Band assignments for the resultant spectrum are summarized in Table 
1.2.  
 
Figure 1.4 IR absorption spectrum of SC  
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Table 1.2 IR absorption spectrum band assignments 
Bands Assignment 
3617 OH (Stretching) 
3300 NH (Stretching) 
3028 CH (Stretching Aromatic) 
3000–2270 CH (Stretching aliphatic) 
1700 C=O (Stretching) 
1600-1500 C=C (Stretching) 
1358, 1170 SO2 (Stretching) 
                                 1240          C-N (Stretching) 
 
1.2.8 Synthesis 
SC is synthesized as follows: an initial reaction between a diketoester (Figure 1.5, 1) and hydralazine 
results in the formation of a pyrazole ring, which is then subjected to N-methylation and hydrolysis to 
produce a carboxylic acid (Figure 1.5, 3).  The compound is then nitrated, resulting in carboximide 
formation. Nitro group reduction is then performed to produce a pyrazole intermediate (Figure 1.5, 5). 
The amine group is then acylated with 2-substituted benzoyl chloride (Figure 1.2, 6), followed by 
cyclization under basic conditions to produce the pyrazolopyrimidinone (Figure 1.5, 7). 
Chlorosulfonylation at the 5’ position of the phenyl ring occurs (Figure 1.5, 8) allowing for ready 
coupling with piperazine to yield the product, sildenafil, which reacts with citric acid to produce 
sildenafil citrate. The synthesis of SC is depicted in Figure 1.5 
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Figure 1.5 The synthesis of SC (21) 
 
 
1.2.9 Structure Activity Relationships 
 SC is an inhibitor of the PDE type 5 enzyme. It has a similar structure to the enzyme, which 
facilitates its interaction with the enzyme substrate. A major problem relating to the use of this 
compound is that several different types of PDE enzymes are found in the human body (22; 23). 
When investigating PDE inhibitors it is therefore important to isolate a molecule that is not only 
potent, but also exhibits a high degree of selectivity for the PDE type 5 enzymes.  
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Initially investigations into the selectivity and potency for PDE type 5 enzymes involved exploring a 
range of 2-alkoxyphenyl-substituted heterocyclic systems. Results indicated that pyrazolo [4,3-
d]pyrimidin-7-one derivatives showed potent cGMP (cyclic guanosine monophosphate) PDE type 5 
enzyme inhibition. Modelling studies suggested that the nucleus of the pyrazolo [4,3-d] pyrimidin-7-
one molecule could mimic the guanosine base of cGMP, as these molecules have a similar shape, size 
and dipole moment (21). The similarity of cGMP and pyrazolo [4,3-d] pyrimidin-7-one is depicted in 
Figure 1.6. 
By changing the substitute at position 3 from a methyl to a propyl group, the potency of the 
compound was increased significantly. It is surmised that, by extending chain length of the substitute, 
the compound would be able to fill a space on the enzyme site that is normally occupied by ribose 
(21). Removing the methyl group at Position 1from the pyrazole decreased the selectivity of the 
compound for the PDE type 5 enzyme (21). 
The 5’-substituent on the 2-ethoxyphenyl ring has the potential to fill a space occupied by the 
phosphate of cGMP in the PDE active site. It was shown that the addition of sulphones or 
sulphonamides increased the affinity of the compound for this enzyme (21). These functional groups 
have the added benefit of being less lipophilic, which improves the low solubility of the compound 
(21).   
        
Figure 1.6 Relationship between pharmacophoric sub-structures of cyclic GMP and pyrazolo                         
[4,3-d]pyrimidin-7-one  (21) 
1.3. STABILITY 
The stability of pharmaceutical compounds depends on two factors viz., the chemical and physical 
properties of the molecule and the impact of environmental factors such as temperature and light on 
the active pharmaceutical ingredient (API) (24). 
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In a study conducted by Badwan  et al.,  SC showed  a high degree of  stability when stored under 
different  climatic conditions (15). Following storage for two months at 40°C, 75% relative humidity 
(RH) and later at 50°C and 75% RH, the compound remained stable with little degradation being 
observed. Similar results were noted when SC was exposed to ultraviolet (UV) light for a period of 
two months.  
 The pH stability profile of SC was characterised over a pH range of 1–13. The profile was studied 
under storage conditions of 65°C for two weeks. Results indicated that minimal degradation of SC 
occurred under these conditions (15) .    
SC has been shown to be stable after undergoing three freeze-thaw cycles involving storage at –20°C 
for one  month followed by thawing  at room temperature for 24 hours (25). 
1.4 CLINICAL PHARMACOLOGY 
1.4.1 PH and paediatric patients 
PH is diagnosed when patients have a mean arterial pressure of  > 25mm Hg at rest or > 30mm Hg 
following  exercise, irrespective of the age (26). Many paediatric cardiologists agree that a more 
appropriate definition of PH in paediatric patients would be a systolic pulmonary artery pressure that 
exceeds 50 % of the systolic systemic pressure at rest (27).    
There are conflicting records of the incidence of PH in newborns. Farrows et al.,  report that the 
incidence of  PPHN is  0.2% (28) whereas another study reports that PPHN occurs in 0.43– 6.8 
patients per 1000 live births (8; 29). The incidence is likely to be greater  in developing countries 
where reporting is poor and very little information is available (8). The mortality rate of PPHN has 
remained stationary at approximately 10–20 % over the last  decade (27).  
 
 
1.4.2 Persistent Pulmonary Hypertension of the Newborn (PPHN) 
Prior to  birth, the pulmonary circulation of the foetus is characterized by high pulmonary vascular 
resistance and low pulmonary blood flow, since the  lungs receive less than 8% of the ventricular 
output (30) as  they  are filled with fluid (31) and gaseous exchange occurs in the placenta. At birth 
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the  pulmonary circulation undergoes significant vasodilatation to facilitate rapid and increased flow 
of blood to the lungs of the neonate (32). This does not occur in all neonates, as some fail to achieve a  
decrease in pulmonary vascular resistance, which leads to respiratory distress and hypoxia, a 
condition known as PPHN (33).  
The mechanism by which  altered lung vascular structure and function arises is still poorly 
understood, but there is increasing evidence  suggesting  that oxidative stress plays  an important  role 
in the pathogenesis of PPHN (33). A ductal ligation model of PPHN has also confirmed that increased 
levels of reactive oxygen species promote vasoconstriction (34). 
There are a number of predisposing factors associated with the development of PPHN and, with an 
increasing knowledge of the condition, the list of such factors keeps increasing. Some of the common 
predisposing factors associated with PPHN are listed in Table 1.3.  
Table1.3 Predisposing factors for PPHN (31) 
Predisposing factors Remarks 
Birth asphyxia  Both intrauterine and perinatal hypoxia 
Early onset sepsis/pneumonia Active constriction of pulmonary vessels possibly 
due to increased thromboxane 
Pulmonary hypoplasia due to causes such as 
congenital diaphragmatic hernia, amniotic fluid 
leak, pleural effusion 
Reduction in the number of intralobar arteries; 
their increased muscularity 
Maternal drug intake of  non steroidal anti-
inflammatory drugs such as  ibuprofen, aspirin, 
indomethacin) and/or use of selective serotonin 
reuptake inhibitors such as  fluoxetine) 
Use of Non steroidal anti-inflammatories 
(NSAID) leads to in-utero constriction of the 
ductus arteriousus and pulmonary vasculature 
remodelling;  the use of selective serotonin 
reuptake inhibitors ( SSRI) in the late third 
trimester is associated with PPHN 
Familial occurrence Familial occurrence is uncommon 
Idiopathic Quite common however unrecognised hypoxia or 
ductal closure may account for a large proportion 
of idiopathic cases 
 
PPHN typically occurs in full-term neonates that are frequently born through meconium-stained 
amniotic fluids (31). 
Infants with PPHN that is related to asphyxia or idiopathic causes may exhibit  severe cyanosis and 
tachypnoea, although respiratory distress may not initially be noticeable (31). Infants with PPHN 
related to meconium aspiration, pneumonia, diaphragmatic hernia or pulmonary hypoplasia present 
with grunting, nasal flaring, chest retractions, tachycardia and shock (31).   
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1.4.3. Use of SC in PPHN 
SC is a selective inhibitor of the phosphodiesterase type 5 enzyme that is found in high concentrations 
in the pulmonary vascular smooth muscle (34).  PDE5 enzymes are responsible for the hydrolysis of 
(cGMP) to form guanosine 5’-cyclic phosphate (4). cGMP is a secondary messenger of nitric oxide 
(NO). NO is a vasodilator and hence an increase in cGMP will lead to an increase in NO, thereby 
promoting vascular smooth muscle relaxation, as represented in Figure 1.7.  
Neurones 
Endothelium
Nitric 
Oxide
Nitric Oxide 
Donors
Guanylate Cyclase
GMP
GTP
cGMP
Protein kinase activation 
lowers Ca++
Vascular smooth muscle 
relaxation
Phospodiesterase 5
Sildenafil 
 
Figure 1.7  A schematic representation of the mechanism of action of SC (35) 
Knowing when to administer SC to a paediatric patient can be a difficult decision for a prescriber as 
there is always the risk of an untoward response when administering medicines off-license. Sola et al.,  
have attempted to provide direction in this regard by stating that potential candidates would most 
likely be term or near-term infants with severe PPHN and refractory hypoxemia (36).  
SC administration is also an appropriate alternative when other treatments fail. Inhaled nitric oxide 
(iNO) is used frequently for  the treatment of PH,  but there are  reports that up to 30%  of infants fail 
to  improve after administration of iNO (8).  SC is also an alternate choice  in developing countries, 
where  iNO is not readily available for use (37).  
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SC is available in tablet form. This provides a challenge for the safe and efficacious administration of 
the compound to paediatric patients who are unable to ingest tablets. SC tablets are therefore crushed, 
dissolved in water and administered either orally or via a nasogastric tube (6).  
1.4.4. Indications 
SC is indicated primarily for the treatment of erectile dysfunction (ED) and is marketed by Pfizer 
under the trade name Viagra®. Recently SC has been approved by the Food and Drug Administration 
(FDA) for the treatment of PH in adults and is marketed as Revatio® (38).  
Besides the approved use of SC in ED and PH, research has shown that SC may be beneficial in a 
number of other conditions, including the treatment of pain in animals and humans. SC has been 
shown to produce an antinociceptive effect in animal models for pain following local, peripheral and 
systemic administration.  
Neurogenesis is the ‘birth’ of new neuronal cells and is essential for synaptic plasticity and formation 
of memory (2). Neuronal growth decreases with age, primarily due to decreased production of cGMP 
(39).  The use of SC, which increases cGMP levels, may therefore be valuable for the improvement of 
brain function.  
Multiple sclerosis is a potentially debilitating inflammatory disease of the central nervous system (2). 
SC has been shown to protect multiple sclerosis patients from neuro-degeneration through increased 
gray matter perfusion in the brain (2).  
1.4.5 Dose 
An appropriate dose of SC for paediatric patients has not yet been defined. A suitable paediatric dose 
for oral administration has however been determined by extrapolation from the adult dose range (3). 
A dose range of 0.5–2 mg/kg every 6 hours was initially considered appropriate but it was noted that, 
although there was an improvement in the clinical status of the patient, the effect was not found to be 
dose-dependent. The major limitation of this study was that only three patients were used and 
therefore a definitive conclusion for appropriate neonate dosing was not achieved.   
A slightly larger study, using a sample size of 14, investigated the effect of SC in children suffering 
from pulmonary arterial hypertension. In this case an initial oral SC dose of 0.25 mg/kg every six 
hours (6) was administered to all patients. The dose, which was increased to 0.5mg/kg every six 
hours, was well tolerated (6).  
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In an intravenous dose-response study, SC was administered to piglets in increasing doses of 0.4, 1 
and 3mg/kg. SC caused a decrease in the mean pulmonary artery pressure and a reduction in the 
pulmonary vasculature by 30%. This effect was achieved at the lowest dose level with no further 
change being noted following administration of higher doses (40). 
Based on case reports and studies conducted on paediatric patients, the optimal initial dose to 
administer  is 0.25–0.5mg/kg every 4–8 hours, together with a dose trituration of 1–2 mg/kg every six 
hours, if necessary (34).  
1.4.6 Overdose 
There is limited information concerning overdose of SC, particularly in paediatric patients.  
In one case report a 19-month male weighing 10.4 kilograms ingested six 50 mg SC tablets. The 
patient presented with facial flushing and priapism. The patient also experienced mild tachycardia for 
approximately 24 hours post-ingestion. No hypotension was observed and the patient was discharged 
the following day having been treated with maintenance IV fluids only (41). 
In another case report a two year old male paediatric patient ingested 75mg SC. The patient presented 
with facial flushing, priapism and diarrhoea. No cardiovascular effects were noted but the patient did 
complain of pain in the penile region, one day after treatment (42). 
1.4.7 Adverse drug reactions of SC in paediatric patients 
Typical adverse reactions of SC in adult patients include flushing, headache and dyspepsia (38). 
Studies conducted in neonates and children with pulmonary hypertension suggest however that there 
is a low incidence of adverse effects and that those that have been reported are considered to be of 
minor importance (7). 
In a limited study, designed to evaluate the safety of oral SC in children, results showed that no 
adverse reactions were observed following administration of the compound (3).    
Despite reports suggesting  a low incidence of adverse reactions following administration of SC to 
paediatric patients, there are special precautions that  need to taken into account before administering 
SC. Intravenous SC has been shown to significantly reduce the systemic blood pressure (43; 44). This  
can be minimised with the concomitant administration of  plasma volume expanders (45). This 
decrease in blood pressure was not  however significant in all paediatric patients and no further 
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treatment was required (6). Another important consideration is that SC can cause deterioration in 
arterial oxygenation and an increase in the alveolar arterial gradient. This is most likely due to the 
increase in intrapulmonary shunting (13; 43).  In premature babies, retinopathy of prematurity (ROP) 
may be of concern; however, only one case of SC-induced ROP has been reported (46). 
1.4.8. Contraindications 
SC is well tolerated and does not alter the biochemical and physiological effects of most other drugs 
(47). The use of organic nitrates is however contraindicated with SC use, as sildenafil enhances the 
vasodilatory effects of the nitrates, which can lead to excessive vasodilation followed by a significant 
decrease of blood pressure  (34; 47). 
1.4.9. Drug Interactions 
SC metabolism is primarily via the CYP 3A4 system and, to a slightly lesser extent, via the CYP 2C9 
system. Consequently, any inhibitor or inducer of these enzyme systems may alter the clearance of SC 
(5). Protease inhibitors such as indinavir, saquinavir and ritonavir are CYP3A4 inhibitors. When co-
administered with SC, the plasma levels of these drugs were not affected, yet the level of SC was 
significantly increased (48; 49). Similar results were observed when erythromycin was co-
administered with SC but the same response was not observed when azithromycin was used 
concomitantly (50).  
Any drug that acts as an inducer of CYP 3A4 and CYP 2C9 is also likely to have an effect on the 
disposition of SC. Bosentan, an endothelin receptor antagonist used for the treatment of pulmonary 
arterial hypertension, induces the activity of CYP 3A4; co-administration of bosentan with SC  
resulted in an increase in bosentan levels, while SC levels decreased (51).  
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1.5 PHARMACOKINETICS 
1.5.1. Absorption 
SC is rapidly absorbed from the gastrointestinal tract (GIT) (3). Despite rapid absorption, SC exhibits 
a low bioavailability of approximately 40%, with maximum observed plasma concentrations being 
reached within one hour of administration (3). Absorption studies using 14C labelled SC revealed that 
approximately 92% of orally administered SC is absorbed, suggesting that the relatively low oral 
bioavailability of SC is not due to incomplete absorption, but rather extensive hepatic first-pass 
metabolism (52). 
A study investigating the pharmacokinetics of SC in hemodynamically challenged neonate patients 
showed that levels of SC 30 minutes after administration via a naso-gastric tube were unpredictable. 
Results showed that SC levels were undetectable in half of the children (53). Possible explanations for 
these finding included general anaesthesia, opiate analgesia and transient neuromuscular blockade, all 
of which have the ability to modify gastric emptying and therefore the absorption from the GIT (53). 
1.5.2. Distribution 
 SC and its major active metabolite, N-desmethyl sildenafil, are approximately 96% protein bound. 
Such binding is independent of the concentration of the drug in the plasma. The volume of 
distribution of  SC at steady state is 105 L (54),  which is far greater than the total volume of body 
water (approximately 42L), indicating that SC is distributed into different tissues (52).  A population 
pharmacokinetic analysis, conducted following oral administration of SC to patients with ED, 
revealed  a volume of distribution of approximately 310L for SC (55). 
1.5.3. Metabolism 
SC is predominantly metabolized by the cytochrome P-450 isozyme CYP3A4 and to a lesser degree 
by CYP2C9 (56). At least 16 different metabolites of SC have been identified, with the primary routes 
of metabolism being N-desmethylation, oxidation, and aliphatic hydroxylation (57). The major 
metabolite is N-desmethyl sildenafil (UK-103, 320), which has been shown to have 50% of the 
activity of SC (3; 57). N-desmethyl sildenafil makes up 40% of the serum concentration and is 
therefore responsible for 20% of the pharmacological activity of SC (5). 
The second most important metabolite is UK-150 564, which is the product of a 2-carbon fragment 
loss from the piperazine ring of SC (52). This metabolite constitutes 25% of the serum concentration 
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and has 10% of the pharmacological activity of SC (52). Therefore, UK-150 564 does not contribute 
significantly to the inhibition of PDE type 5 enzymes. 
1.5.4. Elimination 
Approximately 80% of an oral dose of SC is excreted as metabolites, in the faeces and 13% in the 
urine (57).  The systemic clearance of SC was 41L/hr, following intravenous administration to healthy 
volunteers (58). SC can therefore be regarded as having an intermediary hepatic extraction ratio of 
approximately 50% (52).  Plasma concentrations of SC and N-desmethyl sildenafil are reported to 
decline bi-exponentially with a mean terminal half-life of 3–5 hours (58). Sildenafil is primarily 
eliminated via the hepatic route. Neonates with hepatic dysfunction may therefore exhibit reduced SC 
clearance and the administered dose should be adjusted accordingly (36). 
 
1.6 CONCLUSION 
SC is a versatile molecule that has been approved for the treatment of ED and PH, with current  
research evaluating its use for the treatment of pain, neurogenesis and multiple sclerosis (2). Although 
SC has not yet been approved for the treatment of PH in paediatric patients, it is fast becoming the 
treatment of choice for neonates and infants that exhibit the condition. 
SC  is readily available and well tolerated in paediatric patients and is cheaper than other treatment 
options, making it a favourable choice in developing countries (37). The use of SC is only 
contraindicated when administered together with organic nitrates, due to potential synergistic 
hypotensive effects that the combination could produce.  
SC has an excellent side-effect profile and the drug is generally well tolerated in patients. These data 
have however been generated from small studies or single reports and larger clinical trials are 
therefore required to confirm the safety and efficacy of SC in paediatric patients. The challenge of 
administering SC to paediatric patients is a result of no appropriate dosage form having been 
registered for use in this population group. Thus, SC tablets are typically crushed, dissolved in water, 
and administered either orally or via a nasogastric tube. It is therefore vital that further development 
on the formulation of SC be carried out, to develop an age-appropriate dosage form, which will ensure 
that the patient receives the correct dose of SC in a safe and efficacious manner. The objective of this 
project, therefore, is to formulate SC as an orodispersible tablet, which allows for easy administration 
to paediatric patients. 
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CHAPTER TWO 
DEVELOPMENT AND VALIDATION OF AN HPLC METHOD FOR THE 
DETERMINATION OF SILDENAFIL CITRATE 
 
2.1 INTRODUCTION 
 
Chromatography is  defined as the separation of mixtures by distribution between two or more 
immiscible phases (59). The term “chromatography”, which was first described  in 1901 by the 
Russian botanist Mikhail Tsweet, is translated from Greek  to “colour writing”(60).   
Chromatography involves the use of an adsorbent or stationary phase e.g. silica packed into a column 
and eluted with a suitable liquid or mobile phase. The sample mixture, from which the components 
are intended to be separated, is then introduced onto the top of the column. 
A component of the mixture (solute) that is adsorbed weakly by the stationary phase will move 
through the column faster than other solutes that are more strongly adsorbed.  
Liquid chromatography therefore allows for solutes to be separated based on differences in their 
polarities.  
High Performance Liquid Chromatography (HPLC) is an analytical technique that was developed in 
the 1960’s. As with all chromatographic techniques, its function is the separation of different 
chemical species from each other. The primary advantage of HPLC is  its ability to fulfil this function 
with speed, sensitivity and precision (61). 
2.1.1 Overview of HPLC 
 
The main advantage of selecting liquid chromatography as a preferred analytical method is the fact 
that a number of different mechanisms to achieve a chromatographic separation, exist.  
These separations can be classified into separate categories viz., normal phase (NP), reversed-phase 
(RP), ion-exchange (IE) and size exclusion chromatography (EC).  
2.1.1.1 Normal-Phase (NP) Chromatography 
In NP chromatography , which is used to separate polar compounds (62), the stationary phase is more 
polar than the mobile phase (63), with the mobile phase being typically comprised of a mixture of 
organic solvents, with the exclusion of water. The organic solvents in the mobile phase are non-polar 
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and include solvents such as hexane or benzene.  The column packing in NP chromatography is 
usually an inorganic adsorbent for example silica.  
Alternatively NP chromatography can also be used for the separation  of  polar solutes that are 
generally poorly retained in Reversed-Phase chromatography (64). 
2.1.1.2 Reversed-Phase (RP) Chromatography 
 RP chromatography is a popular choice for HPLC analysis for the following reasons: 
i. it allows for the separation of samples in which components have a wide range of 
polarities. 
ii. bonded non-polar stationary phases are relatively stable and tend to be more robust 
and reproducible than for other HPLC modes. 
iii. many biochemical samples are aqueous solutions that can be injected directly onto 
the column without the need for sample preparation by  extraction  (65). 
In RP chromatography the stationary phase  is non-polar in nature and in most cases silica base is 
covered with chemically-bonded n-alkane chains or other groups such as C18H37 (octadecyl) , C8H17 
(octyl)  or C6H5 (phenyl) phases (66). 
The mobile phases used in RP chromatography are usually extremely polar and normally comprised 
of HPLC grade water in combination with methanol (MeOH), acetonitrile (ACN) or isopropanol; this 
facilitates elution of polar rather than non-polar analytes.  
2.1.1.3 Ion-Exchange HPLC 
Ion-exchange chromatography involves the substitution of one ionic species located on  the stationary 
phase for another ion in the sample (62). The stationary phase is either acidic, often containing 
carbonic or sulphonic acid groups that act as cation exchangers, or alternatively, it  may be comprised 
of a basic stationary phase composed of amine groups that facilitate anion exchange. In the case of 
anionic exchange, the surface carries a net positive charge, designated as R+. If a mobile phase  
(in which anions are present) is used the exchange site will attract and hold a negative counter-ion or 
Y-. Anions in the sample to be analyzed, X-, can then be exchanged with the counter-ion, Y- as the 
mobile phase and sample to be analyzed flows through the column (62).  
In contrast  the exchange of cations can occur where the surface of the matrix carries a net negative 
charge, R- and the counter-ions are cations, Y+ that  will be exchanged for  cations, X+, in the sample 
matrix (67). 
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 Anion and cation exchanges are represented by Equation 2.1 and Equation 2.2 respectively. 
R+Y- + X-  R+X- +Y-   Equation 2.1 
R-Y+ +X+  R-X+ +Y+    Equation 2.2 
2.1.1.4 Size Exclusion Chromatography 
Exclusion chromatography is a chromatographic technique  in which the  separations that  occur are 
due to differences in the molecular weights of the solutes that are to be separated (68).  Solutes with 
larger molecular weights normally elute at an early stage, as the stationary phase is usually a material 
with small pore widths. Analytes of  smaller dimension  will  have a larger space  available for 
transport through the column than the larger molecules that are first eluted (66; 69). 
Exclusion chromatography was initially used to fractionate naturally occurring polymers in aqueous 
solution but has more recently been applied to  the analysis of synthetic polymers (70). 
2.2 REVIEW OF HPLC METHODS USED FOR THE ANALYSIS OF SC 
Prior to the development of an HPLC method for the analysis of SC, a review of the literature was 
undertaken. The relevant aspects of the HPLC methods published for the analysis of SC is 
summarized in Table 2.1. 
The analysis of SC in human plasma,  pharmaceutical dosage forms and  raw material has been 
typically achieved by the use of octadecyl or C18 reversed-phase columns and UV detection has been  
the preferred choice for analysis (25; 71-76).  
The organic modifier of choice is ACN. This is due the fact that ACN exhibits favourable UV 
transmittance at low wavelengths, is polar, and is less viscous than methanol (67).  The organic 
modifier content is generally high, with the %ACN v/v ranging from 45-70% v/v. 
All methods described in the literature review have run times of less than 10 minutes as well as many 
of the methods reporting the successful use of an internal standard (25; 71; 72; 77). 
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Table 2.1 Summary of analytical methods developed for the analysis of SC in different matrices 
Stationary Phase Sample Matrix Mobile Phase 
Flow Rate  
(ml/min) 
Detection 
Retention Time 
(min) 
Internal  
Standard 
Reference 
RP-C18 (Waters) 5µm, 3.9 
i.d. x300mm 
Raw Material and 
Dosage Forms 
MeOH:water:ACN (60:20:20, 
v/v/v) adjusted with 
0.1% glacial acetic acid 
0.5 UV, 290nm 4.2 Cinnarizine (71) 
Phenomenex® Luna C18 
5µm, 150x4.6mm i.d. 
Human Plasma ACN: water (45:55, v/v) 1 UV, 220nm 7.2 
Phenobarbital 
Sodium 
(72) 
Nucleosil® C18® 5µm, 
50x4.6mm i.d. 
Human Plasma 
MeOH:10mM ammonium 
acetate pH7.0 (85:15, 
v/v) 
0.7 -- 1.63 Diazepam (25) 
ChromLith® C18 (Merk) 
5µm, 100x4.6mm i.d. 
Dosage Forms ACN: water (60:40, v/v) 2 UV, 292nm 0.69 -- (73) 
Inertsil® C18, 5µm, 
150x4.6mm i.d. 
Dosage Forms 
ACN: Phosphate Buffer 
(70:30, v/v, pH 7.0) 
0.8 UV, 228nm 4.087 -- (74) 
RP-C18, 5µm, 250x4.6mm 
i.d. 
Dosage Forms 
ACN: Phosphate Buffer 
(60:40, v/v) 
1 UV, 225nm 6.083 -- (75) 
RP-C18, 5µm, 250x4.6mm 
i.d. 
Raw Material 
ACN:0.05M Phosphate Buffer 
(70:30, v/v) 
1 UV, 230nm 5.29 -- (76) 
LiChrospher® C18, 5µm, 
250x4.6mm i.d. 
Raw Material and 
Dosage Forms 
ACN: water (52:48, v/v) 1 UV, 245nm 7.17 Piroxicam (77) 
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2.3 EXPERIMENTAL 
2.3.1 Materials and reagents 
SC was purchased from MTT Pharma & Bio-technology Co., Ltd (Shanghai, China) and diazepam 
was purchased from Sigma Aldrich (Missouri, United States of America).  
ACN (UV cutoff 200nm) and MeOH (UV cutoff 215nm) were purchased from Romnil Ltd 
(Waterbeach, United Kingdom). Sodium hydroxide pellets and potassium dihydrogen orthophosphate 
were purchased from Merck Chemicals Ltd (Gauteng, South Africa). Hydrogen peroxide 30% v/v was 
purchased from a local pharmacy.  
HPLC grade water for mobile phase and sample preparation was purified using a Milli-RO®15 water 
purification system (Millipore Co., Massachusetts, United States of America) that consisted of a 
Super C® carbon cartridge, two ion-X® exchange cartridges and an Organex-Q® cartridge. Prior to 
use, the water was filtered through a 0.22µm Millipak® filter (Millipore Co., Milford, Massachusetts, 
United States of America). 
2.3.2 HPLC system 
The modular HPLC system consisted of a Model P100 dual piston solvent delivery module (Thermo 
Separation Products, San Jose, California, USA), a Model AS100 autosampler (Thermo Separation 
Products, San Jose, California, USA) equipped with a Rheodyne® Model 7010 injector (Rheodyne, 
Reno, Nevada, USA) with a fixed volume 20 μl loop and a Gastight® 250 μl Model 1725 syringe 
(Hamilton Co., Reno, Nevada, United States of America).  
 
A Linear Model 6200-9060 UV/VIS-500 detectors (Linear Instrument Co., Irvine, California, USA) 
was used for detection and data collection was achieved using a Spectra Physics SP 4600 integrator 
(Thermo Separation Products, San Jose, California, USA). Separation was achieved on a 
Phenomenex® Luna C18 (2) 5µm, 150 x 4.6mm i.d. maintained at 22 ± 0.5 °C 
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2.3.2.1 Column Selection 
The stationary phase or column can be described as the “heart” of an HPLC separation as the column 
is the location  where the separation occurs .It is essential that, for  the development of a reproducible 
and robust analytical method, an appropriate stationary phase is selected for use (67).  
The selection of a suitable column for RP-HPLC analysis is dependent on the physico-chemical 
properties of the analyte of interest as these determine the magnitude of the interactive forces between 
the  analyte and the stationary phase during the separation process (67; 70).  
It is clear that all stationary phases reported for HPLC analysis of SC are most likely to be C18 based, 
as they are stable and due to the fact that they are hydrophobic. Consequently they are versatile and 
can be applied to the analysis of  a broad range of molecules (65; 78). 
2.3.2.2 Internal Standard  
The precision of an HPLC method is dependent on a number of factors, including the accuracy with 
which samples are prepared, instrumental precision and method robustness (79). A common approach 
used to ensure the accuracy of a method is the inclusion and use of an  internal standard (IS) (59).  
An IS must be: 
i. well resolved from the compound of interest and any other peaks that may appear on the        
chromatogram. 
ii. of similar retention to that of the compound of interest. 
iii. not be present in the original sample. 
iv. similar and mimic the analyte in sample preparation steps. 
v. stable and unreactive with the compound of interest as well as with  the mobile phase (67). 
The peak heights or areas are responses that are measured in quantitative chromatography.  Equation 
2.3 depicts by way of example a proportional relationship between peak height and a factor such as 
injection volume. By use of an IS, errors due to column changes can be negated (79). 
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       Equation 2.3 
Where, 
   H = peak height 
 to = the dead column time 
 τ = the injection time determined by the ratio of the volume of injection (Vinj)  
 F = flow rate 
 C° = the solute concentration 
 N = column efficiency  
k’ = the retention factor. 
 
If an IS is used, one can calculate a ratio of  the height of the peak of interest and that of the IS peak 
(79) using Equation 2.4. 
     
  
  
 
   
   
 
     
     
    Equation 2.4 
Where, 
Hj = peak height of solute of interest 
Hi = peak height of internal standard 
C°j = concentration of solute of interest 
C°i = concentration of internal standard 
k’j = retention factor of solute of interest 
k’i = retention factor of internal standard 
 
As defined in Equation 2.4, the PHR is the quotient of concentration of solute and the IS corrected by 
the retention factor. The use of the IS technique for the calculation of PHR eliminates the possibility 
of a change in flow rate or injection volume affecting the separation, and therefore produces more 
accurate and reproducible data.  
Diazepam (DZ) was selected  as the internal standard as it does not elute at a retention time similar to 
that of  SC, is readily available and has been successfully applied to  methods for the quantitation of  
SC (25).  
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2.3.2.3 Preparation of Stock Solutions 
Stock solutions of SC (100µg/ml) and IS (100µg/ml) were prepared by accurately weighing 
approximately 10 mg of each compound using a Model AG135 Mettler Toledo (Mettler Instruments, 
Zurich, Switzerland) top-loading analytical balance and quantitatively transferred into separate 100ml 
A-grade volumetric flasks. The compounds were dissolved in an ACN: water mixture in a ratio of 
55:45 and sonicated for two minutes using a Model B-12 Ultrasonic bath (Branson Cleaning 
Equipment Co., Shelton, Connecticut, United States of America). Aliquots of 20, 30, 70, 120, 150, 
170 and 200µl of SC stock solution were transferred to separate 10 ml A-grade volumetric flasks in 
which 25µl of the IS solution had been added. The resultant solutions were diluted serially, using a 
55:45 ACN: water mixture to produce solutions that had concentrations of SC of 0.2, 0.3, 0.7, 1.2, 1.5, 
1.7 and 2μg/ml and that for the IS of 0.25μg/ml.  
 
2.3.2.4 Selection of mobile phase 
The mobile phase was selected by varying the concentration of ACN used in the method and 
determining the time that was taken for the peak to appear on the chromatogram. A suitable time 
required was a time that did not exceed 10 minutes but a time after three minutes after injection of the 
sample so as not to interfere with the solvent front. 
 
2.3.2.5 Preparation of mobile phase 
The mobile phase was comprised of ACN: water in a ratio of 55:45 % v/v. Prior to use the mobile 
phase was degassed under a vacuum using a Model A-25 Eyela Aspirator (Tokyo Rikakikai Co., 
Tokyo, Japan) and filtered through a 0.45µm Durapore ® HVLP membrane filter (Millipore Co., 
Milford, Massachusetts, United States of America).  
2.4 RESULTS AND DISCUSSION 
2.4.1 Effect of Organic Solvent Composition 
The initial mobile phase composition,  selected for evaluation was ACN: water in a ratio of 45:55 v/v, 
which was based on literature data (72). As the content of the organic solvent is increased there was a 
decrease in the retention times of both SC and the IS (Figure 2.1). At lower concentrations of ACN 
there was need for a longer analytical run time; this problem was resolved by increasing the amount of 
ACN in the mobile phase. Shortening the analytical run time means that more samples can be 
analysed in a specified time period, thus increasing the efficiency of the method.  
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The shorter retention time (Rt)  for both analytes is due to the fact that an increase  in the % v/v of 
ACN in the mobile phase decreases the polarity of the mobile phase, therefore leading to preferential  
partitioning of the compound into this phase as opposed to interacting with the stationary phase. The 
organic solvent competes with the bonded phase molecules to attract the analyte and in general the 
higher the proportion of organic modifier in a mobile phase, the shorter the Rt of the analyte(s) of 
interest (67).  
A mobile phase composition of 45 % v/v ACN produced a separation for which the retention times for 
SC and the IS were 6 and 12.8 minutes, respectively. This was not deemed suitable as methods with 
run times of < 10 minutes are considered appropriate for use in our laboratory. When the % v/v ACN 
was > 60% the retention time for SC was short and the peak was not clearly resolved from the solvent 
front. Following a series of experiments, a mobile phase of ACN: water in a ratio of 55:45% v/v was 
selected for use; the Rt of SC and the IS were 3.6 and 6 min, respectively.  
 
Figure 2.1 The effect of organic solvent content on the Rt time of SC and the IS 
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2.4.2 Effect of Flow Rate 
As expected, an increase in flow rate resulted in a shorter Rt for SC (Figure 2.2). Obviously as the rate 
of movement of sample increases, it’s retention time in the column decreases. 
The primary disadvantage of using an elevated flow rate is that the back pressure of the pump is 
increased which in turn may result in a shorter column life and increased wear and tear on the HPLC 
system. Furthermore the use of increased flow rates result in increased mobile phase consumption 
which is, in itself, not cost effective.  
A flow rate of 1ml/min was selected for use as this provides sufficient operating pressure as well as 
suitable Rt with both peaks of interest eluting in less than 10 minutes. Increasing the flow rates above 
1 ml/min did not appear to further reduce the Rt to any significant extent. 
 
Figure 2.2 The effect of flow rate on the Rt of SC and the IS 
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2.4.3 Chromatographic Conditions 
The final chromatographic conditions selected for use for the analysis of SC are summarised in Table 
2.2.  
As can be seen from Figure 2.3, the resulting chromatogram shows a clear separation of SC from the 
IS as well as the solvent front. The SC peak also showed minimal tailing thus ensuring accurate 
results for measurement of peak height or area were obtained.  
Table 2.2 Chromatographic conditions for the analysis of SC.  
Column Phenomenex ®Luna C18 (2) 5µm, 150 x4.6mm 
Flow rate 1ml/min 
Injection volume 20µL 
Detection 245nm 
Temperature 22°C 
Mobile phase ACN: Water (55:45) %v/v 
Operating back pressure 925 psi 
Detector sensitivity 0.005 AUFS 
Chart speed 2.5mm/min 
 
 
Figure 2.3 Typical chromatogram showing the separation of SC (2 µg/ml) and IS (0.25 µg/ml) 
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2.5 METHOD VALIDATION 
2.5.1 Introduction 
The validation on an HPLC method incorporates the following requirements: confirmation of the 
process by means of experimental studies, and ensuring that the performance of the analytical method 
meets the accuracy and precision standards required to achieve an acceptable uncertainty limit (80). 
The importance of validating the proposed HPLC method is to ensure the reliability and 
reproducibility of results generated when using that method, even when carried out by different 
operators using the same analytical equipment.  
Although an important aspect of the validation process is to ensure the acceptability of the method 
that has been developed, it is also to investigate the method thoroughly to determine the limits of 
allowed variability for the conditions to achieve a desired outcome during analysis (59; 67).  
2.5.2 Linearity and Range 
The linearity of an analytical method describes the ability of that method to produce results that are 
directly proportional to the concentration of an API in a series of calibration samples (81). Linearity 
experiments are typically performed over a wide concentration range, as this approach instils 
confidence in the accuracy of results (82). The range that is selected should however  not be 
unrealistically broad, as this may result in the rejection of a method that only exhibits linearity over a 
narrow range of concentrations (81).   
The acceptability of linearity data is usually based on an investigation of the correlation coefficient 
(R2) for a calibration curve with an R2 value of > 0.99 generally considered as evidence of an 
acceptable fit of the regression line to experimental derived data (64).  
The linearity of the method was established by plotting the average peak height ratios (PHR) of SC 
and the IS versus the known concentration of calibration samples. These data are summarized in 
Table 2.3. 
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Table 2.3 Linearity and precision data for the analysis of SC 
Concentration 
µg/ml 
(n=5) 
Average Peak Height Ratio % RSD 
0.2 0.22 ± 0.003 1.33 
0.3 0.33 ± 0.005 1.54 
0.7 0.73 ± 0.018 2.42 
1.2 1.20 ± 0.007 0.57 
1.5 1.49 ± 0.015 1.01 
1.7 1.69 ± 0.018 1.07 
2 2.04 ± 0.013 0.63 
 
The resultant calibration curve is depicted in Figure 2.4 and the equation for the line was                      
y = 1.0161x+0.0298 with an R2 value of 0.9992 indicating that the method was linear over the 
concentration range 0.2 – 2 µg/ml.  
 
Figure 2.4 Calibration Curve for SC 
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The International Conference on Harmonization  (ICH) (84) defines three (3) different classes of 
precision viz., intra-assay precision or repeatability, intermediate precision and reproducibility or 
robustness (84).  
Precision is expressed by the relative standard deviation (RSD) of a set of data.  Therefore if a set of n 
measurements is performed on a sample, the average value obtained is defined using Equation 2.5.   
     
 
   
                                          
Where, 
xi  =  individual measurements, 
n = number of measurements. 
 
The standard deviation can then be calculated using Equation 2.6. 
                   
             
   
                                                                                
The  %RSD can then be calculated using Equation 2.7. 
     
        
    
                   Equation 2.7 
In these studies the limit for %RSD was set at 5%. 
2.5.3.1 Intra-Day Precision or Repeatability  
Repeatability is an indication of the precision of a method used under the same operating conditions 
over a short period of time (85). A minimum of nine determinations covering the specified 
concentration  range are required for repeatability studies (67; 85). 
Repeatability was measured by injecting samples (n=5) to obtain an average peak height ratio and 
calculating the %RSD for each concentration. Samples were selected so as to cover low, medium and 
high concentrations of the calibration range. The results are summarized in Table 2.4. 
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Table 2.4 Intra-Day precision data for SC 
Concentration (µg/ml) Peak Height Ratio  
(n=5) 
Standard Deviation %RSD 
0.25 0.270 0.001 0.476 
1 1.100 0.007 0.652 
1.9 1.933 0.030 1.569 
 
As can be seen the results summarized in Table 2.4, all tests had RSD values of less than 2% 
indicating that the proposed HPLC method can be accurately repeated.  
2.5.3.2 Inter-Day Precision or Intermediate Precision 
The intermediate precision of a method expresses its precision under different laboratory conditions. 
These conditions may include analysis on different days, use of the method by different analysts, or 
use of different instruments. The intermediate precision of this method was assessed by injecting 
samples (n=5) to determine the average PHR and %RSD on three consecutive days.  
Table 2.5 Inter-day precision data for SC 
Day Concentration (µg/ml) Mean concentration 
determined (µg/ml) 
%RSD 
1 0.25 0.252±0.017 1.569 
 1.00 1.08±0.012 0.652 
 1.90 1.91±0.010 0.476 
2 0.25 0.238±0.031 3.533 
 1.00 1.033±0.016 1.556 
 1.90 1.93±0.037 0.235 
3 0.25 0.241±0.017 3.825 
 1.00 1.022±0.023 0.439 
 1.90 1.969±0.016 2.154 
 
Table 2.5 summarizes the inter-day precision results generated using the proposed HPLC method. As 
can be seen from the results, the calculated %RSD never exceeds the set laboratory limit of 5% 
indicating that the method is able to produce precise results over a long period of time.  
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2.5.3.3. Reproducibility 
The reproducibility of a method relates to the precision of the proposed method when used in different 
laboratories. This is necessary when standardization of the method is required for collaborative 
research studies. For the purposes of this research, reproducibility studies were not performed as the 
proposed method was only intended for use in the same laboratory, performed by the same analyst 
using the same analytical system.  
2.5.4 Accuracy 
The ICH guidelines define the accuracy of an analytical method as the closeness between the values 
accepted as ‘true values’ and experimentally-derived values for that sample (86). Accuracy may be 
reported as the percentage recovery from samples analyzed using the proposed analytical method. 
Percentage Bias can also be used to determine the extent of deviation of a result for a sample from the 
true value for that particular sample. The closer the percentage recovery from analyzed samples is to 
100%, and the lower the value for % Bias, the more accurate the analytical method is considered. 
Accuracy was assessed at three levels, viz. high, medium and low sample concentrations to ensure 
accuracy over the range of concentrations under investigation. A tolerance of 5 % was set for the % 
RSD for accuracy and the limit for % Bias was set at < 5%. 
 All % RSD values were <  2% which complies with the limits set in many pharmaceutical industries, 
indicating that the method was accurate (87). Results for accuracy studies are summarized in Table 
2.6. 
Table 2.6 Accuracy data for SC 
Theoretical 
Concentration  
µg/ml 
Actual 
 Concentration  
µg/ml 
%RSD %Bias 
0.25 0.24 0.48 -4.53 
1.0 1.02 0.65 2.43 
1.9 1.81 1.57 -4.91 
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2.5.5 Specificity 
The specificity of an analytical method is defined as its capacity to accurately measure the 
concentration of an analyte in a sample, in the presence of impurities or pharmaceutical excipients 
(88).   
Specificity studies are a crucial aspect of an HPLC method: if a method lacks the capacity to produce 
sample peaks that are clearly resolved from interference(s) from other materials, the accuracy of the 
method is likely to compromise the accuracy of the overall results. 
Specificity tests were performed by comparison of chromatograms developed from the analysis of a 
standard solution of SC and the IS and results based on the analysis of commercially available SC 
tablets.  
The peaks of interest were adequately resolved, as shown in Figure 2.5, and it was noted that there 
were no other peaks present in the chromatogram suggesting that the proposed method can be 
considered specific for the analysis of SC. 
 
Figure 2.5 Selectivity of the chromatogram peaks 
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2.5.6 Limits of Quantitation (LOQ) and Detection (LOD) 
The LOQ of an analytical method is the lowest concentration of an analyte that can be measured with 
acceptable accuracy and precision (64). LOD is defined by the ICH guidelines as the lowest amount 
of analyte that can be detected, which cannot however be quantified to an exact value (89).  
Paino and Moore (90) described four approaches for establishing the LOQ and LOD of an analytical 
method. These include: 
i. determining the lowest concentration for which the % RSD ≤ 5%, 
ii. plotting the standard deviation versus concentration, 
iii. establishing a confidence interval for the best-fit line, or 
iv. use of signal to noise ratio approaches. 
 
The United States Pharmacopoeia (USP) recommends the use of signal to noise ratio assessments to 
establish the LOQ and LOD associated with a particular method. Signal to noise ratio methods 
compare the signals obtained from samples of low and known concentration to those of blank 
solutions (80). Signal to noise ratios of 10:1 and 3:1 are considered appropriate for establishing the 
LOQ and LOD of a method, respectively (80; 81).   
This technique is difficult to reproduce as it relies on the response from a specific detector and 
different detectors produce diverse signal to noise ratios. Thus for the purposes of this research the 
approach of using the lowest concentration for which the %RSD was < 5% was used. Samples of 
known and low concentration were injected (n=5) and the lowest concentration that produced 
precision data in which the %RSD was <5% was selected as the LOQ. The LOD was then calculated 
as the concentration at one third that that was considered to be  the LOQ (90). 
Using the above methods, the LOQ and LOD values were established as 0.2µg/ml and 0.06µg/ml, 
respectively. 
2.5.7 Forced Degradation Studies 
Forced degradation studies are generally performed to demonstrate the specificity of an analytical 
method when developing a stability-indicating HPLC assay. These studies provide information on the 
possible degradation pathways as well as degradation products that could be formed following the 
storage of dosage forms containing the analyte of interest (91). 
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Forced degradation studies are performed under different conditions including, hydrolytic, photolytic, 
acidic, basic and heat environment and at least 10% of the analyte should degrade to ensure  method 
optimization is achieved (92). 
2.5.7.1 Methods  
Typical chromatograms from freshly prepared SC samples were compared to chromatograms 
developed following degradation studies. The ICH guidelines state that the analysis of degradation 
products should be quantitatively and qualitatively analyzed, however for the purposes of this 
research, the peaks were only assessed qualitatively. 
2.5.7.1.1 Sample Preparation 
Approximately 10 mg of SC was accurately weighed and transferred into a 10ml A-grade volumetric 
flask. With the exception of the samples subjected to oxidative degradation studies, SC was dissolved 
and made up to volume in a medium specific for that degradation study, to yield solutions of 
approximately 1 mg/ml.  
2.5.7.1.1.1 Oxidative Degradation 
SC is reportedly susceptible to oxidative degradation (74). Therefore samples were prepared by 
weighing and transferring approximately 10 mg SC into an A-grade volumetric flask and dissolving 
the sample in mobile phase. A 2 ml aliquot of 30% v/v H2O2 was added to the sample and the mixture 
was refluxed for 10 hrs at 50 ± 0.5°C. Aliquots (20µL) were harvested hourly and transferred into a 
volumetric flask followed by the addition of 13 µL of IS solution prepared as described in § 2.3.2.3 
and the samples were made up to volume with mobile phase prior to analysis was added. 
2.5.7.1.1.2 Alkali Degradation 
A 0.1M NaOH solution was prepared by weighing 0.4g NaOH pellets that were transferred to an A-
grade 100ml volumetric flask and dissolved in distilled water. The solution was sonicated for 5 
minutes to ensure that all pellets had dissolved and then made up to volume with distilled water. 
Approximately 10mg of SC was accurately weighed and transferred into a 10 ml A-grade volumetric 
flask and made up to volume with 0.1M NaOH. The sample was refluxed for 10 hrs at 50 ± 0.5°C. 
Aliquots (20µL) were harvested hourly and transferred to a volumetric flask after which 13µL of the 
IS solution prepared as described in§ 2.3.2.3 and then made up to volume with mobile phase prior to 
analysis. . 
35 | P a g e  
 
2.5.7.1.1.3 Acidic Degradation 
A 0.1M HCl solution was prepared by transferring 833µl HCl into an A-grade volumetric flask and 
diluting and making up to volume with distilled water. Approximately 10 mg of SC was weighed 
transferred to an A-grade 10ml volumetric flask and made up to volume with 0.1M HCl. The sample 
was refluxed for 10hrs at 50±0.5°C. Sample aliquots were collected both prior to refluxing and every 
hour during the refluxing process. The aliquots were transferred to a volumetric flask and 13 µL of the 
IS was added as described in §2.3.2.3. The samples were made up to volume with a solution of 
acetonitrile and water (55:45). 
2.5.7.1.1.4 Photolytic Degradation 
Approximately 10 mg of SC was weighed and transferred to an A-grade 10ml volumetric flask. The 
sample was made up to volume with water and exposed to sunlight for 10 hours. Sample aliquots 
(20µL) were taken both prior to and hourly during exposure and diluted with 13µL of IS as described 
in §2.3.2.3 and made up to volume with a solution of acetonitrile and water (55:45). 
 2.5.7.1.1.5 Heat Degradation 
Approximately 10mg of SC was weighed and transferred to an A-grade volumetric flask. The sample 
was made up to volume with water and heated to 50±0.5°C under reflux conditions for 10hrs. Sample 
aliquots (20µL) were taken both prior to and during exposure and diluted with 13µL of IS as 
described in §2.3.2.3 and made up to volume with a solution of acetonitrile and water (55:45). If no 
degradation was observed the experiment was repeated at an increased temperature of 60°C. 
2.5.7.2 Results and Discussion 
2.5.7.2.1 Oxidative Degradation 
Immediately following the addition of H2O2 (hydrogen peroxide) two peaks, (denoted’ A’ and ‘B’) 
were identified at retention times of 1.4 and 2.5 minutes, respectively as shown in the chromatograms 
in Figure 2.6.  Following 10 hrs of refluxing approximately 20 % of the SC remained and a further 
peak, (denoted ‘C’) appeared at a retention time of 1.6 minutes. The appreciable oxidative degradation 
observed in these studies is similar to that observed in other stability studies on SC (74). 
36 | P a g e  
 
     
 
Figure 2.6 Chromatograms following oxidative degradation studies with SC after 1 hr (I) 5 hrs (II) and 10 hrs 
(III) 
The data summarized in Table 2.7 reveals that over the 10 hrs that SC was exposed to H2O2, there was 
a significant decrease in the PHR and so demonstrating the susceptibility of SC to oxidative 
degradation  
Table 2.7 Peak height ratio of SC and IS  
1hr 5hr 10hr 
2.073 1.777 0.434 
 
 
I 
II 
III 
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2.5.7.2.2 Alkali Degradation 
The drug was initially exposed to a 0.1M NaOH solution under reflux conditions but as shown in  
Figure 2.7, no noticeable degradation was observed following 10 hrs of refluxing This result was 
similar to that reported following a stability study conducted by Aboul-Enein and Hefnawy (73) who  
found that SC dissolved  in 0.1M NaOH and stored at ambient room temperature for 24 hrs did not 
degrade appreciably.  
 In situations where no degradation is observed for a specific sample, the experiments should be 
repeated under reflux conditions at a higher molar concentrations of the reactant solution (93). 
Consequently fresh SC samples were prepared as described in §2.5.7.1.1.2 in a 0.2M NaOH solution. 
As can be seen from Figure 2.8 I, II and III, the only evidence if possible degradation is that peak 
height of SC decreases and no other peaks appear in the chromatograms. There is a possibility that 
any possible degradation products do not absorb radiation at the wavelength of  analysis or the 
degradation products formed could be non-chromorphic products or also have decomposed to low-
molecular weight fractions suggesting that detection with mass spectrometry may be necessary (93) 
      
Figure 2.7 Chromatograms developed following refluxing of  SC in 0.1N NaOH at 1hr (I) 5 hr (II) and 10 hr 
(III) 
I II III 
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The data summarized in Table 2.8 suggest that SC is stable  in 0.1M NaOH as there is no significant 
change in the PHR of SC and the IS. This indicates that it may be necessary that the drug be degraded 
in a stronger molar concentration base to achieve significant degradation. 
Table 2.8 PHR of SC and IS under basic conditions (0.1M NaOH) 
1hr 5hr 10hr 
1.967 1.983 1.985 
 
 
      
Figure 2.8 Chromatograms depicting the degradation of SC in 0.2M NaOH at 1hr (I) 2 hr (II) and 10 hr (III) 
I II III 
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The data listed in Table 2.9 suggest that when SC is exposed to stronger basic conditions degradation 
of SC may occur as there is a significant decrease in PHR between 1hr and 10 hr indicating a 
significant decrease of SC present in the sample. 
Table 2.9 PHR of SC and IS under basic conditions (0.2M NaOH) 
1hr 5hr 10hr 
2.166 1.506 0.917 
 
2.5.7.2.3 Acidic Degradation 
 In the case of acidic degradation, no degradation was noted after 10 hours as can be seen from Figure 
2.9. This result is similar to that observed by Abdoul-Enein (73) that showed that no appreciable 
degradation of SC occurred after exposing SC to 0.1M HCl at room temperature for 24 hrs. Bakshi et 
al  advises that in the case where no degradation is noted, the drug sample should be refluxed under 
stronger acidic concentrations (93). For this reason fresh samples were prepared as discussed in 
§2.5.7.1.1.3 and the SC solution were made up to volume in 0.2M HCl. As seen in Figure 2.10 III, 
after refluxing SC in 0.2M HCl, the drug has completely degraded. 
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Figure 2.9 Chromatograms depicting the degradation of SC in 0.1M HCl at 1hr (I) 5 hr (II) and 10 hr (III) 
The data shown in Table 2.10 indicate the stability of SC in 0.1M HCl as there is no significant 
change in the PHR of SC and the IS. 
Table 2.10 PHR of SC and IS exposed to acidic conditions (0.1M HCl) 
1hr  5hr 10hr 
1.054 1.053 1.056 
 
I II III 
41 | P a g e  
 
  
Figure 2.10 Chromatograms depicting the degradation of SC in 0.2M HCl at 1 hr (I) 5 hr (II) and 10 hr (III) 
The data summarized in Table 2.11 shows that in the presence of strong acidic conditions, there is 
significant degradation of SC and after 10 hours there is no SC peak remaining.  
Table 2.11 PHR of SC and IS under acidic conditions (0.2M HCl) 
1hr 5hr 10hr 
1.496 1.148 No SC remaining 
 
 
 
 
 
 
I 
II III 
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2.5.7.2.4 Photolytic Degradation 
The chromatograms generated following injection of samples subjected to light exposure revealed no 
evidence of degradation and no corresponding decrease in the PHR suggesting that SC is stable in the 
presence of light.  
 
Figure 2.11 Chromatograms of samples following exposure of SC to light for 1 hr (I) and 10hr (II) 
The data listed in Table 2.12 displays the fact that no degradation occurs after SC is exposed to light 
for 24hrs as there is no change in PHR. 
Table 2.12 PHR of SC and IS after SC exposure to light 
1hr 10hr 
1.696 1.694 
 
I 
II 
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2.5.7.2.5 Heat Degradation 
Sample of SC heated to 50, 60 and 70 °C for 10 hours revealed no obvious evidence of degradation.  
These  results are similar to stress studies that suggested that SC was stable at elevated temperatures 
(74). 
 
Figure 2.12 Chromatograms depicting no degradation of SC when exposed to heat at 60ºC for 10 hrs (I) and 
70ºC for 10 hrs (II)  
As can be seen from the data summarized in Table 2.13 there is no change in the peak height ratios 
when SC was exposed to elevated temperatures showing that SC does not degrade at high 
temperatures. 
 
I II 
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Table 2.13 PHR of SC and IS after SC exposed to heat for 10 hrs 
50°C 60°C 
1.350 1.368 
 
2.6 SYSTEM SUITABILITY 
2.6.1 Introduction 
System suitability tests were proposed for use by the FDA in 1974 (94). Following validation of a 
particular method, system suitability tests should be performed to verify the resolution and 
repeatability of an analytical system is adequate to perform subsequent analyses (85). System 
suitability tests are based on the concept that the equipment, analytical operations and samples are an 
integrated organization that can be evaluated as a whole. 
Failure of system suitability tests can be indicative of a number of problems with a method including 
the use of incorrect mobile phase compositions or inadequate preparation of standard solutions. It 
could also be a sign that leaks may be present in an analytical system or that the column has degraded  
(88). Therefore it is good practice to perform system suitability tests routinely.  
2.6.2 Method 
For the purposes of this research visual system suitability tests were performed. Visual comparisons 
were made between chromatograms developed from test solutions to those following analysis of 
standard solutions.  Chromatograms from standard solutions are example chromatograms derived 
from the validation process or  previous system suitability tests (95).  
In additions calculation of the resolution and tailing factor can also be undertaken to ensure system 
suitability. 
2.6.2.1 Resolution 
The resolution of a method describes the extent of separation between two peaks and this parameter 
can be calculated using Equation 2.8.  
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Where, 
Rs = the resolution factor, 
VR1  = the retention time of peak 1, 
VR2  = the retention time of peak 2, 
w1  = the width of peak 1, 
w2  = the width of peak 2. 
 
Resolution factors > 1.5 are considered acceptable for analytical purposes (95). 
Calculation of the resolution factor from chromatograms resulted in a factor of 1.6 and shows that the 
peaks are sufficiently resolved to produce accurate results. 
2.6.2.2 Tailing Factor 
Peak tailing occurs when a peak deviates from a Gaussian or expected symmetrical shape. Peak 
tailing is commonly observed when  separating basic compounds on C18 stationary phases due to 
interaction of the analyte with silanol functional groups located on the stationary phase backbone (67). 
Excessive peak tailing is an issue as it can decrease peak height and therefore produce inaccurate 
results. 
 
 Peak tailing is also a problem if minor peaks run soon after a larger peak, for example while 
completing stability-indicating studies. It is possible that a minor peak could be hidden under the tail 
of a major peak and so reduces the ability of a method to facilitate quantitation of the components of 
the mixture being analyzed.   
 
The tailing factor can be calculated using Equation 2.9. 
 
 
                                     
     
  
                                                                          
 
Where, 
Tf = tailing factor, 
   a = the half width of peak 1 at 5% of the peak height, 
   b= the half width of peak 2 at 5% of the peak height.  
 
46 | P a g e  
 
Peaks of interest that have a tailing factor < 1.5 are suitable for quantitation in HPLC. Calculation of 
the tailing factor revealed that the a value of 1.125 was obtained suggesting that the mobile phase 
used for this separation is adequate 
 
2.7 CONCLUSIONS 
A reversed-phase HPLC method for the quantitation of SC in vitro has been developed, successfully 
validated and subsequently applied to the analysis SC dosage forms.  
The use of a validated analytical technique is essential for the collection of reliable data. The main 
purpose being to ascertain that the peak can be clearly resolved from other peaks in the 
chromatogram. Successful resolution is reliant on a number of different factors, including the type of 
column and the composition of the mobile phase. 
The internal standard method was made use of whereby the peak height ratio of the peak of interest to 
the internal standard is determined thereby eliminating injection errors from the results and generating 
more accurate data. The internal standard chosen for the method was diazepam based on its use in a 
previous SC HPLC study. 
The method was found to be linear over the range 0.2 – 2µg/ml with the calibration curve having an 
R2 value of 0.999. The proposed method has acceptable accuracy and precision and can be used for 
the analysis of SC in raw material and dosage forms. The analyte of interest, SC, and the IS were 
adequately separated with a retention time of 3.6 and 6 min, respectively. Consequently the method 
has a relatively short analytical run time of 7 minutes and is appropriate for quality control purposes. 
Furthermore the method is simple and the mobile phase used for the separation does not require 
complicated preparation procedures or components.  
Forced degradation studies revealed that the method is stability-indicating with no interfering peaks 
detected and therefore the method can be applied in formulation development and long term stability 
studies of SC containing dosage forms.  
Suitability parameter tests were carried out during the entirety of the method validation process to 
ensure that the results being produced are accurate. 
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 CHAPTER THREE 
PREFORMULATION AND POWDER ASSESSMENT 
 
3.1 INTRODUCTION 
The biological and analytical requirements needed for the registration of an active pharmaceutical 
ingredient (API), whether of natural or synthetic origin are the focus of much attention in the 
pharmaceutical industry. The ever increasing requirements with regard to ensuring safety, quality and 
efficacy has meant that the development of new medicines is characterised by higher assay values and  
lower impurity content (96). However, the quality of a dosage form does not depend only on the 
characteristics of the active substance but also on the excipients used to manufacture the dosage form 
and many stability problems seen in development of dosage forms are  due to incorrect matching of 
excipients and an API (97). 
Preformulation studies are the first step in the rational formulation of an API into a usable medicine 
(98).  These studies – that investigate the physicochemical properties of the drug substance, alone and 
in combination with excipients - are designed to identify properties that may influence formulation 
design and method of manufacture of the resulting dosage form.  
There are many options available to a formulator with regards to deciding which preformulation tests 
should be completed on an API. It is typically important to evaluate the solubility, pKa, particle size 
and morphology of the API as well as investigating potential interactions that may occur between an 
API and excipients that may be used to produce the dosage form.  
The physiochemical properties of SC were discussed in Chapter One and in this chapter the 
physicochemical and molecular properties of not only the API but the potential excipients for 
inclusion in SC orodispersible tablets were investigated to ascertain the influence they could have on 
the successful development of fast-dissolving tablets.  
3.1.1 Physicochemical Properties 
3.1.1.1 Particle Size and Shape  
The shape of a particle, defined by the  exterior morphology of the material, has a significant impact 
on the  particle distribution in a powder (99). A qualitative description of the shape of powder 
particles can be made by  using  descriptive terms such as ‘spherical’, ‘granular’, ‘crystalline’, 
‘fibrous’ and/or ‘flaky’ (100).  
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The shape of a particle is an important factor to consider when undertaking preformulation studies as 
it can influence many critical powder properties, such as flowability, compatibility, content 
uniformity, and dissolution rates (101). The flow properties of powders form an integral part of 
preformulation studies, and the design of oral dosage forms as quality control parameters for raw 
materials and product uniformity must be established. Particle shape  plays a crucial role in the 
success of  blending, granulation and other manufacturing processes (102).  Irregularly shaped 
particles generally contribute to poor flow properties of a powder, whereas spherical powder particles 
tend to exhibit good flowability (103).  
The size of the particles in a powder blend is generally the largest dimension of the  individual 
particles in that blend (103). Particle size also plays a major role in the successful blending of 
powders and therefore the content uniformity of the final dosage form (103). A wide distribution of 
powder particle sizes results in segregation, and ultimately non-uniformity of dosage forms.  
3.1.1.2 Powder Density 
3.1.1.2.1 True Density 
True density is defined as the density of the material, exclusive of the pores or inter-particle voids that 
are larger than molecular or atomic dimensions, in a crystal lattice (104).  
The true density of organic excipients typically falls in the range 1.0-1.6g/cm3 (103) whereas the 
density of inorganic excipients generally exceeds 2.0g/cm3 (103). A gas pycnometer is commonly 
used to determine the true density of powders. 
3.1.1.2.2 Bulk Density 
The bulk density of a powder is calculated using Equation 3.1 and is the mass of the powder divided 
by the volume that the powder occupies.  
Bulk Density = 
 e ight of the powder (g)
 olume of the powder  ml  
                                
The volume of the powder  includes  air located between the particles of the powder (105; 106). The 
density of a powder is primarily dependent on the  size and shape of the particles in addition to the 
tendency of particles to adhere to each other (104). The bulk density of a powder is an important 
parameter as it is used to establish the batch size for manufacture in a specific blender and/or  
granulator (104).  
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The bulk density of a material is also used to calculate Carr’s Index (CI) which provides an indication 
of the compressibility of a powder and therefore the potential for use as a suitable tablet formulation 
component. The CI guidelines are summarized in Table 3.1 and are used by formulators to assess the 
flowability of powders for tablet manufacture. In general a low index is indicative of excellent flow 
properties whereas a high index of 40 is indicative of extremely poor flow.  
Table 3.1Carr’s Index Guidelines (107) 
C rr ’s I dex  (%) Type of Flow 
5-15 Excellent 
12-18 Good 
18-23 Satisfactory 
23-35 Poor 
35-38 Very Poor 
40 Extremely Poor 
   
3.1.1.2.3 Tapped Density 
The tapped density of a powder, calculated using Equation 3.2, is the ratio of the total mass of a 
powder to the volume occupied by that powder after it has been compacted or tapped for a specific 
period of time. 
Tapped Density= 
 e ight of the powder (g)
 olume of powder after being tapped (ml)
                   
 Tapping the powder removes small voids or air entrapped between the particles in a powder blend. 
 The tapped density is used to calculate the Hausner ratio (HR) that also provides an indication of the 
flow properties of a powder.  
3.1.1.3 Angle of Repose  
The determination of the angle of repose (AOR) is also used assess the flowability of a powder. 
 In order to determine the AOR of a powder the material is poured onto a flat surface where it forms a 
heap. The particles initially stack, until the angle available for the addition of subsequent particles to 
the heap is large enough to overcome friction and the particles will slide down the surface of the heap 
until the gravitational forces balance the  inter-particulate forces, and movement ceases (107). The 
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heap of particles tends to form a conical shape with the sides of the heap producing an angle between 
the surface on which the powder resides and the free surface of the powder known as the angle of 
repose, which is indicative of the cohesion between particles and therefore an indirect measure of 
powder flowability (107). The guidelines for AOR are summarized in Table 3.2 with values of < 25 
being the most desirable and indicative of good flow properties. Powders in which constituent 
particles have  rough and irregular surfaces produce high AOR values (108) indicating poor flow 
characteristics.  
Table 3.2 Angle of Repose Guidelines (109) 
Angle of Repose (in degrees) Type of Flow 
<25 Excellent 
25-30 Good 
30-40 Satisfactory 
>40 Very Poor 
 
3.1.2 Molecular properties of the drug 
3.1.2.1 Polymorphism  
An important factor to be established in preformulation studies is the crystal form of the API and 
whether the API exists in more than one polymorphic form. Polymorphic forms of an API often 
present with different physicochemical properties including  melting point and solubility and other 
factors that influence dosage form performance (110).  
The identification of polymorphs is typically achieved  using X-Ray Powder Diffraction that permits 
the characterisation of the crystal form of an  isolated solid (110). It is however important that more 
than one technique is used  to identify the presence of the polymorph  and techniques such as 
Differential Scanning Calorimetry (DSC), Thermogravimetric Analysis (TGA), Infrared (IR) or 
Raman Spectroscopy and solid state NMR (Nuclear Magnetic Resonance) are often used to achieve 
this (110).   
Anhydrous SC has  no structural isomers or  polymorphic forms (111) but a new form of the citrate 
salt has recently been observed during solubility studies of SC at 4°C (111). This “new” form of SC 
has been characterized as a hydrate and is known as sildenafil hemi-citrate. It has been shown that 
material is not produced under the conditions used for the commercial manufacture of SC. It was also 
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noted that the different stoichiometry of the hemi-citrate hydrate form prevents its formation on  
storage of either the raw material or  solid dosage forms (111). 
3.1.3 API-Excipient Interactions 
The bulk of a dosage form is generally made up of excipients that are included to facilitate the 
manufacture of a product. Excipients have historically been considered as inert support for the 
medicaments, however this view has changed and excipients are now recognised as components that 
may interact with an API to produce unwanted physical and/or chemical transformation (112). 
Drug-excipient interactions may take a long time to manifest during real time stability tests and are 
not always readily identified or predicted by stress and/or preformulation studies. It is therefore 
important for a formulator to have knowledge of the susceptibility of an API to undergo degradation 
reactions by understanding the chemistry of the molecule they are dealing with. 
These interactions are not necessarily detrimental; they can also be beneficial. Drug-excipient 
interactions are usually separated into categories that are designated physical or chemical interactions 
(113).  
3.1.3.1 Physical API-excipient interactions 
Physical interactions involve no chemical changes to an API or excipient and can be difficult to 
detect.  
A beneficial physical interaction can occur during mixing when smaller particles, typically the API, 
interact with the surfaces of larger particles (usually excipients) through physical forces. 
Consequently, a more homogenous powder blend is produced (113).  
In contrast detrimental physical interactions may alter the performance of a dosage form. For 
example, a primary amine can interact with the microcrystalline cellulose. When dissolution is carried 
out in water, a small amount of the drug may be bound to the cellulose and will not be released. A 
dosage form that contains a high API concentration may not be a matter of great concern, however for 
low dose formulations, this may lead to dissolution changes and batch failure (113).  
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3.1.3.2 Chemical API-excipient interactions 
Chemical interactions between an API and an excipient, impurities or residues of an excipient may 
occur and are almost always detrimental, as degradation products are likely to result. 
One of the few known beneficial chemical API-excipient interactions occurs in association with 
nystatin, and the excipients, pectin and glycerine. The combination of these materials results in 
increased therapeutic activity of nystatin and prolonged release due to the formation of intermolecular 
hydrogen bonds between the hydroxyl functional group of nystatin and the appropriate functional 
groups located on the excipient molecules (114).  
An example of a chemically based API-excipient interaction occurs between diclofenac sodium and 
the polysaccharide based, polymer, chitosan. The release of diclofenac is inhibited at low pH  due to 
the formation of an ionic complex of the drug and cationic polymer (115).  
Many API are susceptible to oxidative degradation. Atorvastatin is one such compound and special 
consideration needs to be given when this compound is paired with excipients such as  fumed silica or 
fumed titania that have an ability to promote oxidative degradation reactions (98).  
3.2 METHOD 
3.2.1 SEM 
Particle morphology of materials was investigated using a Vega LMU© Scanning Electron Microscope 
(Tescan, Czechoslovakia Republic). A small amount of SC, microcrystalline cellulose (MCC), 
mannitol, fructose, crospovidone (CRP), sodium starch glycolate (SSG) and crosmarmellose Sodium 
(CMS) were dusted onto separate graphite plates and coated, under vacuum, with gold for 20 minutes. 
The samples were then viewed using SEM at an accelerated voltage of 20kV. 
3.2.2 Powder Density 
Approximately 10g of SC, MCC, mannitol, CRP, SSG and CMS were separately weighed and passed 
through a sieve. The powders were sieved in accordance with FDA guidelines that state that the 
powders must be sieved with apertures to break up agglomerates which may have formed during 
storage (116). This must be done gently to avoid changing the nature of the powder.  Each powder 
was then transferred into a separate 100ml graduated measuring cylinder where the bulk density was 
determined by measuring the volume that the powder occupied (Vbk). The tapped density of each 
powder was determined with the aid of a Model SVM 203 tapped density tested (Erweka GmbH, 
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Heueastamm, Germany) operated at a rate of 220 taps per minute for two (2) minutes. Following the 
two minutes of agitation the volume of the tapped powder was read (Vtp).  
The CI, porosity and HR were calculated using Equations 3.3, 3.4, and 3.5, respectively.  
  
                                           
CI= 
  tp  bk 
 tp
 x 100                                                
     
   
 
  x 100                                                  
HR=
 tp
 bk
                                                                 
Where,  
ε = powder porosity 
 bk =bulk density where v=vbk 
  tp =tapped density where v=vtp 
 CI = Carr’s Index 
 HR = Hausner Ratio 
 
The true density of the powder was calculated by compaction of the powders. SC, MCC, mannitol, 
CMS, CRP and SSG were each filled into a tablet die and manually compressed with a compression 
force of 30N to form 150mg tablets using an F3 Manesty® single punch press (Manesty Machines 
Ltd, Liverpool, United Kingdom). This compression force was selected as it is the same force that the 
tablets are to be compressed at in the manufacturing of the orodispersible tablets (ODT). By using the 
same compression force to calculate the true density of materials used to formulate the tablets one can 
ascertain whether the true density will have a detrimental effect on the production of a suitable dosage 
form. The weight and volume of each tablet (n=5) were measured and the true density was calculated 
using Equation 3.6.  
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 =
m
v
                                                              
Where,    
  = de nsity (g/ml)  
 m = mass of powder (g) 
 v= volume occupied by powder (ml) 
 
3.2.3 Angle of Repose 
The AOR was measured using a funnel method. Approximately 10g of powder was weighed and 
placed in a funnel. The height of the funnel was adjusted to a point where the tip of the funnel was 
just above the apex of the heap of powder. The powder was allowed to flow freely through the funnel 
onto a glass plate surface. A diagrammatic representation of the angle of repose is seen in image 
Figure 3.1 and was calculated using Equation 3.7. 
 
Figure 3.1Diagrammatic representation of the method of calculating the angle of repose 
       
r
h
                                                            
Where, 
  h = height of a pile of powder 
  r = radius of the heap of powder  
  θ= angle of repose 
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3.2.4 IR Spectroscopy 
The IR absorption spectra of SC and excipients were generated using a Spectrum 100 FT-IR ATR 
Spectrophotometer (Perkin Elmer®Ltd, Beaconsfield, United Kingdom).  The spectra were generated 
from samples of individual components and 1:1 binary mixtures of SC and excipient. Samples of 
binary mixtures were prepared by weighing approximately 0.5g of each component and gently 
blending the mixture using a mortar and pestle. A small amount of the mixture was placed on a 
diamond crystal and analysed in the wave number range, 4000-650cm-1 at a resolution of 4cm-1. 
3.2.5 DSC 
DSC is the measurement of the energy change that occurs as a sample is heated at a constant rate 
(117). The principal process involves the heating of two ovens to the same temperature at the same 
rate. One heater contains the sample in a sealed pan and the other containing an empty pan serving as 
the reference. If a change in the sample occurs such as melting, energy will be consumed  and the 
process is classified as an endothermic reaction (118) whereas, if the sample were to crystallise, 
energy is released due to the occurrence of an exothermic reaction. As the reference remains at a 
constant temperature, a thermogram displaying the thermodynamic events of that sample is produced 
showing a releases or uptake of energy.  
Approximately 2mg samples of SC, potential individual excipients and binary mixtures of SC and 
individual excipients in a 1:1 ratio of were analysed using DSC. DSC thermograms were generated at 
temperatures between 30 and 250ºC using a Model DS-60(Shimadzu®, Tokyo, Japan) with equipment 
and PC control unit TAC 60 (Shimadzu®, Tokyo, Japan) at a heating rate of 10ºC/min and a nitrogen 
flow rate of 20ml/min. Data analysis was undertaken  using Pyris™ Manager Software.  
3.3 RESULTS AND DISCUSSION 
3.3.1 SEM 
SEM imaging is used to obtain information relating to the size and shape of materials and in this case 
the API and excipients. This provides additional information about the potential flow properties and 
compressibility of raw materials and the powder blend.  
SEM was chosen as a suitable method because of the high resolution of the images obtained and its 
rapidity and ease of operation, which enables the generation of suitable images within a short period 
of time.  
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Furthermore SEM has a high depth of field which allows for analysis of the surface texture of 
particles, resulting in excellent characterisation of particle morphology. An understanding of the 
texture of particle surfaces is important, as this property may  influence the surface area, settling 
velocity and adherence of a powder or raw material to the particle  (119).  
SEM images of SC and raw materials that were considered as components of a tablet formulation are 
depicted in Figure 3.2.   
SEM imaging of SC (Figure 3.2 (I)), reveals the presence of many well-defined rod-shaped crystals. 
These crystals may at times be brought together forming irregular flat aggregates (120) and therefore 
suggests that SC may exhibit poor bulk flow properties. 
MCC exhibits irregular, elongated crystals (Figure 3.2 (II)). MCC particles vary in size and exhibit 
rough particle morphology. Based on these properties it is likely that MCC will exhibit poor flow 
properties. One cannot however make a judgement on the flow properties of a powder simply by 
looking at an image and further tests such as angle of repose are required before a final assessment 
can be made. The variable particle size of MCC, revealed by SEM imaging, indicates that it may be 
necessary to sieve the material when manufacturing a dosage form to ensure that uniformity in the 
product is achieved.    
The particle size and shape of mannitol (Figure 3.2 (III)) and fructose (Figure 3.2 (IV)) were 
compared to establish which material would be a more appropriate tablet diluent for the purposes of 
manufacturing a rapidly disintegrating tablet. As can be seen from Figure 3.2 (IV) fructose particles 
are far larger in size than those of mannitol and all other excipients.  Fructose occurs as cubic-shaped 
crystals with a smooth surface whereas mannitol occurs as smaller cubic and rod-shaped crystals 
which also have a smooth surface.  Therefore, even though both mannitol and fructose exhibit 
properties that point to good flow properties due to their cubic shape and smooth surface, mannitol 
would most likely be the most suitable diluent. Mannitol has a similar particle size to the other 
excipients investigated and therefore there is less chance of segregation of powders occurring.  
CRP (Figure 3.2 (V)) particles were highly porous and slightly granular in shape. SSG (Figure 3.2 
(VI)) particles showed a high degree of sphericity and were nonporous with a very smooth surface 
which is indicative of SSG having good flow properties. CMS (Figure 3.2 (VII)) particles exhibited a 
fibrous shape with nonporous characteristics. All three superdisintegrants have similar particle sizes 
indicating a low probability of segregation occurring. 
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VII 
Figure 3.2 Typical SEM images showing the particle morphology of (me) SC, (II) MCC, (III) mannitol, (IV) 
fructose, (V) CRP, (VI) SSG and (VII) CMS. 
 
3.2.2 Powder Density 
3.2.2.1 True Density 
The reported and actual true density values determined in this study are summarized in Table 3.3. 
Table 3.3 True Density of raw materials 
Material Actual 
(g/ml) 
Literature 
(g/ml) 
Reference 
SC 1.62±0.04 No reported values - 
MCC 1.93±0.05 1.51-1.67 (121; 122) 
Mannitol 1.27±0.02 1.44 (103) 
CMS 1.72±0.08 1.53 (122) 
CRP 1.76±0.01 1.3 (123) 
SSG 1.69±0.02 1.44 (122) 
 
The true density value of a powder provides useful information that can be applied to the 
characterization of the mechanical properties of  powders on which properties of a tablet such as  
hardness  and tensile strength are reliant (124). Due to the fact that powders flow under the influence 
of gravity, dense particles are generally less cohesive than low density particles of similar size and 
shape (125).  
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Determination of the true density of the API and potential excipients is a vital part of preformulation 
studies with regard to ODTs as these data are used to determine the porosity of a powder. 
The data summarized in Table 3.3 reveal that experimentally determined values for density generally 
deviate from those reported in the literature. This is most likely due to the fact that true densities are 
typically calculated using a helium pycnometer (103), an instrument that was not accessible for the 
purposes of this research. The data was generated empirically by measuring the weight and volume of 
a tablet compact. The deviations noted may therefore be attributed to the use of this approach and 
variations in machined tooling. 
3.2.2.2 Bulk and Tapped Density 
Data on the bulk and tapped density for materials used in these studies are summarized in Table 3.4, 
with previously reported values for these parameters included for comparative purposes. The Bulk 
and tapped densities calculated along with the true densities determined in these studies were used to 
calculate CI, HR and porosity of SC and the potential excipients. These results are summarized in 
Table 3.5. Comparisons between the actual data and data obtained from literature are in agreement 
with each other and we can therefore conclude that calculations conducted with the data e.g. CI and 
HR are accurate.   
Table 3.4 Bulk and tapped density values of raw materials 
Material Bulk Density Tapped density 
 Actual 
(g/ml) 
Literature 
(g/ml) 
Reference Actual 
(g/ml) 
Literature 
(g/ml) 
Reference 
SC 0.564±0.021 0.595 (126) 0.756±0.023 0.764 (126) 
MCC 0.286±0.015 0.26-0.31 (122; 127) 0.385±0.015 0.337 (122) 
Mannitol 0.513±0.007 0.430 (122) 0.714±0.115 0.734 (122) 
CMS 0.501±0.012 0.46-0.529 (122; 128) 0.769±0.011 0.72-0.819 (122; 128) 
CRP 0.313±0.007 0.3-0.4 (122; 128; 
129) 
0.401±0.011 0.4-0.5 (122; 128) 
SSG 0.802±0.021 0.756-0.76 (128; 129) 0.947±0.089 0.98 (122) 
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Table 3.5 CI, HR and Porosity data of raw materials  
Material CI HR Porosity 
SC 34.6±1.15 1.51±0.02 53.33±1.42 
MCC 25.71±3.59 1.35±0.06 80.05±1.46 
Mannitol 26.99±1.91 1.37±0.04 43.78±0.74 
CMS 31.85±1.02 1.53±0.02 41.74±1.63 
CRP 21.95±3.60 1.25±0.07 77.22±1.60 
SSG 19.89±2.47 1.21±0.04 54.50±1.53 
 
The value for porosity is derived from the powder density and is usually determined using mercury 
porosimetry (104). It is generally thought that granules that exhibit a greater degree of porosity will 
dissolve faster than denser granules as water is known to pass rapidly through porous substances 
(104). Porosity is an important consideration in preformulation studies as the intended dosage forms 
need to disintegrate rapidly and the greater the porosity the more likely the dosage form will 
disintegrate quickly. 
MCC is considered the most compressible of any of the directly compressible excipients and exhibits 
the greatest porosity (127) and producing a tablet of a specific hardness using MCC requires less 
compression force than for that using other materials.MCC is therefore usually combined with other 
fillers to achieve an ideal compactability and flowability for a direct compression formulation. When 
designing formulations there is a need to use excipients that exhibit a high degree of porosity as the 
porous surfaces provide adsorption sites to ensure that fine drug particles in low-dose formulations are 
homogenously distributed (127).  
The CI indicate that CRP and SSG are likely to exhibit  good flow and compressibility properties 
whereas the API and other excipients evaluated would exhibit poor flow and compressibility 
properties. Although the data for SC reveals that it may not exhibit good flow and compressibility 
properties, this may not be important because only a small dose (3mg) of SC is required in the tablet 
and therefore such a small amount will not make a great difference when incorporated into a powder 
blend. 
Values for HR are listed in Table 3.5. HR values < 1.25 are generally considered to indicate that 
material are likely to exhibit good flow properties whereas those > 1.25 tend to exhibit poor flow 
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(130). The HR data confirm that only CRP and SSG exhibited good flow and therefore reinforce the 
possible need for a glidant in the formulation.  
The data obtained from these studies is valuable as the intended method of manufacture of SC tablets 
is direct compression. It is important therefore to assess the flowability of the raw materials to ensure 
that content uniformity will be achieved when the powder flows from the hopper to the die cavity. 
The data revealed that the direct compression approach may be successful as a method of manufacture 
of fast dissolving tablets if the formulation includes a glidant. 
3.2.3 Angle of Repose 
The results of AOR studies are summarized in Table 3.6 and the guidelines of AOR results discussed 
previously in §3.1.2 were used to assess the flowability of the raw materials. 
Table 3.6 Angle of Repose values for raw materials 
Material Actual Literature Reference 
SC 40.6±0.60 42.3 (126) 
MCC 33.6±0.76 34.4 (122) 
Mannitol 38.2±1.46 38 (127) 
CMS 30.7±1.74 30-36 (130; 131) 
CRP 42.2±1.34 43-44 (129; 130) 
SSG 31.7±1.70 29-33 (129; 131) 
 
The data summarized in Table 3.6 reveal that the API and all excipients investigated show satisfactory 
or very poor flow properties, confirming the CI and HR data.  These results reinforce the fact that a 
glidant may be necessary in the formulation in order to ensure the flow properties of the powder blend 
are adequate to produce high quality, homogenous dosage forms using direct compression. 
Glidants improve the flow properties of a powder blend by interposing between particles to reduce 
surface irregularity and therefore preventing interlocking of particles and decreasing inter-particulate 
friction that may be present (132).  
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3.2.4 DSC 
DSC is a commonly used thermal analysis method in the pharmaceutical industry(110). Although 
there is acknowledgement that the presence of a physical or chemical interaction does not necessarily 
point to an incompatibility, it is generally agreed that any change observed in a DSC thermogram, is 
explicit proof that an interaction has occurred (133). 
There are many advantages of using DSC as a tool that include a rapid evaluation of potential 
interactions using only small amounts of sample (134). However higher temperatures are used for 
analysis that may introduce artefacts to the technique and events that are not typically witnessed at 
room temperature may be produced. This is due to the fact that at increased temperatures the kinetics 
of reactions, which could possibly alter the physicochemical properties of a sample under 
investigation, are increased (134).   
The DSC thermograms for SC, individual excipients and 1:1 binary mixtures of API and excipient are 
exhibited in Figures 3.3- 3.5 and 3.7 - 3.20.  SC (Figure 3.3) has a melting endotherm peak at 195.4°C 
which is  in agreement with that of a previous DSC study (15). It can be concluded that the bulk SC 
that is being used in the preformulation studies, and ultimately in the manufacturing process, is pure.   
 
Figure 3.3 DSC thermogram of SC generated at a heating rate of 10°C/min. 
As expected the DSC thermogram of MCC (Figure 3.4) reveals no thermal events in the range 30-
250°C  as MCC does not melt in this temperature range. 
The thermogram of the binary mixture of SC and MCC (Figure 3.5) revealed one endothermic peak at 
195°C due to the presence of SC, suggesting that no potential interactions between SC and MCC are 
likely to occur.  
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Figure 3.4 DSC thermogram of MCC generated at a heating rate of 10°C/min 
 
Figure 3.5 DSC thermogram of a binary mixture of SC and MCC generated at a heating rate of 10°C/min. 
 
The thermogram for mannitol reveals one endothermic peak at 168°C (Figure 3.7). This is in 
agreement with previous thermal analysis studies conducted on mannitol that showed a single 
endothermic event that occurs at 167°C (135-137).  
The thermogram of the binary mixture of SC and mannitol (Figure 3.8) displays a sharp peak at 
167°C, indicating the presence of mannitol, in addition to a smaller and broad endothermic peak at 
176.7°C. The peak for SC is not present in the thermogram indicating that at high temperatures an 
interaction between SC and mannitol occurs. This interaction is more than likely due to a small 
amount of reducing sugar that may be present in mannitol (138; 139), thereby precipitating a Maillard 
reaction.  
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The Maillard reaction typically occurs between a reducing sugar and a primary amine however it may 
also occur in the presence of secondary amines (98). A schematic representation of the Maillard 
reaction is depicted in Figure 3.6  in which the glycosidic hydroxyl functional group of a reducing 
sugar interacts with the primary or secondary amine to form an imine structure (103).      
 
An IR scan of a binary mixture SC and mannitol was performed as described in §3.3.4 and all 
characteristic bands of SC were visible (Figure 3.25). Therefore, due to evidence of a potential 
interaction when using thermal analysis, long term stability testing may well be necessary for dosage 
forms in which therapeutic amounts of SC are included with excipients such as mannitol.  
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Figure 3.6 Maillard reaction with secondary amine 
 
Figure 3.7 DSC thermogram of mannitol generated at a heating rate of 10°C/min. 
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Figure 3.8 DSC thermogram of a binary mixture of SC and mannitol generate at a heating rate of 10°C/min. 
The thermogram generated following DSC analysis of CMS (Figure3.9) reveals no major thermal 
events in the range 30-250°C as CMS does not melt in this range. However, there is a small but broad 
peak that occurs over the range 30-70°C which most likely can be attributed to the volatilization of 
water. 
Analysis of a binary mixture of SC and CMS (Figure 3.10) shows that there are no interactions 
between SC and CMS as only a solitary peak; representative of SC was observed at 195°C.  
 
Figure 3.9 DSC thermogram of CMS generated at a heating rate of 10°C/min. 
 
Figure 3.10 DSC thermogram of a binary mixture of SC and CMS generated at a heating rate of 10°C/min. 
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The DSC thermogram generated following the analysis of CRP (Figure 3.11) reveals the presence of a 
broad endothermic peak from 30-80°C which is possibly  due to the volatilization of adsorbed water 
(140). No other thermal events were observed in the range investigated as CRP melts at a temperature 
above those to which the materials were exposed. 
Analysis of a binary mixture of CRP and SC revealed no interactions similarly to the DSC analysis of 
CMS. 
 
Figure 3.11 DSC thermogram of CRP generated at a heating rate of 10°C/min. 
 
Figure 3.12 DSC thermogram of a binary mixture of SC and CRP generated at a heating rate of 10°C/min. 
 
No endo- or exothermic peak events were observed when SSG was analysed using DSC as the 
material does not melt, but rather chars or burns at 200°C. There is however a slight endothermic peak 
at approximately 60°C which is most likely due to volatilization of water. The thermogram generated 
following thermal analysis of a binary mixture of SC and SSG revealed only one endothermic peak at 
195°C that was characteristic of SC, indicating that SC and SSG are more than likely compatible.  
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Figure 3.13 DSC thermogram of SSG generated at a heating rate of 10°C/min. 
 
Figure 3.14 DSC thermogram of a binary mixture of SC and SSG generated at a heating rate of 10°C/min 
 
The thermogram generated following DSC analysis of magnesium stearate (Figure 3.15) shows an 
endothermic peak at a temperature of 110°C that is representative of the melting point of magnesium 
stearate. There is an additional exothermic peak at a temperature of 182°C that is due to the 
crystallization of magnesium stearate (141).  
Analysis of a binary mixture of SC and magnesium stearate (Figure 3.16) reveals that there is a 
potential interaction between the API and lubricant magnesium stearate as there appears to be a 
decrease in the melting point of SC.  
It has been suggested that the interaction between API and the lubricant  may be due to the presence 
of impurities, such as magnesium oxide in the magnesium stearate that have the ability to catalyze 
degradation by altering the pH of the micro-environment to a more alkaline condition. However in 
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terms of long term compatibility this is unlikely as SC was shown to be stable under alkaline 
conditions as reported in §2.5.7.2.2. 
A more appropriate explanation for the interaction between SC and magnesium stearate has been 
described by Miller and York (142) who proposed a possible mechanism for the interaction that was 
observed between acetylsalicylic acid and magnesium stearate. Their position was that the small 
particle size of magnesium stearate permits the formation of a surface film around the API and the 
close contact between API and excipient lowered the melting point of acetylsalicylic acid. This 
scenario may well exist with SC and magnesium stearate, with the fine magnesium particles coating 
the SC particles and lowering the melting point. 
Eutectic mixtures of two or more compounds have a melting point that is lower than each of that of 
the separate compounds (143) and ibuprofen, for example, in the presence of stearate salts formed a 
eutectic mixture with a lowered melting that then sublimates (144). This may also have occurred 
between SC and magnesium stearate but requires further investigation. 
Infrared absorption scans show magnesium stearate and SC are compatible at room temperature 
(§3.2.4). 
 
Figure 3.15 DSC thermogram of magnesium stearate generated at a heating rate of 10°C/min. 
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Figure 3.16 DSC thermogram of a binary mixture of SC and magnesium stearate generated at a heating rate of 
10°C/min. 
 
No endothermic or exothermic events were observed in the range 30-250°C following DSC analysis 
of CSD (Figure 3.17). This result is not surprising as CSD melts at a temperature of 1610°C and 
therefore falls outside the temperature range investigated. The thermogram of a binary mixture 
(Figure 3.18) of SC and CSD revealed one endothermic peak at 195°C confirming that no interaction 
between SC and CSD occurs.  
 
Figure 3.17 DSC thermogram of CSD generated at a heating rate of 10°C/min. 
 
Figure 3.18 DSC thermogram of a binary mixture of SC and CSD generated at a heating rate of 10°C/min. 
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The DSC thermogram generated following the analysis of talc (Figure 3.19) revealed no peaks as talc 
has a melting point of approximately 1500°C (145) and therefore does not fall within the temperature 
range investigated.  
Analysis of a binary mixture of SC and talc (Figure 3.20) once again revealed one endothermic peak 
at 196°C confirming that there are no interactions between the API and talc. 
 
 
 
 
 
 
 
Figure 3.19 DSC thermogram of Talc at a heating rate of 10°C/min 
 
Figure 3.20 DSC thermogram of a binary mixture of SC and talc at a heating rate of 10°C/min 
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3.2.5 IR Absorption Spectroscopy 
IR absorption  spectroscopy is used extensively in the pharmaceutical industry  for the identification 
of drug molecules and to confirm molecular structures (146). 
The absorption band frequencies used for the interpretation of IR spectra is listed in Table 3.7. 
Table  3.7 Infrared absorption band assignment of SC (15) 
Wave Number (cm-1) Group Assignment 
3613 OH stretching 
3293 NH stretching  
3028 CH stretching (aromatic) 
3000-2270 CH stretching (aliphatic) 
1700 C=O stretching 
1600-1500 C=C stretching 
1358, 1174 SO2 stretching 
1240 CN stretching 
 
SC has several significant peaks (Figure 3.21). The peak at 1240cm-1 is representative of the bridging 
of the two different ring systems viz.,  the pyrazolopyrimidine and piperazine ring systems and the 
presence of this band in an IR absorption spectrum is crucial as it confirms that the two ring systems 
are attached (126).  Another important peak  is the broad band found in the spectrum that appears at a 
wave number of 1700cm-1 and is attributed to the C=O functional group present on the pyrazole ring 
system (126).  
The band observed at 3293cm-1 represents NH symmetric and asymmetric stretching. The 
enlargement of  peaks in the range 3600-2700cm-1 is due to the presence of hydrogen bonds in the 
citrate complex (120). The three important peaks observed in this range are 3028cm-1, 2942cm-1 and 
2874cm-1 and are attributed to the  =C-H aromatic, CH3 asymmetric and CH3 symmetric vibrations in 
the molecule (120).  
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Figure 3.21 Infrared absorption spectrum of SC 
 
Infrared spectroscopic analysis of MCC (Figure 3.22) reveals the presence of several characteristic 
peaks. The broad peak at 3286cm-1 is representative of OH functional group stretching while the 
peaks at 2899cm-1 and 1427cm-1 can be attributed to CH and CH2 vibrations, respectively (147).  
The IR spectrum of a 1:1 binary mixture of SC and MCC (Figure3.23) reveals that there are no overt 
incompatibilities reactions between the API and excipient with all representative bands of SC and 
MCC present in the IR absorption spectrum of the binary mixture.  
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Figure 3.22 Infrared absorption spectrum of MCC. 
 
Figure 3.23 Infrared absorption spectrum of a 1:1 binary mixture of SC and MCC 
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The absorption spectrum for mannitol includes a number of characteristic peaks (Figure3.24). The 
very broad peak at 3387cm-1 represents OH band stretching. The three peaks at 2985cm-1, 2949cm-1 
and 2903cm-1 may be attributed to CH stretching while the peaks at 1280cm-1 and 1260cm-1  
correspond to primary and secondary alcohol OH plane deformation (148). The peaks at 1077cm-1 and 
1040cm-1represent primary and secondary alcohol CO stretching, respectively (148).  
 
Figure 3.24 Infrared absorption spectrum of mannitol. 
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To ensure that no interaction between SC and mannitol occurred, an IR spectrum of a 1:1 binary 
mixture of SC and mannitol was generated (Figure3.25) and revealed the presence of all characteristic 
peaks for SC and mannitol. DSC results showed that there is an incompatibility between mannitol and 
SC. However due to the fact that DSC analysis takes place at elevated temperatures, IR was used to 
determine whether that interaction also occurs at room temperature. It was thought that the Maillard 
reaction had occurred with reducing sugars found in mannitol, reacting with the secondary amine to 
form an imine. The spectrum highlights that no imine product was formed as a characteristic peak for 
this material would appear at a wave number of 1630cm-1 (149). The absence of this peak confirms 
the fact that at room temperatures a Maillard reaction is not likely to have taken place.  
 
Figure 3.25 Infrared absorption spectrum of a 1:1 binary mixture of SC and mannitol. 
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IR spectroscopic analysis of CMS reveals the presence of a broad peak at a wavelength of 3275cm-1 
(Figure 3.26) that is representative of H-bonding while the broad peak at 1015cm-1 is characteristic of 
the C-O bonds. 
 
Figure 3.26 Infrared absorption spectrum of CMS. 
 
The infrared absorption spectrum of a 1:1 binary mixture of SC and CMS (Figure 3.27) reveals no 
interaction between the two powders with the characteristic peaks of SC visible in the spectrum. 
 
Figure 3.27 Infrared absorption spectrum of a 1:1 binary mixture of SC and CMS 
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The IR absorption spectrum of CRP (Figure3.28) reveals the presence of a peak at 2944cm-1 which is 
representative of aliphatic CH stretching. The prominent peak at 1678cm-1 is attributed to carbonyl 
stretching while CH2 band stretching is represented by a peak at  a wavelength band of 1420cm
-1  
(123) . Analysis of a 1:1 binary mixture of SC and CRP (Figure3.29) revealed the presence of no 
incompatibilities. The peak at 1678cm-1 was not observed, most likely due to peak overlapping as the 
IR spectrum of SC has a characteristic long and broad peak at 1700cm-1. 
\\
 
Figure 3.28 Infrared absorption spectrum of CRP. 
 
Figure 3.29 Infrared absorption spectrum of a 1:1 binary mixture of SC and CRP. 
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IR analysis of SSG (Figure 3.30) reveals a broad peak at 3290cm-1 that is attributed to H bonding with 
the broad band at 1000cm-1 being representative of the C-O bonds.  
The infrared absorption spectrum of a 1:1 binary mixture (Figure 3.31) highlights the fact that no 
interactions are likely to occur between SC and SSG with all important peaks of not only SC but also 
SSG visible in the binary mixture spectrum.  
 
Figure 3.30 Infrared absorption spectrum of SSG. 
 
Figure 3.31 Infrared absorption spectrum of a 1:1 binary mixture of SC and SSG. 
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The OH stretching vibration of the magnesium hydroxide (MgOH3)  in talc (Figure 3.32)  is 
represented at a wave number of 3677cm-1  (150). The broad peak at approximately 990cm-1 is due to 
Si-O-Si bond vibration while the peak observed  at 665cm-1 is attributed to Mg-O-Si vibrations (151). 
The IR spectrum of a 1:1 binary mixture of SC and talc (Figure 3.33) reveals that there is no 
interaction between the two powders as all characteristic peaks of both the API and excipient are 
present. There is however a decrease in the intensity of the Si-O-Si vibration of the talc and the 
1695cm-1 vibration of SC which is most likely due to the presence of hydrogen bonding.  The use of 
DSC experiments confirm the compatibility of the two powders as discussed in §3.2.4. 
There is also a decrease in the intensity of the 1700cm-1 vibration of SC that may be attributed to 
dilution of the drug in the binary mixture. 
 
 
Figure 3.32 Infrared absorption spectrum of talc 
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Figure 3.33 Infrared absorption spectrum of a 1:1 binary mixture of SC and talc 
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The IR spectrum for magnesium stearate (Figure 3.34) reveals twin peaks at 1576 and 1455 cm-1 
which are attributed to the presence of asymmetric carboxylate (COO-) stretching and symmetric 
carboxylate stretching, respectively. The peaks at 2955 and 2849 cm-1 represent C-H stretching while 
the broad peak at approximately 3257 cm-1 represents OH stretching of the associated water molecule 
(152).
 
Figure 3.34 Infrared absorption spectrum of magnesium stearate 
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Figure 3.35 Infrared absorption spectrum of a 1:1 binary mixture of SC and magnesium stearate. 
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these physical characteristics is that it allows the formulator to identify potential problems with regard 
to content uniformity of the dosage form. If the powder blend does not exhibit good flow properties 
the tablet dies will not be filled correctly, and hence the production of non-uniform tablets would 
occur.  
Of all excipients evaluated, MCC exhibited good compressibility and porosity. Powder property 
assessments however revealed that the some excipients, for example CMS, displayed poor flow 
properties.  The inclusion of a glidant would therefore be a most likely requirement for the successful 
manufacture of a quality and homogenous dosage form if those excipients were to be included in the 
formulation.  
Thermal analysis is a popular analytical technique that provides crucial information with respect to 
the existence of polymorphic forms of an API as well as the compatibility of an API with excipients. 
However, as far higher temperatures than those to which a product would usually be exposed are 
used, preformulation studies should also include IR absorption spectroscopy to confirm or negate the 
results generated using DSC.  
DSC analysis highlighted the fact that there are interactions between mannitol, magnesium stearate 
and SC, albeit at high temperatures. These interactions were not confirmed using IR analysis, which 
are performed at room temperature and therefore it can be inferred that these interactions are most 
likely due to the high temperatures that the binary mixtures were exposed to.   
IR analysis revealed no incompatibilities between the API and the potential raw materials and showed 
that IR analysis used in combination with thermal analysis are important methods to ascertain 
interactions between API and drug excipients.  
It can be concluded that preformulation studies conducted in this chapter revealed that none of the 
potential excipients showed any incompatibility with the intended API. However, long term real time 
stability studies may be necessary if these materials are to be used in the production of SC containing 
dosage forms. The data also provided an indication that with regard to the flowability characteristics 
of the raw materials, direct compression may be a suitable method of manufacture during the 
development of orodispersible SC tablets. This approach is further investigated and reported in 
Chapter Four.  
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CHAPTER 4 
FORMULATION DEVELOPMENT AND MANUFACTURE OF FAST ORODISPERSIBLE 
SILDENAFIL CITRATE TABLETS 
4.1 INTRODUCTION 
Unless a disease affects the paediatric population to a large extent, most medicines are not tested or 
labelled for use in infants and children. The main reason for the lack of appropriate dosage forms for 
paediatric patients is the fact that neonates and infants are seen as being a relatively small population 
group and therefore provide a  limited return on the substantial investment  pharmaceutical companies 
make in drug product development studies (154). There is also the perception of a need for more 
stringent ethical considerations, legal liability and regulatory requirements when conducting clinical 
studies in children (154). 
The lack of paediatric formulations is a worldwide challenge, with approximately 70% of drugs 
approved for adult use in the United States of America not labelled for use in infants and children 
(155). In Europe a similar situation is observed, where only 33% of all medicines licensed by the 
European Agency for Evaluation of Medicinal Products (EMEA) in the period from October 1995 to 
September 2005 were labelled for paediatric use, 23% for use in infants and 9% in newborn babies 
(156). 
The lack of availability of suitable dosage forms for use in this population group often results in the 
use of extemporaneously manufactured medicines. Consequently it is common practice to crush SC 
tablets, dissolve the residue in water and to administer this mixture to the patient via a naso-gastric 
tube. Alternatively SC suspensions are manufactured using methylcellulose or a combination of Ora-
Sweet and Ora-plus as the suspending agent (157).  These suspensions have been shown to be stable 
over a period of 91 days with no change in pH, odour or physical appearance noted (157).  Stability 
issues however are not the only concern with regard to extemporaneous preparations.  
Extemporaneous preparations are not ideal dosage forms for use in paediatric patients as there are 
many issues in respect of the stability, safety and dosing of these preparations.  
For example, potent drugs such as morphine are too concentrated for accurate measurement of the 
small doses required to treat neonates and infants (154). Therefore it may be necessary to dilute a 
commercial preparation, which may then result in the production of a dosage form in which the 
preservative efficacy is questionable. There is also the difficulty that in seriously ill neonates, fluid 
intake restrictions exist and there is a limit to the volume of medication that can be administered at 
any one time.  
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Due to the dangers of administering extemporaneously manufactured medications, different dosage 
forms that will allow for the safe and effective delivery of a useful API to paediatric patients need to 
be further investigated.  
Fast dissolving and orodispersible tablets are currently an important research niche and are an 
alternate means of delivering an API, to extemporaneous preparations, since they can be easily 
administered to a paediatric patient and are formulated to dissolve and release the API for absorption, 
rapidly. 
4.1.1 Tablet Compression  
Solid oral dosage forms are the most popular method of formulating an API for administration as they 
are safe and convenient to administer and are economical to manufacture on a large scale, by the 
pharmaceutical industry (158).  
The basic principles of tablet compression in which granular or powdered materials are compressed in 
a die between two punches using a tablet press have remained the same since the tablet, as a dosage 
form was initially conceptualized (159). 
A typical manufacturing process for the production of tablets includes milling, granulation, drying, 
blending, compression and tablet coating (160), with each unit operation possibly further 
disaggregated into  several additional processing steps. 
The process of converting a powder into a tablet is fundamentally dependent on an interparticulate 
bonding process. The classification of these bonds is broadly divided into five types according to  the 
Rumpf classification (161): 
i. Formation of Solid bridges 
ii. Bonding by liquids (capillary and surface tension forces) 
iii. Binder bridges (viscous binders and adsorption layers) 
iv. Intermolecular and electrostatic forces 
v. Mechanical interlocking 
In the case of direct compression the two predominant bonds thought to be important in ensuring 
dosage form integrity are those that occur  due to intermolecular forces and the formation of solid 
bridges (161). Bonding by intermolecular forces is also known as adsorption bonding and occurs 
when two solid surfaces are brought into close contact so that adhesion or adsorption to one another is 
achieved. Common intermolecular forces include  an der  a al’s forces and hydrogen bonding (162) 
in addition to dispersion forces(161). 
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The formation of solid bridges is also referred to as the diffusion theory of bonding (161). The 
formation of these bonds occurs when solids are mixed and become slightly fused at their interface, 
thereby forming a continuous phase between the two particles (161). It is the presence of the 
continuous face between particles that makes solid bridges the strongest of all bonds between particles 
in a tableting process (162). 
Mechanical interlocking describes the hooking of irregular shaped particles (161) and it is thought to 
also play a role in the bonding of powders in directly compressed tablets, however they are considered 
to be less significant in comparison to the other two types of bonds, previously discussed.  
4.1.2 Orodispersible Tablets (ODT) 
Solid oral dosage forms are one of the more popularly used dosage forms, however they do have some 
shortcomings. The common drawback of these dosage forms is the difficulty that some patients have 
in swallowing and therefore their use may lead to non-adherence  in patients, especially in the 
paediatric and geriatric populations (158; 163). 
ODTs provide an alternate approach to delivering an API to these populations and can be referred to 
by variety of different names including orodispersible tablets, orally disintegrating tablets, quick 
disintegrating tablets, fast dissolving tablets, rapid dissolving tablets, porous tablets, quick melt tablets 
rapid melt tablets and fast disintegrating tablets. The European Pharmacopoeia has adopted the term 
orodispersible tablet “for a tablet that disperses or disintegrates in less than three minutes in the mouth 
before swallowing” (164). 
In general, an ODT is a tablet that dissolves or disintegrates in the oral cavity without the need for 
administration with water or chewing to facilitate tablet break up.  
An ideal ODT should (165): 
i. require no water for oral administration, yet dissolve/disperse/disintegrate in the mouth in a 
matter of seconds. 
ii. have a pleasing feel in the mouth. 
iii. have an acceptable taste or be appropriately taste-masked. 
iv. demonstrate acceptable hardness and friability properties. 
v. leave minimal or no residue in the mouth after administration. 
vi. exhibit low sensitivity to environmental conditions such as humidity. 
vii. allow for the manufacture of the tablet using conventional processing and packaging 
equipment. 
 
87 | P a g e  
 
4.1.2.1 Advantages of ODT 
ODT exhibit all the advantages of solid dosage forms including enhanced stability, accurate dosing, 
ease of handling by patients and a small packing size (164). In addition they are easily administered to 
persons that are unable to swallow, such as paediatric and elderly patients. Furthermore some API are 
absorbed from the mouth, pharynx and oesophagus as the saliva passes down alimentary canal into 
the stomach, and therefore formulating these compounds as an ODT can increase the bioavailability 
of that drug (166). This increased bioavailability is due to reduced pregastric metabolism and may 
also result in the need for administration of a lower dose with an associated decrease in unwanted side 
effects (166). 
ODT can easily be administered to patients who do not have immediate access to potable water and 
therefore can be a valuable dosage form for delivering essential medicines in developing world 
countries.  
4.1.2.2 Limitations of ODT 
ODT tablets typically have low mechanical strength and are usually more friable than other solid 
dosage forms and therefore require special handling and packaging techniques (167).The tablets may 
also have an unpleasant feel in the mouth due to the presence of a high percentage of disintegrant(s) in 
the tablet formulations.  
Tablets with large doses of API are, in general, difficult to formulate in comparison to low dose 
formulations due to the fact that if a formulation only requires a small amount of API, there is more 
freedom to incorporate excipients that facilitate disintegration to the formulation.  
ODT may be difficult to administer to patients who take anti-cholinergic medication or who suffer 
from conditions that result in a dry mouth and decrease in salivary grand secretions, such as Sjogren’s 
Syndrome (168).  
A further disadvantage of ODT is that they are usually hygroscopic and therefore careful 
consideration with regards to manufacturing parameters, environment and packaging need to be taken 
into account (163). 
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4.1.3 Methods of manufacture of ODT 
4.1.3.1 Direct compression 
The direct compression method of manufacture is the simplest and most cost-effective approach to 
produce solid dosage forms. This manufacturing approach involves the use of conventional 
manufacturing equipment in addition to commonly available tableting excipients. Heat and water are 
not used in the manufacturing process and therefore the  stability of the product may also be improved 
(161).   
The manufacturing process involves only a limited number of individual steps and can be summarized 
as a method in which powders are blended and then compressed between two punches in a die to form 
a tablet (169).  
The disintegration and dissolution of a ODT manufactured using the direct compression method is 
based on the activity of disintegrants and the presence of water soluble excipients. Disintegration 
efficacy is strongly affected by tablet size and hardness and large, hard tablets can have a 
disintegration time greater than those usually desired for application as ODT (170). 
4.1.3.2 Moulding 
Moulded ODT are manufactured using water soluble excipients. A powder mixture is moistened with  
a solvent, typically ethanol or water and then compressed into tablets under a pressure lower than that 
used for conventional tablet compression (170). More recently moulded dosage forms have been 
manufactured by preparing a molten matrix in which the drug is dissolved or dispersed (heat 
moulding) or by evaporating the solvent from the drug solution/suspension at standard pressure (no-
vacuum lyophilisation) (170).  Moulded tablets are less compact than compressed tablets and exhibit a 
porous structure that increases disintegration and subsequent dissolution of the API (168).  
4.1.3.3 Freeze drying (Lyophilization) 
Freeze drying was one of the first techniques applied to the manufacture of ODT (166) and is a 
process in which water is removed from a frozen product by sublimation. The API is dissolved or 
dispersed in an aqueous solution of a carrier/polymer and the resultant  mixture is then poured into the 
wells of blister packs, after which the trays holding the blister packs are passed through a frozen 
liquid nitrogen tunnel to freeze the API solution (171).  The freeze drying process continues after 
which the blister packs are moved to refrigerated cabinets.  
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The ideal characteristics of an API for use in a  freeze drying process is a degree of aqueous  
insolubility,  fine particle size in addition to exhibiting good stability in disperse systems (166). 
Difficulties that could possibly be experienced when having to manufacture a dosage form with a 
water soluble API using the freeze drying approach is the formation of eutectic mixtures, as  the 
freezing point depression and formation of glassy solids that occurs on freezing may collapse the 
structure following sublimation of the vehicle (166). 
The advantage of using a freeze drying method of manufacture of dosage forms at low or non-
elevated temperatures is the elimination of the potential deleterious effects on stability of the API 
when using high temperatures.   
4.1.3.4 Melt Granulation  
Melt granulation is a process whereby pharmaceutical powders are agglomerated by use of a binder 
that melts at a relatively low temperature. The advantage of this technique over conventional 
granulation approaches is that no water or organic solvents are used in the process and therefore no 
drying of the granules is required, resulting in shorter production times.  
The binder is typically a hydrophilic wax like material such as Superpolystate©, PEG-6-stearate (165) 
which has a melting point of between 33 and 37°C. The material not only acts as a binder in the 
formulation but aids in the disintegration of the tablet as it will melt in the mouth at body temperature 
(172).  
4.1.3.5 Choice of Method of Manufacture 
The method of manufacture selected for the production of ODT was direct compression. Direct 
compression was selected since it is an economical approach to use with regards to excipients, time 
and equipment. The method makes use of commonly available excipients that are not excessively 
expensive,  and does not require a great number of steps in the production of the tablets resulting in 
short manufacturing times. There is the added advantage that tablets manufactured using direct 
compression disintegrate into primary particles and not granules which occurs when manufactured 
using wet or dry granulation (173). This eliminates the need for granule disintegration and ensures 
rapid dissolution of API occurs following administration. 
4.1.4 Excipients  
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The development and manufacture of a successful solid oral dosage form is dependent on the choice 
and amount of excipients that are incorporated into the formulation of that dosage form.  
Excipients are ideally inactive, non-toxic and should not interact with the API or other excipients to 
be included in the dosage form (174). Excipients are included in the pharmaceutical dosage form in 
order to aid the manufacturing process, support or enhance stability and/or enhance patient 
acceptability of the medicine (174). However, the safe and successful use of excipients in the 
manufacture of products for use in adult patients does not necessarily imply they will be safe for use 
in children. Excipients should be used with special care, particularly  in neonate and infant patients 
due to the fact that their physiology and organ development are very different to those of adult 
patients (175). 
Excipients are categorized by the primary role they play in the manufacture of a pharmaceutical 
dosage form and include dilution, disintegration, binding, lubrication, flavouring, sweetening amongst 
others.    
4.1.4.1 Binders 
Binding agents are incorporated in a solid oral formulation to promote the formation of agglomerates 
during granulation or cohesive compacts during the compression process (176). The binder is often 
dissolved in a vehicle or granulating fluid that is added to a powder blend when tablets are 
manufactured using the wet granulation method. In the case of direct compression tableting, the 
binder is added to the powder mixture directly and blended prior to compression.  
Most binders used in the wet granulation process are polymeric in nature and starch, gelatine and 
polyvinylpyrrolidone (PVP) are popular options (176). The most effective binder used in direct 
compression manufacture is MCC (176).  
4.1.4.2 Diluents 
In general the dose of an API is low in relation to the size of a tablet and therefore formulation must 
include excipients that are used to increase the size of the tablet so as to ensure it is of suitable 
dimensions for compression and ease of handling by patients or care-givers. The excipients that fulfil 
this role are known as diluents and should be inert materials  as they are generally used in large 
quantities in solid dosage forms (177). 
The common assumption relating to diluents is that they are inert however they have the potential to 
influence the stability and performance of a pharmaceutical product. For example, dibasic calcium 
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phosphate is an inorganic salt that is commonly incorporated in formulations as a filler/binder in 
direct compression formulations. The surface of this material is alkaline and therefore incompatible 
with drugs that may be sensitive to alkaline environments (160). 
There are a number of materials that are suitable for use as diluents with many formulation scientists 
in the pharmaceutical arena favouring the use of lactose and MCC for many applications (122).  
4.1.4.3 Disintegrants 
Disintegrants are included into a tablet formulation to facilitate the breakdown of a  tablet into 
granules (178) thereby increasing the surface area of API exposed to the gastrointestinal fluids and 
facilitating dissolution of the compound. A schematic representation of this process is shown in 
Figure 4.1.   
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Figure 4.1 Schematic representation of the action of the disintegrant. Adapted from Wells, J.I. and Rubinstein, 
M.W. (1976) (179) 
Tablet disintegrants are categorized into two classes viz., traditional or superdisintegrants. The term 
superdisintegrants was first used when referring to SSG, CMS and CRP and relate to their increased 
effectiveness  in comparison to traditional disintegrants such as starch or alginic acid that were used 
previously (180). 
4.1.4.3.1 Mechanism of Action of Disintegrants 
Intact tablet Granules Primary drug particles  
Low rate of drug dissolution Moderate rate of drug 
dissolution 
Relatively rapid rate of drug 
dissolution 
Drug in solution in gastrointestinal fluid 
Absorption 
Drug in blood 
Disintegration Deaggregation 
Increase in effective surface area of drug exposed 
to gastrointestinal fluids 
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Disintegrants may function by a number of mechanisms that may operate in isolation on some 
occasions or where multiple mechanisms might be in evidence. These mechanisms include swelling, 
wicking, repulsion and elastic deformation of raw materials. 
Swelling occurs due to the affinity of a disintegrant for water. The disintegrant absorbs water and  
particles subsequently swell to a point when the adhesiveness of the other excipients in the 
formulation  are surpassed, with the result that the tablet falls apart (181).  
Wicking is also referred to as capillary action that occurs due to the porosity of a tablet and provides a 
pathway for the penetration of liquids into the core of the tablet. The liquid is drawn or “wicked” into 
these pathways through capillary action and destroys the inter-particulate bonds that hold the tablet 
together, thereby facilitating tablet disintegration (181).   
Materials that recover the energy of elastic deformation following powder compaction may also fulfil 
the role of a disintegrant in a formulation. Starch is thought to be “elastic” in nature suggesting that 
the particles deform when placed under pressure yet return to their original shape when the applied 
stress is removed (181). Following application of tableting compression forces to a powder blend 
containing starch, it is thought that the starch particles are permanently deformed and are “energy 
rich”.  hen the tablet is subsequently exposed to water the energy potential of the deformed starch  is 
triggered leading to disintegration of the tablet (182).   
Repulsion mechanisms are an attempt to explain the swelling of tablets that are formulated with ‘non 
swellable’ disintegrants and it has been proposed that non swelling particles facilitate  disintegration 
by the introduction  of electric repulsive forces, following the addition of water, thereby  promoting 
tablet disintegration (181). 
4.1.4.4 Anti-frictional agents 
4.1.4.4.1 Lubricants 
The purpose of a lubricant in a formulation is to overcome or reduce friction. In the tableting context  
the friction that occurs between the die wall and the sides of the tablets are the frictional forces that 
should be overcome (183). Inadequate lubrication can result in the production of tablets with a pitted 
or scratched surface and is the consequence of the failure of a tablet to be detached from the surfaces 
of the die cavities. Lubricants are classified according to their aqueous solubility viz. insoluble and 
soluble lubricants (178).  
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Insoluble lubricants are generally added to a powder blend during the final mixing stage prior to 
compression. The concentration of the lubricant used is an important consideration in formulation as 
lubricants can have a deleterious effect on tablet disintegration and subsequent dissolution of an API. 
Commonly used insoluble lubricants include magnesium stearate, stearic acid and glyceryl behenate 
(178).  
Soluble lubricants are included in a formulation when it is necessary to overcome the potential 
detrimental effect of using insoluble lubricants and examples include polyethylene glycol and lauryl 
sulphate salts (178). 
Lubricants tend to play a secondary role when included in ODT formulations. Lubricants may make a 
tablet more palatable as it disintegrates as the lubricant has the ability to remove grittiness and 
facilitate the transport  of an API from the mouth to the stomach (184).  
4.1.4.4.2 Glidants 
Glidants are included in pharmaceutical formulations to reduce friction that may be generated 
between particles (185) and therefore serve to improve  the flow properties of the components of a 
powder blend.  
Glidants are thought to enhance the flow properties of a blend by one or more of several possible 
mechanisms (186) such as reducing roughness by filling surface irregularities, reducing attractive 
forces by physically separating bulk powder particles, modifying electrostatic charges, acting as 
moisture scavengers or acting as ball bearings between bulk powder particles. 
Commonly used glidants for tablet formulations include talc and colloidal silicon dioxide (159).  
4.1.4.4.3 Anti-adherents 
The function of an anti-adherent is to reduce the adhesion between powders and punch surfaces 
thereby prevent particles sticking to punch surfaces resulting in a reduction of tablet imperfections.  
Many powders can  adhere to the punch surfaces and this phenomenon is known in the 
pharmaceutical industry as ‘picking’ or sticking’ that  can be a result of  a high moisture content of a 
powder blend or humidity of the manufacturing environment (161).  The adherence of particles to 
punches can lead to the build-up of a thin layer of material on the surface which can cause the 
production of uneven tablets (161).  
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Commonly used anti-adherents include talc and starch however many lubricants such as magnesium 
stearate have some anti-adherent properties and are included in a blend to fulfil both functions.   
4.1.4.4 Adsorbents 
Adsorbents are included into tablet formulations when liquid or semi-solid excipients or API are to be 
included in a dosage form. The successful production of a tablet requires that only solid components 
be compressed and the use of an adsorbent excipient to which the liquid/semisolid component is 
bonded during a mixing process ensures that compaction is possible (178). The use of adsorbents is 
not without its challenges and may lead to the production of abrasive tablets. It is therefore important 
that fine and grit-free grade adsorbents are used when manufacturing such tablets (176) and 
commonly used adsorbents include kaolin, bentonite or magnesium carbonate. 
4.1.4.5 Colourants and Flavourants 
Colourants are included into a tablet formulation to increase the aesthetic appeal of a dosage form and 
to ensure ease of identification (178).  Colourants are usually added during the coating stages of 
production but can also be included in a blend prior to compression where the dye  is either added as 
an insoluble powder or dissolved  in the granulation liquid (161).  
Concerns over the safety of colouring agents used in formulations have been raised and relate to the 
unwanted side effects that were noted when food colourants are used [6). These colourants are 
therefore subject to regulations that are not usually associated with other pharmaceutical excipients 
that are otherwise  required to be safe and non-toxic (160). Country specific legislation to control the 
use of colorants in pharmaceutical formulations also provide for purity specifications [6) and have led 
to a decrease in the number of permitted colours for pharmaceutical applications (160). 
Colourants are classified as water-soluble dyes or water-insoluble pigments. Water-soluble dyes are 
usually applied in the granulation process to ensure the dye is evenly distributed throughout a 
formulation. Uneven distribution of colours can occur since the migration of the dye during drying 
may occur (160). To overcome the problem of uneven colour distribution water-insoluble pigment can 
be dry blended prior to the final compression.  
Flavourants and other taste-masking excipients are incorporated into a formulation to produce a more 
palatable dosage form. Flavouring agents are often thermolabile and cannot be added prior to a unit 
operation involving heat (161). Flavourants are included in formulations to manufacture more 
pleasing dosage forms that will hopefully improve patient adherence to therapy.  
96 | P a g e  
 
4.2 METHODS 
4.2.1Materials 
SC was purchased from MTT Pharma and Bio-Technology Co., Ltd (Shanghai, China) and MCC 
(Emcocel 90M) was purchased from Penwest Pharmaceuticals Co. (Nastola, Finland). CRP was 
purchased from BASF® (Ludwigshafen, Germany) and CMS, SSG, CSD, mannitol (SD200), talc and 
magnesium stearate were donated by Aspen Pharmacare (Eastern Cape, South Africa) 
4.2.1.1. Microcrystalline cellulose  
MCC may be  included in a formulation as a filler, although it can also be used as a binder and  also 
facilitates tablet disintegration  (122; 160). MCC is both crystalline and amorphous depending on the 
orientation of the cellulose chains in the material (161). MCC is available in a variety of different 
grades that are reflective of alternate  particle size and moisture content (122) with the larger particles 
sizes exhibiting better flow ability as discussed in Chapter Three, vide infra.  
MCC is compatible with many drug molecules, however it is hygroscopic and  must be used with 
caution  in formulations that contain molecules  that are susceptible to hydrolysis in the solid state 
(161). 
4.2.1.2 Mannitol  
Mannitol is used as filler in many chewable formulations. It is a white crystalline non-hygroscopic 
powder with a faint odour (122) which makes it an ideal excipient for use in ODT formulations. 
Although the primary role of mannitol in formulations is a filler it fulfils multiple roles and since it is 
soluble in water (128) it enhances the disintegration of tablets. Furthermore mannitol, a sugar,  has a 
negative heat of solution and produces a cooling sensation in the mouth with a pleasant taste when 
chewed or dissolved (128).  
Mannitol can be used in varying amounts in a formulation based on the dose of API to be delivered 
from the formulation.  
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4.2.1.3 Crospovidone (CRP) 
CRP is included in tablet formulations as a disintegrant. It is a white to creamy-white powder that is 
hygroscopic,  has a faint odour and is insoluble in water (122). As CRP is non-ionic, the disintegration 
properties that it imparts to a tablet are not influenced by pH (128).  
The optimum concentration of CRP for use in formulations is 2-5% w/w, however tablets containing 
up to 13% w/w CRP have been successfully produced (187).  The mechanism by which CRP 
promotes disintegration of tablets is predominantly though capillary action (181). 
4.2.1.4 Croscarmellose sodium (CMS) 
CMS is a white, free flowing powder that is used in tablet formulations as a disintegrant (122).  
CMS is a cross linked polymer of carboxymethyl cellulose sodium (188) that is insoluble in water but 
is a highly absorptive material with exceptional cold water swelling properties (188). Due to the high 
density of cross linking, CRP has the ability to swell rapidly in water without forming a gel  (181) and  
disintegration occurs by a process of wicking and swelling (181). 
4.2.1.5 Sodium starch glycolate (SSG) 
SSG is the sodium salt of the carboxymethyl ether of starch and is  a very fine white to off white 
powder that is free flowing, odourless and  practically insoluble in water (122).  
The effect of the presence of a large hydrophilic carboxymethyl group disrupts the hydrogen bonding 
within the polymer structure and allows water to penetrate the molecule with the polymer becoming 
water soluble (181). SSG is widely used as a disintegrant in both tablets and capsules with a  
recommended concentration for use in a formulation of  between 2-8% w/w (122). 
4.2.1.6 Colloidal silicon dioxide (CSD) 
CSD is a non gritty amorphous powder that is bluish white in colour. It is odourless and consists of 
fine spherical particles of small size and excellent water-adsorbing properties (160).  
CDS is included in formulations as a glidant and to impart smoothness to the surfaces of punches,  
however it is often required to be used in combination with additional lubricants  to facilitate tablet 
ejection from die cavities (160).  
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4.2.1.7 Talc  
Talc is a compound that is primarily comprised of magnesium silicate and on occasion, small 
quantities of aluminium silicate (177). Talc is a very fine white to off white crystalline powder and is 
used in formulations as a glidant. It has been shown that there is no significant difference between 
using 0.25% w/w and 1%  w/w talc in tablet formulations (189). 
The effectiveness of talc is limited by its hydrophobic nature and the use of increasing levels of the 
material result in a significant decrease in tablet wetting and consequently, reduced dissolution rates. 
4.2.1.8 Magnesium stearate 
Magnesium stearate is a commonly used lubricant in tablet formulations. It is a fine, white bulky 
powder with a characteristic odour and is insoluble in water (177) that  when used in concentrations 
greater than 5% w/w retards drug release from solid dosage forms  (122). The impact of blending time 
on dosage form performance must be evaluated when formulating dosage forms with magnesium 
stearate, as increased blending times may reduce dissolution rates and the crushing strength of tablets 
(122). 
4.2.2 Manufacturing equipment 
All raw materials were weighed using a Mettler Model PM4600 top loading analytical balance 
(Mettler Instruments, Zurich, Switzerland) with a sensitivity of 0.01g. Blending was performed using 
a cube mixer (Erweka®, Munich, Germany) attached to a drive unit (Kraemer Electronik GmbH®, 
Damstadt, Germany). Tablet compression was performed using a Manesty®F3 single punch press 
(Manesty®., Liverpool, England) tooled with 7mm flat-faced punches at a speed of 20 r.p.m. All 
materials were sieved prior to processing using wire cloth sieves conforming to a DIN 4188 standard.  
 
 
4.2.3 Method of manufacture  
Tablets were manufactured using a direct compression method to produce dosage forms that each 
contained 3 mg SC. The dose of SC was based on the data following a literature review and 
evaluation of the typical doses used to treat neonate patients (Chapter One).  
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 Mannitol or fructose was used as the primary diluents in combination with microcrystalline cellulose 
(MCC) as an additional diluent. CRP, CMS and SSG were included in the formulation as 
disintegrants. Magnesium stearate, talc and CSD were included as anti-frictional agents. 
A diagrammatic representation of the method of manufacture is located in Figure 4.2 
SC, diluents and disintegrants were screened through a #20 sieve and magnesium stearate, talc and 
CSD which were screened through a #44 mesh sieve. The powders were placed into the cube blender 
and mixed for 10 minutes without magnesium stearate.  The powders were blended for a further three 
minutes following addition of the magnesium stearate.  
The blend was compressed to form 7mm diameter flat-faced tablets using a Manesty® F3 single 
punch press set to a compression force of 30N. 
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Figure 4.2 Method of manufacture of SC ODT 
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ODT have a high sensitivity to humidity, as many of the excipients used to produce the tablets are 
hygroscopic. It was noted during the initial stages of developing a suitable formulation that if the 
tableting was performed in an environment in which the relative humidity was > 50% picking 
occurred, resulting in batch failure. Picking is an action in which solid particles of a tablet blend 
adhere to the surfaces of a punch resulting in small pits becoming apparent on the surface(s) of the 
tablet.  
Consequently the RH of the tableting room was constantly monitored during formulation and 
manufacture of SC tablets. Furthermore, to ensure continuity when Central Composite Design 
experiments were conducted, and in the absence of an environmentally controlled tableting facility, 
production was performed between 00H00 - 06H00 am when the RH of the facility was found to be at 
the lowest level. 
The initial formula was developed following a literature review of formulae used for the manufacture 
of orodispersible tablets. However the literature review revealed that the dose of SC used was far 
higher than the dose that was required in this formulation. Previous formulae also did not appear to 
disintegrate rapidly enough as was required for this formulation. Modification with regard to the 
concentration of diluents and disintegrants were therefore required to distil a suitable formula for use.  
The batch formulae used for the development of a suitable ODT are summarized in Table 4.1. 
Table 4.1 Formulae used for the manufacture of SC ODT by direct compression 
 SC 001 
% w/w 
SC 002 
% w/w 
SC 003 
% w/w 
SC 004 
% w/w 
SC 005 
% w/w 
SC 006 
% w/w 
SC 007 
% w/w 
SC 2 2 2 2 2 2 2 
CMS 8.5 8.5 8.5 8.5 8.5 8.5 8.5 
CRP  3 3 3 3 8.5 13.5 
SSG - - - 4 8 8 8 
MCC 15 15 15 15 15 15 15 
Talc 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
Mg stearate 1 1 1 1 1 1 1 
CSD - - 1 1 1 1 1 
Fructose 70.4 - - - - - - 
Mannitol - 70.4 69.4 65.4 61.4 55.9 50.9 
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Following the initial development of these formulations, Batch SC003 was further optimized in 
respect of disintegration by increasing disintegrant concentration and ensuring that the tablet retained 
suitable mechanical strength characteristics. The success of the optimization procedure was evaluated 
by assessing content uniformity of the tablets using a validated HPLC method (Chapter Two) in 
addition to assessing the disintegration time of these tablets.  
The content limits of the API was set at 100±10% with an RSD of <5%.  The friability limit was set at 
< 1% and other physical characteristics such as disintegration and wetting time in addition to in vitro 
dispersion time were required to be as low as possible.  
4.2.4 Physical characteristics of ODT  
4.2.4.1 Physical properties of powder blends 
All powder blends were assessed by evaluating bulk and tapped density, flowability and compression 
characteristics.  
Approximately 10g of each powder blend was assessed as discussed in §3.2.2 and § 3.2.3 and the bulk 
and tapped density, angle of repose, CI and HR established. 
4.2.4.2 Physical characteristics of tablets 
4.2.4.2.1 Mechanical strength of tablets 
The mechanical strength of a tablet is an important characteristic that must  be measured as it provides 
a formulation scientist with an indication of the extent to which a tablet can withstand the mechanical 
shock that it will be exposed to during manufacture, packaging and transportation (167).  
The most commonly used methods for testing mechanical strength are attrition-resistance or fracture-
resistance methods.  
4.2.4.2.1.1 Attrition-resistance tests 
Attrition-resistance test methods, mimic forces to which a tablet is subjected during handling through  
production to administration of a tablet to a patient (161) and are also referred to as friability tests.  
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During friability testing, tablets are subject to repeated abrasion through rotation for a specified 
number of cycles in a friability tester. The tablets are held in a transparent drum  containing a blade  
that carries tablets to a central height that permits them to fall as the drum rotates (190). The 
movement of the drum and tablets results not only in continuously falling from a set, small height but 
that they also rub against each other. The tablets are dusted and weighed prior to and following testing 
and the percent lost from the original weight is calculated. A friability of less than 1% is considered 
acceptable, whereas friability values > 1% are cause for batch rejection.     
The friability of the tablets was determined using a Model TA3R friabilator (Erweka GmbH, 
Hausenstamm, Germany). Twenty (20) tablets were randomly selected, de-dusted and weighed using 
a Mettler Model PM 4600 top-loading balance (Mettler Instruments, Zurich, Switzerland). The tablets 
were tumbled at a rate of 25 rpm for 4 minutes or 100 drop cycles and then removed from the 
friabilator, de-dusted and reweighed. The friability of the tablet was calculated using Equation 4.1. 
        
  -  
  
          Equation 4.1  
  
Where,  
w1 = weight prior to testing 
w2 = weight after testing 
Fr = friability 
 
4.2.4.2.1.2 Fracture-resistance tests 
Analysis of the fracture resistance of tablets involves the application of a load to the tablet and the 
determination of the force needed to fracture or break the tablet along the diameter of the compact. A 
schematic representation of the tensile strength test is shown in Figure 4.3. 
       
Figure 4.3 Diagram of the tensile strength of a tablet 
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The tensile strength of the manufactured tablets was calculated using Equation 4.2. 
 
                                                                     
  
   
                                       Equation 4.2 
Where,  
σo = tensile strength (MPa) 
F = crushing strength (N) 
d = tablet diameter (mm) 
T = tablet thickness (mm) 
 
4.2.4.2.2 Weight Uniformity 
Weight uniformity is an important criterion for evaluation of tablets within a batch as it provides an 
indication of the content uniformity of that batch. Therefore it can be seen as an indication of the 
efficiency of mixing of an API and the excipients that make up a formulation. If the tablets tested 
exceed the limits of weight variation as set out by the United States Pharmacopoeia (USP) [9) as 
shown in Table 4.2 the batch must be rejected [9).  
Table 4.2 Weight variation limits as specifies in the USP (163) 
Average weight of tablet % Deviation 
80 mg or less ± 10 
More than 80 mg but less than 250 mg ± 7.5 
250 mg or more ± 5 
 
The individual weights of 10 randomly selected tablets were measured using a Mettler Model AG 135 
top-loading electronic balance (Mettler Instruments, Zurich, Switzerland) that had a sensitivity of 0.1 
mg. The average weight and %RSD for the batch was then established.  
 
 
 
105 | P a g e  
 
4.2.4.2.3 Crushing strength and diameter 
The crushing strength of the tablet is defined as the force that is applied across the diameter of a tablet 
in order to break the tablet (168). The harder the tablet the greater resistance the tablet exhibits to 
chipping, abrasion or breakage when stored or handled prior to use.  
The crushing strength and diameter of the tablets were measured using a Model PTB 311 E Hardness 
Tester (PharmaTest AG®, Hainburg, Germany). Each tablet was placed in the tester and a crushing 
force applied to the tablet and the crushing strength and diameter were measured simultaneously.  
4.2.4.2.4 Disintegration test 
The disintegration time is a crucial characteristic that must be monitored during the development of a 
ODT, due to the fact that the formulation needs to disintegrate rapidly to exert a therapeutic effect.  
The disintegration time of tablets was measured using a Model ZT 61 tablet disintegration apparatus 
(Erweka GmbH®, Heusenstamm, Germany). Six tablets were randomly selected from each batch and 
a single tablet was placed into separate cylinders of the basket-rack and covered with a disc. The 
basket was set to oscillate vertically at a speed of 30 oscillations per minute in a beaker containing 
800ml of distilled water that was maintained at 37 ± 0.2°C. The time for disintegration of each tablet 
was recorded and noted at the completion of disintegration testing 
4.2.4.2.5 Tablet assay  
Twenty tablets were randomly selected and ground into a fine powder using a mortar and pestle. An 
aliquot equivalent to the weight of one tablet (150mg) was weighed using a Model AG 135 top 
loading analytical balance (Mettler Instruments®, Zurich, Switzerland). The powder blend was 
transferred into a 25ml A-grade volumetric flask and dissolved in ACN: water in a ratio of 55:45 and 
sonicated for 5 minutes using a Model B-12 Ultrasonic bath (Branson Cleaning Equipment Co., 
Shelton, Connecticut, United States of America). The solution was then made up to volume with an 
ACN: water mixture in a ratio of 55:45. Approximately 2ml of the solution was filtered through a 
0.22µm Acrodisc® PSF syringe filter (Pall Corporation, Port Washington, New York, United States of 
America) and an aliquot of 167µl of the filtered solution was transferred into a 10ml A-grade 
volumetric flask. A 13µl aliquot of IS solution was added to the volumetric flask and the resultant 
solution was made up to volume with an ACN: water mixture in a ratio of 55:45.  
The solution was analysed using a validated HPLC method and analysis was performed in triplicate.  
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4.2.4.2.6 Water Absorption Ratio Studies 
The water absorption ratio is usually investigated in the development of ODT to provide an 
understanding of the capacity of the disintegrants included in the formulation  to swell and/or wick in 
the presence of a small amount of water (191). 
The most popular method used to determine the water absorption ratio is undertaken by using a piece 
of tissue paper folded twice and placed on a petri dish containing 6ml buffer solution. The tablet is 
placed on the tissue paper and allowed to completely wet. The tablet is then removed from the petri 
dish and weighed.  
As the tablets disintegrated rapidly after wetting, it was not possible to be move and reweigh the 
individual units. Therefore a simple approach was to place the tissue paper and petri dish on a tarred 
scale and then to place the tablet on the petri dish to ascertain the initial weight of the system. Buffer 
was then added drop wise with a plastic pipette until the tablet was completely wetted. The final 
weight of the tablet was then established and the water absorption ratio calculated. All studies were 
performed in triplicate. The water absorption ratio was calculated using Equation 4.3. 
 
                                    a ter Absorption Ratio=
 a - b  
 b
 x 100                                                                                                                          
             Where,  
 Wa= weight of the tablet after wetting 
 Wb= weight of the tablet before wetting 
 
4.2.4.2.7 Wetting Time 
The wetting time of ODT  is an important physical characteristic as it provides an indication of the 
disintegration efficiency of the tablet (192) with faster wetting times implying faster tablet 
disintegration and more rapid drug release. 
The wetting time of the tablets (n=6) were determined by folding a piece of tissue paper twice (12cm 
x 10.75cm) and placing the tissue paper onto a petri dish containing 6ml buffer solution (pH6.8). The 
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tablet was placed on the tissue paper and the time taken to completely wet the tablet was recorded. All 
determinations were performed in triplicate.  
4.2.4.2.8 In vitro Dispersion Test 
The use of in vitro dispersion tests as additional indicator of the disintegration time of the tablets is 
common and the dispersion test defines the time taken for tablets to undergo uniform dispersion. 
The in vitro dispersion time of tablets (n=3) from each batch that was manufactured was determined 
by placing the tablet in a beaker containing 10ml buffer solution (pH 6.8).  No degree of agitation was 
used to enhance dispersion and the end point of the test was set at the time taken for the tablet to lose 
its original shape. Upon visual inspection the separation of the tablet into clearly defined particles was 
considered the end-point and this time was noted as the in vitro dispersion time.  
4.2.4.2.8.1 Preparation of buffer 
The buffer used in these studies was prepared by weighing 0.68g of dihydrogen orthophosphate on 
Mettler AG 135 top loading balance (Mettler Instruments, Zurich, Switzerland) and then transferring 
into a 1000ml A-grade volumetric flask. The powder was dissolved in distilled water  and sonicated 
for 5 minutes using a Model B-12 Ultrasonic bath (Branson Cleaning Equipment Co.,Connecticut, 
United States of America) and then made up to volume with distilled water. The pH of the buffer was 
adjusted to pH 6.8 with sodium hydroxide.  
4.2.5 Blend homogeneity studies 
Blending can be thought of as a “reshuffling” process involving the movement of individual and/or 
groups of particles to produce a homogenized blend of solids in bulk (193). 
Blending times that are typically used for the manufacture of tablets  range between 2 and 10 minutes 
(194), however with low dose formulations longer blending times may be necessary. The USP 
recommends that blend uniformity testing be performed on  dosage forms that contain < 50mg API 
per dosage unit or if the API content of the dosage form is <50 % w/w of the each unit (195). The 
acceptance limits set by the USP for blend uniformity testing is 100±10% of the expected content with 
an  associated % RSD of < 5% (196).  
During initial formulation studies, a blending time of 10 minutes without the addition of magnesium 
stearate and a further 3 minutes blending of the powder mixture with the magnesium stearate was 
selected for use. A blend homogeneity study was performed on Batch SC 003 only. Blend 
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homogeneity studies were only performed on this batch to evaluate the mixing process and the 
optimum blending time was further evaluated using an experimental design approach and is reported 
in Chapter Five, vide infra.  
Blend homogeneity studies were performed by measuring the API content of the powder samples of 
blend at after being mixed for13 minutes. Approximately 100mg (n=6) of the powder blend was 
collected from six separate areas of the cube blender using a stainless steel laboratory spatula and 
weighed using a Mettler AG 135 top loading balance (Mettler Instruments, Zurich, Switzerland) and 
transferred into a 50ml A-grade volumetric flask. The powder was dissolved in an ACN: water 
mixture (55:45) and sonicated for 5 minutes using a Model B-12 Ultrasonic bath (Branson Cleaning 
Equipment Co., Shelton, Connecticut, United States of America) and made up to volume with the 
ACN: water mixture(55:45). Approximately 2ml of each solution was filter through a 0.22µm 
Acrodisc® PSF syringe filter (Pall Corporation, Port Washington, New York, United States of 
America) and 500µl of the filtered solution was transferred into a10ml A-grade volumetric flask with 
13µl of IS solution. The sample was made up to volume with an ACN: water mixture (55:45) and 
analysed using a validated HPLC (Chapter 2). 
4.2.6 Content uniformity of tablets 
Following the establishment of an appropriate blending time the content uniformity of the tablets of a 
batch was investigated. Content uniformity is the measurement of variation in API from one dose unit 
to the next.  
Content uniformity testing should be conducted on all coated tablets other than film coated tablets, 
transdermal systems, suspensions in single-unit containers or in soft capsules, pressurized metered-
dose inhalers and suppositories  (196). 
 
During manufacture of any dosage form the excipients are added at different stages  and factors such 
as powder density, particle sizes and  shapes may contribute to differences in the resultant uniformity 
of content of the tablets in a batch (190). It is therefore necessary to test for uniformity of content of 
each batch that is manufactured to ensure that each tablet conforms to the acceptance criteria and that 
each batch can be considered of suitable quality, for use.  
Ten tablets from the batches under investigation were randomly selected and crushed separately using 
a mortar and pestle. Approximately 100mg of each powder blend, equivalent to 2mg of SC was 
weighed and transferred into 50ml A-grade volumetric flask. The powders were dissolved in an ACN: 
water mixture (55:45) and sonicated for 5 minutes using a Model B-12 Ultrasonic bath (Branson 
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Cleaning Equipment Co., Shelton, Connecticut, United States of America) and then made up to 
volume with ACN: water (55:45). Approximately 2ml of each of the solutions was filtered through a 
0.22µm Acrodisc® PSF syringe filter (Pall Corporation, Port Washington, New York, United States of 
America) and 500µl of each filtered solution transferred into a 10ml A-grade volumetric flask 
containing 13µl of IS solution. Each sample was made up to volume and analysed using a previously 
validated HPLC method.   
4.3 RESULTS AND DISCUSSION 
4.3.1 Physical properties of the powder blend 
A summary of the properties of the different powder blends that were tested is summarised in Table 
4.3. 
Table 4.3 Assessment of Powder blends 
Batch No. Bulk Density Tapped 
Density 
Angle of 
Repose 
CI HR 
SC 001 0.510 0.680 41.63 25 1.33 
SC 002 0.504 0.642 33.69 21.46 1.27 
SC 003 0.525 0.671 30.96 21.63 1.28 
SC 004 0.510 0.674 28.61 24.39 1.32 
SC 005 0.520 0.679 28.61 23.41 1.31 
SC 006 0.500 0.644 26.57 22.39 1.29 
SC 007 0.491 0.636 28.30 22.86 1.30 
 
Batch SC 001, which made use of fructose as the primary diluent exhibited slightly poorer flow 
properties than other blends, as can be seen from the relatively high angle of repose for Batch SC 001 
in comparison to the other batches. This is an indicator to potential content uniformity problems. 
When mannitol was used as the primary diluent, the powder blends exhibited improved flow 
properties when compared to fructose.  
As can be seen from the data for Batch SC 003, the incorporation of a glidant improved the flow 
properties of the blend further and inclusion of a glidant is most likely necessary to ensure uniformity 
with regards to the content of API present in the tablets.   
The addition of increased amounts of disintegrant in Batches SC004 -SC 007 did not reduce the flow 
properties of the blend, suggesting that an increase in the amount of disintegrant to facilitate faster 
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disintegration times should not have a negative impact on the flow properties of powder blends and 
should not result in large variations in content uniformity 
4.3.2 Physico-mechanical properties of the tablets 
A summary of the physico-mechanical properties of following testing of all batches manufactured are 
summarised in Table 4.4. 
All tablets that were produced passed the uniformity of weight test as all batches had weight data with 
relative standard deviations of < 7.5%.   Weight variations tests are very important consideration 
when formulating dosage forms as large variations in weight may be an indication of poor flow 
properties of powders (103)  and will most likely result in the production of batches of tablets that are 
not uniform with regards to API content. The results of weight variation analyses indicate that the 
batches of SC tablets produced will most likely exhibit a suitable content uniformity. However since 
the formulation is a low-dose product, weight variation cannot be the only method used to assess 
content uniformity and other methods such as quantitative determination of the content of SC  in each 
tablet must be established using a validated analytical method.  
The tablets manufactured with fructose showed a large variation in disintegration times and had assay 
values that exceeded the USP limits of 100±10%. This is likely due to the large particle size of 
fructose that was confirmed using SEM imaging (Chapter Three). Larger particles tend to have better 
flow properties than smaller particles but when formulated with smaller particle sizes, the different 
particles may segregate(160). Segregation of the powder blend may then result in inaccurate filling of 
dies and lead to the production of tablets that have a large variation in dose within a single batch 
(161).  Mannitol was therefore thought to be a more appropriate diluent as the particle size of 
mannitol was similar to the other excipients used in the formulation.  
All tablet batches conformed to the friability limit of 1% despite exhibiting relatively low hardness, 
that is a required feature of ODT. These results indicated that the tablets were mechanically strong 
enough to withstand shock but not excessively hard so as to result in increased disintegration times.  
The water absorption ratio is an important characteristic that needs to be investigated in the 
development of an ODT formulation as it provides a relatively good indication of the speed of 
disintegration. The data produced in these studies suggest that there is an inverse relationship between 
the water absorption ratio and the disintegration time for these tablets, as an increase in the 
disintegrant concentration led to an increase in the water absorption ratio. Since the water absorption 
ratio is indicative of the time for disintegration it can be inferred that an increase in disintegrant 
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concentration will result in an increase in the water absorption ratio and ultimately a decrease in 
disintegration times. The standard deviation observed for Batch SC 001 was high due to the fact that 
segregation of the blend may have occurred and therefore inaccurate filling of the die results in 
varying amounts of disintegrant in each tablet and consequently variable disintegration times. 
An inverse relationship was noted for wetting and in vitro  dispersion times and the concentration of 
the disintegrant and it was revealed that increased disintegrant concentrations shortened the wetting 
and dispersion times for these products. The short disintegration time is a neceesary and desirable  
property of orodispersible tablets and therefore an important factor that needs to be monitored in the 
development of an appropriate formulation for SC tablets.  
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Table 4.4 Physico-mechanical properties of SC tablets 
Batch No. Weight  
mg 
Crushing 
Strength 
 N 
Diameter 
mm 
Tensile 
Strength 
Friability 
% 
Disintegration 
time  
s 
Water 
Absorption 
Ratio 
Wetting 
time  
s 
In vitro 
dispersion 
s 
Assay 
% 
SC 001 188±6.96 19.17±4.29 7.23±0.03 0.712 0.98 51±23 55.47±4.18 18.13±0.15 45.53±2.60 164.19 
SC 002 153.5±5.87 21.33±2.07 7.23±0.03 0.803 0.41 80±3 61.83±0.68 20.33±1.40 45.89±1.43 95.64 
SC 003 151±7.18 20.58±2.97 7.23±0.03 0.872 0.85 81±2 61.22±0.74 15.93±0.25 43.89±0.33 102.49 
SC 004 145±6.07 23.44±2.30 7.24±0.01 0.873 0.78 23±2 64.99±1.42 14.43±0.50 38.46±0.49 98.02 
SC 005 153.5±6.71 26.01±2.65 7.26±0.08 0.958 0.62 10±2 68.70±0.54 12.23±0.32 36.16±0.35 98.50 
SC 006 150.5±5.10 22.01±2.54 7.24±0.01 0.813 0.66 9±1 68.94±0.65 8.57±0.70 35.28±0.52 98.34 
SC 007 149.5±5.99 19.65±3.98 7.25±0.03 0.728 0.69 8±1 71.05±1.49 4.2±0.17 35.28±0.49 101.45 
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4.3.3 Blend homogeneity 
The difficulty with blending excipients used when formulating and manufacturing ODT is that the 
majority of the materials are hygroscopic and high humidity environments can have a significant 
impact on the cohesiveness of a blend. Consequently an increase in the moisture content can lead to 
the formation of unwanted agglomerates. Therefore optimal blending times must be established so as 
to  achieve  uniformity of a blend without compromising the quality of the materials required for 
compression, through  moisture uptake (193). 
When blending under conditions in which agglomerates may form, the uniformity of a blend  
improves to a point where agglomerates are formed after which increasing agglomerate sizes result in 
a subsequent  decreases in uniformity (193). 
The results of blend homogeneity tests conducted on Batch SC 003 are summarized in Table 4.5. 
Table 4.5 Blend Homogeneity study on Batch SC 003 
Batch Sample Expected 
Content (mg) 
Actual 
Content (mg) 
Content % %RSD 
SC 003 1 2 2.10 104.80 3.87 
 2 2 1.95 97.30  
 3 2 2.10 105.22  
 4 2 2.09 104.42  
 5 2 2.15 107.32  
 6 2 2.10 104.90  
 
The data summarized in Table 4.5 reveal that the limits set by the USP regarding blend uniformity 
analysis for this batch were in the range 100±10% with a RSD of <5%, had been achieved.  Therefore 
it can be concluded that a blend time of 10 minutes without magnesium stearate followed by blending 
for a further 3 minutes with magnesium stearate are appropriate blending times to produce uniform 
ODT of SC. 
4.3.4 Content Uniformity 
The use of weight as an indicator of the uniformity of dose is not appropriate for tablets, unless the 
expected dose to be delivered is high and the API forms a large proportion of the tablets. For tablets in 
which low  doses of drug are included, low variations  in weight do not guarantee uniformity of 
content, whereas large weight variations are likely to preclude content uniformity being achieved 
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(160). It is therefore necessary to assay a small number of dose units from each batch to ensure that 
the correct dose is present in each of those units. 
The content uniformity limit set by the USP are of 85-115% (197) and the results of content 
uniformity testing are summarized in Table 4.6. 
Tale 4.6 Content uniformity results 
Batch Expected 
Content (mg) 
Actual 
Content (mg) 
Content % %RSD 
SC 004 3 2.75±0.48 91.78 5.09 
SC 005 3 2.91±0.50 96.91 5.84 
SC 006 3 2.92±0.50 97.39 5.74 
SC 007 3 2.76±0.50 92.06 4.70 
 
The data reveal that despite changes in the amount of mannitol and disintegrants used in the 
formulation a blend time of 13 minutes was sufficient to produce tablets that were uniform in content 
and that falls within the USP limits set for that parameter. It can therefore be concluded that the 
method of manufacture is suitable to produce SC tablets formulated and manufactured using the 
proposed method. 
4.4 CONCLUSIONS 
An ODT containing SC has been successfully developed and manufactured using the direct 
compression approach. The tablets have acceptable mechanical strength attributes while at the same 
time disintegrate rapidly which is acceptable for these types of dosage form. The use of three 
superdisintegrants in combination in the formulation resulted in tablet disintegration occurring in 
approximately 8 seconds.  
Direct compression was successfully used to manufacture an ODT formulation of SC. The use of 
direct compression is a convenient method of manufacture as the approach facilitates shortened 
manufacturing times whilst making use of commonly available equipment and excipients. 
Mannitol was selected as an appropriate filler as it has a similar particle size to SC and the other 
excipients that were used to manufacture the SC ODT. The similar particle size decreases the chance 
of particle segregation during blending and manufacture as witnessed when fructose was used as a 
diluent. The minimization of segregation resulted in the manufacture of tablets of suitable content 
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uniformity and the batch fell within the specification for the dose limits that had been set for this 
parameter  
A blending time of 13 minutes was established as suitable to produce a blend and tablets that met the 
USP acceptance criteria with each blend sample containing 100±10% with an associated % RSD <  
5%. All tablets that were manufactured met the specification limits for friability and mechanical 
strength and would be able to withstand transport and handling and yet exhibited desirable and fast 
disintegration times. 
Extemporaneous preparations, although not always the safest way to administer medications to 
paediatric patients are often the only option available to a pharmacist who has to initiate therapy in 
marginalized patient populations. Research efforts have now turned to producing orodispersible 
tablets to offer pharmacists a safe and effective alternative to using extemporaneous preparations. 
Extensive research is however required with regard to developing and manufacturing these 
formulations as they are not without their own challenges in considering excipient selection and 
stability attributes. 
The tablets that were produced in these studies form the basis of a new SC containing ODT and the 
current formulation must therefore be further optimized. The tablets produced in this work formed the 
basis of a new SC containing ODT and the formula was further optimized as described in Chapter 5. 
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CHAPTER FIVE 
THE APPLICATION OF RESPONSE SURFACE METHODOLOGY IN THE 
OPTIMIZATION OF A SILDENAFIL CITRATE ORODISPERSIBLE FORMULATION   
AND QUALITY CONTROL TESTING OF THE TABLETS 
 
5.1 INTRODUCTION 
For many years formulations have been developed by scientists using the knowledge gained from 
previous production experience. This approach is generally appropriate for the development of 
formulations that do not have critical challenges such as inclusion of poor solubility compounds, high 
or low doses into a dosage form or that require a product to have exact physical-chemical properties 
for effective performance using a specific route of administration. Consequently at times, adequate 
formulations only, are developed as the selection of appropriate controllable variables can be 
complicated by the presence of competing objectives. It is therefore important to have a clear 
understanding of controllable (independent) variables and performance (dependent) variables when 
attempting to develop a successful dosage form (198). 
An efficient and effective method for obtaining the required information that is needed to clearly 
understand the relationship between input variables and outcomes is the use and application of 
statistical principles. The use of a statistical design approach allows for the efficient application of 
resources and also provides a means of generating a mathematical model that can subsequently be 
used to optimize a formulation or manufacturing process (198; 199).  
The Experimental Design approach is one that affords a researcher the opportunity of setting  up a 
series of experiments to simultaneously evaluate a number of  factors, at a specific number of levels in 
a predetermined number of assessments performed randomly (200).  
Design of Experiments (DOE) is an extremely efficient tool for this purpose, as the outcome provides 
a fixed amount of information that has been generated with considerably less effort than if one were to 
use the traditional “ modification of one variable at a time” approach (199). An important feature of 
the DOE approach is the random order in which experiments are performed, thereby ensuring that 
premature decisions relating to an outcome are not made prior to considering all the evidence 
provided from all the data generated (199). The use of this approach also ensures that a random 
distribution of errors is likely to occur during experimentation.  
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Amongst the many advantages of using an experimental design approach are savings in time, money, 
API and the ability to evaluate interactions between input variables when optimizing a formulation or 
manufacturing process (201). 
5.1.1 Response Surface Methodology 
Response surface methodology (RSM) is an experimental strategy that was developed in the 1950’s 
(202). RSM is comprised of a group of mathematical and statistical techniques that are based on 
fitting  experimental data generated  from studies established using an experimental design, to 
empirical models and that are subsequently used to define a relationship between the responses 
observed and the independent input variables (203; 204).  RSM is able to define the effect of 
independent variables alone and in combination with the manufacturing processes under investigation.  
A typical RSM study begins initially with the definition of a problem to be investigated and involves 
establishing which variables and associated responses are to be studied, monitored, measured and how 
these will be measured. A summary of the subsequent RSM approach  includes (202): 
i. Performance of the relevant DOE.  
ii. Estimation of the coefficient in the relevant response surface equation. 
iii. Checking of the adequacy of the equation to describe the fit. 
iv. Studying the response surface to identify and evaluate the region(s) of interest. 
 
The relationship between a response and an input variable  can be described  by Equation 5.1 (204). 
                                                     
Where,  
y = relevant response 
f = unknown function of a response 
x1, x2,.....xn =  independent variables 
n= number of independent variables 
ε = statistical error that represents other sources of variability not accounted for by f 
 
The term RSM originates from the graphical perspective generated after fitness of the mathematical 
model has been established (203; 204) with a graphical representation of the data presented primarily 
as a three-dimensional (3D) image and/or as contour plots.  
Contour plot can be described as: 
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i. Mound-shaped that has elliptical contours with a stationary point at the position of a 
maximum response. 
ii. Saddle-shaped that has a hyperbolic system of contours with a stationary point that is neither 
a maximum nor minimum point. 
iii. Constant (stationary) ridge response surface in which the contours are presented as concentric 
elongated ellipses with a stationary point in the region of the design region.   
iv. A rising (or falling) ridge response surface with a stationary point that is outside the design 
region (205). 
The stationary point is a combination of design variables where the surface presents as either a 
maximum and/or a minimum in all directions. If the stationary point is a maximum in one direction 
and minimum in another direction, the stationary point is termed a saddle point. When the surface is 
curved in one direction but is fairly constant in another this is considered a ridge response (206). 
By plotting a response, y, against one or two input variables a surface, known as the response surface 
can be generated in two or three dimensions. In general the form of the function,  f, is unknown and 
may be very complicated depending on the effect of the input variables on the response. Therefore 
RSM aims at approximating f by use of a suitable, ordered polynomial equation in some region(s) of 
the values for the independent process variables (207). The mathematical or polynomial equations that 
describe the relationship(s) between the independent and dependent variables may be first, second or 
third order, depending on how the output variables or responses react to changes in the input 
variables. 
If the response is a linear function of the independent variables, then the function can be written as a 
first order model (Equation 5.2). In this model the response variables that fit a linear model are 
generally variables that are significantly affected by a small change in the value of the input factors 
and that exhibit little or no interaction(s) between the input variable terms.  
Second order equations are used to generate linear and quadratic response equations that exhibit 
interactions between the input factors and can be represented by Equation 5.3. 
It has been reported that second order models are also applicable to input factors that exhibit extensive 
variability over an experimental domain and these relationships are best described using Equation 5.4 
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                                                                                                                    Equation 5.2 
                                                                                                      Equation 5.3 
                                                          
           
                            
Where,  
  y= response 
  x1, x2, .......xn = input factors 
  β0 = constant that represents the intercept 
  βi = coefficient of first order term 
  βii = coefficient of second order term 
  βij = coefficient of second order interaction  
 
The values of the coefficients in the model are generated through multiple linear regression analysis 
of the data that has been collected. A coefficient with a positive value points to an agonistic effect of 
the input factor on the response, whereas coefficients with negative values indicate an antagonistic 
effect.  
5.1.1.1 Choice of Response Surface Design  
5.1.1.1.1Central Composite Design (CCD) 
A CCD was originally presented by Box and Wilson and is based on a factorial design with additional 
points to estimate the curvature of that design. CCD encompasses a full factorial or fractional factorial 
approach which can be represented, as shown in Figure 5.1, as the eight corners of a cube.  
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Figure 5.1 Schematic diagram representing the levels studied in a Central Composite Design (203) 
 
There are the six points, known as the axial or star points, located in the centre of each face of the 
cube with a final point located in the middle of the cube that is known as the centre point (203). The 
axial points are experimental runs where all but one of the factors to be investigated are set at the 
intermediate level under consideration. The axial points are all equidistant from the centre point and 
are denoted using the symbol, alpha (α).  The factors under consideration are usually investigated at 
five different levels and are always represented by coded values viz., -α,  -1,  0, +1 and +α. The 
distance of the axial points from the centre point is dependent on the number of factors investigated in 
the design and is established using Equation 5.5. 
                             
 
                                      
Where,  
  k= the factor number 
α = axial point 
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The number of experiments required for a CCD approach is calculated using Equation 5.6 
                                                        
Where,  
N= the experiment number 
k= the factor number  
C0= the replicate number of the central point 
 
The number of experiments required in an experimental study is important as it determines how much 
data will be generated, in addition to being an indicator of the amount of time that will be required to 
conduct the study.  
5.1.1.1.2 Box-Behnken Design (BBD) 
The BBD describes a class of second-order designs based on a three-level incomplete factorial 
approach which are also represented as coded values viz., -1,  0 and  +1 (208). In this design approach, 
the treatment combinations are located at the midpoint(s) of the edge of the process space and at the 
centre, as represented in Figure 5.2. 
 
 
Figure 5.2  Schematic diagram representing the levels studied in a Box-Behnken Design (203). 
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The number of experiments for Box-Behnken Designs can be calculated using Equation 5.7.  
                                                              
Where,  
  N= the number of experiments  
  k= the factor number 
  C0 = the replicate number of the central point 
 
For  experiments in which there are three or less input variables the BBD design offers some 
advantage over the CCD approach, in that a fewer number of experimental runs are required. 
However this advantage does not exist when four or more parameters are to be investigated. A further 
advantage of BBD is that it does not include the need to evaluate situations in which all factors are 
simultaneously held at their highest and lowest levels. The use of a BBD therefore allows a 
formulation scientist to avoid undertaking experiments that are to performed under extreme conditions 
and that may produce substandard results due to the inclusion of data generated from these extreme  
high and low levels (203).  
5.1.1.1.3 Doehlert Design 
The Doehlert design is an experimental design approach in which different factors can be studied at 
different levels simultaneously (209). This aspect of the Doehlert design is an important characteristic 
when using some input variables that may be subject to restrictions such as for example cost or 
experimental constraints (limited amounts of raw material or limited amount of time available) 
thereby making it a practical and economic alternative to other, second-order experimental design 
approaches (203). This design describes a circular domain of two input variables, a spherical domain 
for three input variables and a hyper-spherical space for situations in which more than three input 
variables are to be investigated and which highlights the uniformity of the input variables to be 
studied in the experimental domain (203).  
The schematic design space of a Doehlert design for two variables is shown in Figure 5.3 , and is 
represented by a central point and six points of a regular hexagon.  
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Figure 5.3 Doehlert design for the optimization of two variables with some possibilities for the displacement of 
the initial design, using previous points (203) 
An interesting feature of the Doehlert design is that new factors may be introduced during the course 
of a study without losing relevant and/or valuable information from the data already generated from 
the experimental runs that have already been completed.  
The number of experiments required for a Doehlert design is determined using Equation 5.8 (203). 
                                                                               
 Where,  
  N= the number of experiments 
  k= the factor number 
  Co= the replicate number of the central point 
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5.1.1.1.4 Choice of Experimental Design 
An evaluation of the main effects and interactions of the input and response (output) variables was 
performed using CCD statistical screening design and is summarized in Tables 5.1 and 5.2, 
respectively. 
Table 5.1 Summary of the factors evaluated, the actual amounts used and corresponding coded values  
Independent Variables Levels Used, Actual (Coded) 
Very Low  
(-2) 
Low  
(-1) 
Medium  
(0) 
High  
(+1) 
Very High  
(+2) 
x1=CMS (%, w/w) 6.80 7.65 8.5 9.35 10.2 
x2=CRP (%,w/w) 10.80 12.15 13.5 14.85 16.2 
x3=SSG (%, w/w) 6.40 7.20 8.00 8.80 9.60 
x4 = Blending Time 
(min) 
7 10 13 16 19 
 
Table 5.2 Summary of the Dependent variables monitored and the constraints set for these variables 
Dependent Variables Constraints 
y1= Disintegration time (Dt) Minimal 
y2= Wetting Time Minimal 
y3= Assay of content 90<y3<110 
 
The tablet formulation developed in Chapter 4, Batch SC 007, was used as a basis for optimization. 
As discussed in §4.3.2 it was shown that as the concentration of the disintegrant increases, there was a 
decrease in both disintegration and wetting times. As ODT need to disintegrate as rapidly as possible  
the concentration of tablet disintegrant(s) in a formulation is an important independent factor and each 
of the three concentrations of superdisintegrant were selected as independent factors to be evaluated 
for their ability to shorten the Dt. The fourth independent variable to be evaluated was the blending 
time of the powder mix in the manufacturing process. This variable is important, as the blending time 
is crucial for the successful manufacture of high quality, low dose solid oral products.  
The three dependent variables monitored were Dt, wetting time and API content. Wetting time and 
content assay were  selected as they are indicative of the rate of disintegration and the suitability of 
the blending time, respectively.  
A CCD design was selected as it has the advantage that it requires five levels for each factor to be 
evaluated, resulting in a better estimation of the responses that are monitored and achieved. The use of 
the Box-Behnken design for example, results in experiments being conducted at three levels only and 
therefore a greater level of uncertainty exists in the data that are generated.  
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5.1.1.2 Mathematical Optimization 
Optimization is a mathematical method used to determine an optimum response and is defined as the 
most advantageous state of existence of the system under investigation (199). Multiple linear 
regression equations generated from statistically designed experiments provide a description of the 
change of a response with a change in input factors and further, allows for the determination of input 
variables that will produce an optimized response. 
A difficulty that occurs in optimization procedures, is the need to establish a compromise between the 
anticipated response variables. This challenge is often encountered in the process of optimization of 
tablets where the optimum tablet may be one that has superior strength and little or no friability, yet 
must also have a short disintegration time. Often an increase in tablet hardness results in an increase 
in the disintegration time of a tablet and therefore a compromise between these contradictory response 
variables is necessary to achieve an optimized formulation.  
5.1.1.3 Advantages of RSM 
The primary advantage of  RSM in relation to classical experimental methods and approaches of data 
evaluation in which only one variable is investigated at a time, is that a large amount of information 
can be generated from a relatively small number of experiments (204).  RSM is therefore less time 
and cost consuming than the classical approach that requires a large number of experiments to be 
conducted to be able to explain the behaviour of a system (204; 205).    
A further advantage, with the use of RSM is that  it is possible to observe interaction effects of the 
independent input parameters on the response(s) being monitored (204). The model equation that is 
generated from the data is able to be used to explain the effect of combinations of independent input 
variables on the outcome of a process or product.  
5.1.1.4 Disadvantages of RSM  
A primary disadvantage of RSM is that fitting data to a second order polynomial for systems that 
contain some curvature is often not well accommodated by the second order polynomials that are 
produced. If the system cannot be explained by a first or second order polynomial, it may be 
necessary to reduce the range of independent input variables under consideration as this may then 
increase the accuracy of the model being considered (204).  
Another disadvantage is that although RSM has the potential to evaluate interaction effects of the 
independent input  parameters, it is unable to be used to explain why an interaction(s) has occurred 
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(210). A further disadvantage is that RSM is poor at predicting the potential outcomes for a system 
operated outside the range of study under consideration (210). 
5.1.2 Quality Control Testing 
5.1.2.1 In vitro drug release testing 
Drug absorption from a solid dosage form following  oral administration is dependent  on the release 
of the API from that dosage form, subsequent dissolution and/or solubilisation of the API under 
physiological conditions and also the permeability of the API through the gastrointestinal tract 
membranes (GIT) (211). Since these steps are of significant importance for effective drug delivery, in 
vitro dissolution testing is highly relevant to the prediction of the potential in vivo performance of  
dosage forms.  
Dissolution testing is a quality control technique that is used to assess drug release profiles from  
pharmaceutical dosage forms. Dissolution  testing  is considered important as  drug release from a 
dosage form is essential in order to produce a therapeutic effect. An API  must be released from the 
dosage form and  dissolve in the gastrointestinal tract (GIT) fluids  prior to absorption (212). 
Consequently dissolution testing may be considered an  indicator of the  potential for drug release 
from a solid dosage form. 
Drug dissolution is crucial to ensure that there is batch to batch consistency within a manufacturing 
process.  
5.1.2.2 Theory of Dissolution  
The dissolution of a solid into a liquid can be separated into two distinct  stages (213).  Initially an 
interfacial reaction results in the release of solute molecules from a solid phase and involves a phase 
change that permits molecules of the solid to become molecules of a solute in that solvent. The 
solution in contact with the solid is saturated since it is in direct contact with the solid in that liquid. 
Subsequently the molecules of the solute migrate through the boundary layers surrounding that solute, 
via a passive diffusion process, to the bulk of the solution. The transport of the molecules away from 
the solid-liquid interface into the bulk of the liquid follows a process that is described by the Noyes-
Whitney relationship. The Noyes-Whitney equation is discussed in §5.1.2.2, vide infra. . 
As is the case with any reaction that involves more than one step, the overall rate of reaction is 
determined by the rate of the slowest step of that process. In the case of dissolution testing the 
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interfacial step  is instantaneous and therefore the diffusion of a dissolved solute across the static 
boundary is the rate determining step in dissolution of solid into a liquid.  
A diagram depicting the boundary layers and change in concentration surrounding a dissolving 
particle is shown in Figure 5.4 
 
Where,  
C= the concentration of the solute in the bulk liquid  
  Cs= the concentration of solute in the saturated solution 
 
Figure 5.4 The stages of dissolution (213) 
5.1.2.3 Factors affecting API dissolution 
Sold drugs need to dissolve prior to absorption. The dissolution of a solid or API can be described by 
the Noyes-Whitney equation (Equation 5.9) (214), which describes the dissolution of spherical 
particles, when the dissolution process is diffusion controlled and involves no chemical reaction to 
facilitate the process of dissolution. 
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Where,  
 
  
  
= rate of dissolution of drug particles 
D= diffusion coefficient of the drug in solution in the gastrointestinal fluids 
A = the effective surface area of the drug particles in contact with the gastrointestinal fluids 
h= the thickness of the diffusion layer around each particle 
Cs= the saturation solubility of the drug in solution in the stagnant or diffusion layer 
C= the concentration of the drug in the gastrointestinal fluids 
 
Consequently the physicochemical properties of an API are an important factor when considering the 
dissolution of that material. The dissolution medium is usually an aqueous based fluid that may 
include  a buffer or in rare cases, purified water. Therefore the aqueous  solubility of an API is a 
critical determinant in the rate of solution of the raw material. Additional  factors that can impact the 
rate of solution of a molecule include the  particle size and crystalline state of the API (215). 
Furthermore several key properties of a pharmaceutical product, including dosage form type, expected 
potency, desired mechanism of release and the excipients used  in the dosage form are also important 
factors to consider when selecting a dissolution test method. For example, USP Apparatus I or the 
basket method is known to be prone to gelatin build-up if the baskets are not cleaned properly 
following each test (216). 
When developing an appropriate dissolution test procedure the impact of test parameters that may 
affect the dissolution rate must also be evaluated. The degree of agitation of the dissolution method is 
one of the important factors that affect the dissolution of an API (217). To ensure the elimination of 
variability in the rate of drug release from a delivery technology,  it is important that factors such as 
temperature, pH, in addition to  the nature, composition and volume of dissolution medium to be used 
are adequately controlled (215). By way of example,  a change is in test method parameters that may 
impact dissolution rates include changes in temperature that may result in release of dissolved gas, 
and the resultant  bubbles may adversely impact dissolution rate measurements (215). 
In addition the dissolution test apparatus may also have an impact on the release of an API from a 
dosage form. To ensure that the release of a drug is accurately assessed, the dissolution apparatus 
needs to be appropriately calibrated and used in accordance with the relevant specifications. 
Specifically, vibration and wobble of the Apparatus must be eliminated so that the flow patterns of the 
dissolution medium remain  consistent from test procedure  to test procedure (215).  A summary of 
the most significant factors that can affect drug dissolution rates are summarized in Table 5.3. 
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Table 5.3 Summary of the factors affecting API dissolution 
Factor Physicochemical parameter Physiological parameter 
Surface area of drug Particle size, wettabilty Surfactants in GIT  fluids 
Solubility in diffusion layer Hydrophilicity, crystal 
structure, solubilization 
pH, buffer capacity, bile, food 
composition 
Amount of drug already 
dissolved 
 Permeability, transit 
Diffusivity of drug Molecular size Viscosity of luminal contents 
Boundary layer thickness  Motility patterns and flow rate 
Volume of solvent available  GIT secretions, co-administered 
fluids 
 
5.1.2.4 Dissolution Test Apparatus 
The major components of dissolution testing equipment include  a heated water bath, paddles or 
baskets and shafts, vessels, sampling and analytical test procedures and equipment  (216). 
The official compendia viz., BP and USP list several official apparatus for dissolution testing in 
addition to providing other relevant information relating to the conduct of these tests. The official 
methods listed in both compendia include Apparatus 1 or  rotating basket, Apparatus 2 or  paddle 
apparatus, Apparatus 3 or  reciprocating cylinder, Apparatus 4 or flow-through cell, Apparatus 5 or  
Paddle over disk, Apparatus 6 or rotating cylinder and Apparatus 7 or  reciprocating holder methods 
(216).  
USP Apparatus 1 and USP Apparatus 2 are the most commonly used dissolution apparatus despite the 
fact that sources of error can be introduced,  if procedures for testing are not closely inspected prior to 
and monitored during use. The paddles for USP Apparatus 2 may be coated with Teflon in certain 
methods and if the material peels from the surface of the paddle and is shed, it could result in the 
disturbance of the fluid dynamics in the dissolution vessel. The hydrodynamics of a test system can 
also be disturbed when using paddles that have  rusted or that have dents present on their surface  and  
can lead to contamination of the test medium if they are not cleaned between test procedures (216). It 
is therefore important to ensure that the paddles are cleaned correctly after each experimental run. The 
basket or USP Apparatus 1 method is also not without some challenges as the baskets can become 
frayed and misshaped following  excessive use leading  to a change in the mesh size which ultimately 
may affect the dynamics of the test system(216).  
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5.2 EXPERIMENTAL 
5.2.1 Materials and Equipment 
All materials and equipment that were used for the studies conducted and reported in this chapter are 
listed in §4.41 and 4.4.2, respectively, vide infra.  
5.2.2 Statistical analysis of data 
The significance of the model(s) that were elucidated in these studies was analysed using Analysis of 
Variance (ANOVA) type three (partial sum of squares) studies at a 5% level of significance. Design 
Expert® (Stat-Ease Inc., Minneapolis, Minnesota, United States of America) statistical design 
computer software was used to analyse the data that was generated. The predicted residual error sum 
of squares (PRESS) was used to assess which of the input factors had a significant impact on the 
response(s) under investigation.  
5.2.3 Physical properties of tablets 
The tablets were subject to dissolution, assay, disintegration, friability, crushing strength, tensile 
strength, wetting, in vitro dispersion, thickness, diameter and weight testing. These procedures were 
performed as described in §4.2.4. 
5.2.4 In vitro release testing 
In vitro release studies of SC ODT tablets was performed using USP Apparatus 2 (Hanson Research 
SR 8 PLUS , California, United States of America) fitted with an Autoplus™ Multifill™ and 
Maximizer Syringe Fraction Collector. Six tablets were dropped into the dissolution vessels, each 
containing 900ml of vacuum degassed 0.05M Phosphate buffer (pH 6.8).  The buffer was prepared as 
described in § 4.2.4.2.8.1. 
The paddles were set to rotate at 75rpm, despite the fact that a speed of 50rpm is recommended for 
dissolution testing of ODT, and slower paddle speeds may be used to generate dissolution profiles that 
may be compared due to appropriate discrimination of the resultant dissolution profiles generated 
using the method. However a speed of 50rpm resulted in the formation of a mound of particles at the 
base of the dissolution vessel and therefore accurate sampling may not have been possible. USP 
Apparatus 1 may have certain application for ODT testing for in vitro studies but is not commonly 
used due to the physical properties of the tablets under investigation. Tablet fragments from the 
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disintegrated tablet, for example, may become trapped on the inside and at the top of the basket near 
the spindle where little effective stirring occurs,  thereby reducing the reliability of the test method, 
with the result that variable and poorly reproducible results may be generated (218). 
The temperature of the dissolution medium  was maintained at 37±0.5°C for all studies and 5ml 
aliquots of the dissolution fluid was  collected for analysis at 5, 10 and 15 minutes following the 
commencement of the test. An equal volume of medium was replaced after each sample had been 
collected. A 3ml aliquot of each sample was harvested  using an electronic pipette (Boeckel & Co. 
GmbH, Hamburg, Germany) and transferred into a 5ml A-grade volumetric flask followed by the 
addition of 6µl of IS solution that had been prepared as previously described in §2.3.2.3, for HPLC 
analysis. The resultant solution was made up to volume using an ACN: water solution in a ratio of 
55:45 that had been filtered through a 0.22µm Acrodisc® PSF syringe filter (Pall Corporation, Port 
Washington, New York, United States of America) prior to analysis. Sample content was 
quantitatively determined using the validated HPLC method that has been described in Chapter Two, 
vide infra. 
5.2.5 Experimental Design 
The mathematical relationship between the input and response variables was generated using Design 
Expert® 8.0.4 software (Stat-Ease Inc, Minneapolis, Minnesota, United States of America). The 
independent variables were studied at five levels viz. very high, high, medium, low and very low. In 
these studies, in respect of the amount of superdisintegrant used in the formulation, the medium point 
was considered the amount of the excipient(s) used to manufacture Batch SC 007, an ODT technology 
manufactured as described in Chapter Four.  
The coded and actual values generated using CCD design of experiments for the experimental 
formulations is summarized in Table 5.4 
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Table 5.4 Coded and actual values of independent variables generated using a CCD design  
Batch 
No. 
   Independent Variables  
 x1 x2 x3 x4 
 Coded Actual Coded Actual Coded Actual Coded Actual* 
SC 008 0 8.5 0 13.5 0 8 2 16+3 
SC 009 1 9.35 -1 12.15 -1 7.2 1 13+3 
SC 010 1 9.35 1 14.85 1 8.8 -1 7+3 
SC 011 -1 7.65 1 14.85 1 8.8 -1 7+3 
SC 012 -1 7.65 -1 12.15 1 8.8 -1 7+3 
SC 013 -1 7.65 1 14.85 -1 7.2 -1 7+3 
SC 014 0 8.5 -2 10.8 0 8 0 10+3 
SC 015 0 8.5 0 13.5 0 8 0 10+3 
SC 016 0 8.5 0 13.5 0 8 0 10+3 
SC 017 -1 7.65 -1 12.15 1 8.8 1 13+3 
SC 018 -2 6.8 0 13.5 0 8 0 10+3 
SC 019 2 10.2 0 13.5 0 8 0 10+3 
SC 020 0 8.5 0 13.5 0 8 -2 4+3 
SC 021 0 8.5 0 13.5 0 8 0 10+3 
SC 022 -1 7.65 1 14.85 1 8.8 1 13+3 
SC 023 1 9.35 -1 12.15 1 8.8 -1 7+3 
SC 024 0 8.5 0 13.5 0 8 0 10+3 
SC 025 0 8.5 2 16.2 0 8 0 10+3 
SC 026 0 8.5 0 13.5 0 8 0 10+3 
SC 027 1 9.35 -1 12.15 1 8.8 1 13+3 
SC 028 1 9.35 -1 12.15 -1 7.2 -1 7+3 
SC 029 -1 7.65 -1 12.15 -1 7.2 1 13+3 
SC 030 0 8.5 0 13.5 -2 6.4 0 10+3 
SC 031 1 9.35 1 14.85 -1 7.2 1 13+3 
SC 032 0 8.5 0 13.5 0 8 0 10+3 
SC 033 -1 7.65 1 14.85 -1 7.2 1 13+3 
SC 034 0 8.5 0 13.5 2 9.6 0 10+3 
SC035 -1 7.65 -1 12.15 -1 7.2 -1 7+3 
SC 036 1 9.35 1 14.85 -1 7.2 -1 7+3 
SC 037 1 9.35 1 14.85 1 8.8 1 13+3 
 
*As discussed in Chapter 4, the blending of powders was separated into two different segments. The 
first segment involved blending all excipients excluding magnesium stearate and the second segment 
where the powders were blended for a further 3 minutes followed the addition of  magnesium stearate.  
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5.3 RESULTS AND DISCUSSION  
5.3.1 Physical characteristics of powder blend 
A summary of the physical characteristics of the powder blends that were manufactured using a CCD 
are summarized in Table5.5. The results indicate that all powder blends had a CI < 24 and a HR < 1.3 
indicating that the flow properties of all powder blends, was satisfactory. These results were 
confirmed by angle of repose measurements with all values for this parameter being established as < 
30°. From these results it can be concluded that the flow properties of the blends are adequate to 
assume that flow of powder blends from the feed hopper on the press, into the die cavity should result 
in the production of tablets of uniform weight.  
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Table 5.5 Physical properties of the powder blends manufactured according to a CCD approach 
Formulation Bulk Density(g/ml) Tapped Density(g/ml) CI HR Angle of Repose 
SC 008 0.50 0.65 21.95 1.28 29.74 
SC 009 0.54 0.70 22.50 1.29 29.74 
SC 010 0.52 0.67 21.43 1.27 26.57 
SC 011 0.50 0.63 20.00 1.25 23.20 
SC 012 0.51 0.64 21.43 1.27 21.04 
SC 013 0.51 0.65 22.50 1.29 23.20 
SC 014 0.54 0.68 20.51 1.26 28.30 
SC 015 0.50 0.63 21.43 1.27 21.80 
SC 016 0.52 0.65 18.92 1.23 23.20 
SC 017 0.48 0.59 19.05 1.24 24.78 
SC 018 0.50 0.64 21.95 1.28 26.57 
SC 019 0.50 0.64 21.95 1.28 26.57 
SC 020 0.53 0.67 21.05 1.27 26.57 
SC 021 0.52 0.67 21.43 1.27 26.57 
SC 022 0.48 0.62 22.50 1.29 30.65 
SC 023 0.50 0.64 21.95 1.28 26.57 
SC 024 0.51 0.65 21.05 1.27 24.78 
SC 025 0.50 0.65 22.50 1.29 26.57 
SC 026 0.52 0.65 19.51 1.24 29.74 
SC 027 0.52 0.65 19.51 1.24 27.41 
SC 028 0.49 0.65 23.81 1.31 23.20 
SC 029 0.53 0.69 22.50 1.29 24.78 
SC 030 0.51 0.63 19.05 1.24 29.74 
SC 031 0.49 0.63 21.43 1.27 28.30 
SC 032 0.51 0.65 21.95 1.28 26.57 
SC 033 0.53 0.67 21.05 1.27 28.30 
SC 034 0.55 0.69 20.51 1.26 28.30 
SC 035 0.49 0.62 20.00 1.25 28.30 
SC 036 0.53 0.67 21.05 1.27 29.74 
SC 037 0.54 0.69 21.43 1.27 24.78 
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5.3.2 Physical characteristics of tablets 
A summary of the results following an evaluation of the physical characteristics of the tablets 
produced is listed in Table 5.6.  All tablets that were produced were white in colour and had a smooth 
feel on the surface indicating that no picking or sticking had occurred.  
The crushing strength of the tablets was similar for all batches and the variability of the disintegration 
times was minimal. All batches passed the weight variation test with % RSD values  < 7.5% for all 
batches, further indicating that the powder blends exhibited good flow properties. 
All tablets met the compendial standards for friability with values of < 1% reported (219). The 
successful development of a solid oral dosage form requires that the resultant tablets have a low 
crushing strength to facilitate rapid disintegration, whilst still demonstrating a friability of < 1%.  
The in vitro dispersion and wetting times of the tablets infer that a rapid disintegration time for these 
tablets is possible and this was confirmed when evaluating the results of disintegration testing with a 
maximum time of 11s recorded for all batches.  
The high water absorption ratios that are reported are a consequence of the large amount of 
disintegrants that were included in the formulation to facilitate the rapid disintegration of the tablets 
that had been manufactured.  
Content uniformity testing of each of the batches of tablets were carried out to establish content 
uniformity of the manufactured batches. The analysis was performed as described in §4.2.6. It was 
noted that formulation SC 020 exhibited poor content uniformity that was evident by the low assay 
value and high standard deviation of the result. It was thought that the result may be due to a short 
blending time of that particular formulation however this relationship could only be confirmed with 
the use of CCD. 
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Table 5.6 Physical Characteristics of Tablets 
Batch 
No. 
Weight 
(n=10) mg 
Thickness 
(n=10) mm 
Diameter 
(n=10) 
mm 
Crushing 
Strength 
(n=10) N 
Tensile 
Strength 
MPa 
Friability 
(%) 
Dt 
(s) 
Wetting 
Time (s) 
Water 
Absorption 
Ratio 
In Vitro 
Dispersion 
Time (s) 
Assay (n=3) 
% 
SC 008 159.54±1.60 2.89±0.07 7.33±0.02 18.37±1.32 0.55 0.65 8 4.29±0.02 151.62±9.24 35.92±0.17 98.65±4.40 
SC 009 156.67±7.07 2.85±0.14 7.32±0.03 18.17±2.49 0.55 0.61 8 4.29±0.06 121.98±10.42 36.68±0.69 92.81±4.44 
SC 010 154.44±8.81 2.90±0.10 7.33±0.02 20.41±3.40 0.61 0.59 8 3.89±0.19 141.17±6.83 26.76±0.32 86.67±4.41 
SC 011 153.75±7.44 3.00±0.00 7.33±0.02 19.77±2.13 0.57 0.64 11 4.46±0.23 145.67±10.98 38.60±0.60 101.47±1.22 
SC 012 154.07±10.73 2.85±0.15 7.30±0.01 19.98±3.66 0.61 0.62 8 4.79±0.18 140.98±8.79 35.79±0.46 92.09±3.70 
SC 013 145.83±6.69 2.85±0.04 7.32±0.01 17.69±1.94 0.54 0.69 5 4.44±0.23 120.45±14.51 39.54±0.56 82.05±4.97 
SC 014 151.43±9.00 2.86±0.04 7.33±0.00 18.55±2.61 0.56 0.69 8 4.38±0.15 115.09±14.32 36.64±0.55 95.63±3.87 
SC 015 158.77±3.50 2.79±0.10 7.32±0.01 18.51±1.76 0.58 0.98 8 4.26±0.24 145.84±19.52 35.41±1.20 96.76±2.89 
SC 016 149.03±7.38 2.64±0.17 7.31±0.02 18.98±1.90 0.63 0.64 7 4.32±0.16 146.61±6.65 35.89±0.17 96.16±3.04 
SC 017 154.74±5.13 2.86±0.02 7.25±0.02 18.81±3.25 0.58 0.65 9 4.64±0.17 128.78±6.70 36.67±0.14 103.89±1.78 
SC 018 151.25±8.34 2.83±0.10 7.32±0.02 19.88±1.98 0.61 0.64 8 4.58±0.29 117.19±9.19 37.68±0.45 96.41±3.25 
SC 019 154.30±4.89 2.72±0.16 7.33±0.02 17.41±2.79 0.56 0.65 6 4.55±0.26 129.31±10.84 36.45±0.17 97.88±2.87 
SC 020 150.13±7.39 2.67±0.19 7.31±0.01 20.18±3.70 0.66 0.66 7 4.25±0.26 139.93±5.51 36.23±0.20 75.11±8.66 
SC 021 158.28±5.03 2.75±0.11 7.33±0.01 17.13±1.37 0.54 0.67 6 4.31±0.10 146.63±7.88 35.98±.0.67 98.42±2.63 
SC 022 153.65±7.12 2.79±0.16 7.32±0.01 19.46±2.11 0.61 0.67 7 4.15±0.08 149.89±5.67 36.12±0.18 97.54±2.69 
SC 023 156.60±6.75 2.79±0.13 7.29±0.03 17.90±4.54 0.56 0.54 8 4.37±0.23 146.22±13.42 35.42±0.21 114.98±6.03 
SC 024 149.72±7.46 2.79±0.17 7.32±0.02 19.33±2.29 0.60 0.74 7 4.32±0.20 143.48±16.44 35.78±0.17 98.63±3.87 
SC 025 155.76±4.23 2.74±0.07 7.32±0.02 18.09±2.74 0.57 0.61 7 4.26±0.14 161.61±9.17 35.69±0.23 96.51±4.03 
SC 026 154.92±8.45 2.80±0.16 7.32±0.01 19.34±2.56 0.60 0.63 10 4.29±0.12 143.77±10.90 35.90±0.15 98.91±4.59 
SC 027 152.06±7.04 2.60±0.15 7.27±0.01 24.71±1.93 0.83 0.74 8 4.42±0.09 139.91±16.71 35.79±0.19 99.03±3.56 
SC 028 156.69±6.99 2.80±0.22 7.31±0.02 17.46±2.48 0.54 0.82 9 4.30±0.24 142.45±6.55 35.92±0.18 88.37±5.01 
SC 029 147.92±5.49 2.78±0.18 7.31±0.03 16.88±4.17 0.53 0.65 9 4.44±0.22 112.54±13.48 36.20±0.23 96.23±4.12 
SC 030 148.05±7.23 2.72±0.17 7.30±0.04 19.96±2.51 0.64 0.65 8 4.42±0.15 132.47±8.99 35.32±0.22 96.21±3.89 
SC 031 152.41±8.23 2.79±0.07 7.31±0.02 19.64±3.05 0.61 0.74 8 4.32±0.16 154.61±13.45 35.34±0.40 98.45±2.98 
SC 032 152.30±5.66 2.82±0.15 7.31±0.01 18.76±2.34 0.58 0.65 8 4.30±0.17 141.54±7.84 35.81±0.12 99.13±2.46 
SC 033 150.26±7.19 2.64±0.17 7.31±0.02 18.98±1.90 0.63 0.63 10 4.49±0.16 161.71±11.23 35.40±0.96 97.44±1.99 
SC 034 152.12±10.91 2.79±0.15 7.30±0.01 18.45±3.74 0.58 0.63 8 4.55±0.22 114.12±12.85 35.76±0.32 96.72±3.70 
SC 035 149.83±7.33 2.68±0.28 7.30±0.01 18.86±3.26 0.61 0.65 9 4.42±0.23 121.68±17.46 36.62±0.13 89.90±4.81 
SC 036 155.71±6.73 2.77±0.22 7.31±0.01 19.48±3.34 0.61 0.62 8 4.49±0.19 152.90±14.08 34.85±1.6 90.01±2.56 
SC 037 156.20±7.19 2.78±0.23 7.31±0.02 20.75±3.79 0.65 0.66 8 4.05±0.09 160.01±15.34 36.68±0.69 99.82±4.01 
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5.3.3 Response Surface Modelling 
5.3.3.1 Disintegration time (Dt) 
As the purpose of these studies was to develop an ODT, the impact of the Dt of the tablets was 
investigated using RSM to establish which of the input variables may have had a significant impact on 
the performance of the dosage forms. 
The data was analysed to determine the significance of the models that were produced. However it 
was discovered that the resultant model was not significant when fitted to a quadratic model and 
therefore this approach was not suitable to navigate the intended design space. Therefore the model 
was reduced to a linear form and the linear model was also not significant indicating that the data did 
not fit the model.  
A possible reason for the lack of fit to both models is that the critical concentration of the 
disintegrants had been reached in the formulation and no further increase in the amount of any of the 
superdisintegrants used would have had a noticeable effect on the Dt of the tablets.  
The critical concentration of disintegrants plays an important role in the disintegration time of an 
ODT and use of amounts of material below this concentration usually results in disintegration times 
that are inversely proportional to the disintegrant concentration, whereas higher  concentrations result 
in approximately constant or increased disintegration times (158; 170).   
5.3.3.2 Wetting Time 
The wetting time for SC ODT tablets was best described by the use of a quadratic model. The 
polynomial model used to investigate the relationship between the input factors and the wetting time 
is summarized in Equation 5.10. 
                                                                 
                                  
                   
   
              
            
                  
          
               
Where,  
y= Response 
x1 = amount of CMS  
x2 = amount of CRP  
x3 = amount of SSG  
x4 = Blending time 
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RSM analysis reveals that the concentration of CMS and CRP in the formulation had a significant 
effect on the wetting time of the tablets and the amount of SSG and the blending time did not play a 
significant role in the performance of the dosage form. These results indicated that the addition of 
CMS and CRP at higher levels significantly decreases the wetting time of the formulation and may 
perhaps decrease the Dt slightly.  
As can be seen in the Figure 5.5 (I) the contour graph displays a ‘rising ridge’ shape and both Figure 
5.5 (I) and (II) reveal that  an increase in the amount of CMS and CRP results in a decrease in the 
wetting time of the tablets as an increase in the disintegrant concentration in the formulation leads to 
an increase in the porosity of the dosage form, thereby facilitating the uptake of water. 
        
Figure 5.5 Contour plot (I) and 3D representation (II) of the interaction of CMS and CRP on the wetting time of 
SC ODT   
As discussed in Chapter Four, CRP and CMS facilitate tablet disintegration via different mechanisms. 
CMS disintegrates via a swelling process whereas CRP causes tablets to disintegrate by a process of 
wicking as liquid is drawn through porous pathways in the core resulting in disruption of inter-
particulate bonds and tablet break up. These differences in mechanism of disintegration may result in 
a synergistic relationship in the ODT where the combination of the disintegrants results in a more 
significant decrease in the wetting time of the tablets, than if only one disintegrant were used.  
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Figure 5.6 Contour plot (I) and 3D representation (II) of the effect of CMS and SSG on the wetting time of SC 
ODT 
SSG did not play a significant role in the wetting time of the SC ODT. As shown in Figure 5.6  low 
levels of SSG result in a wetting time that is maximized and as higher levels of SSG are reached the 
wetting time increases which is most likely due to the swelling effect of SSG when used in 
concentrations over 8% w/w in formulations. It has been observed that SSG can have a detrimental 
effect on the wetting and disintegration times of  tablets  since it is able to form  a viscous gel layer 
that is a barrier to the penetration of a dissolution medium (220). 
As depicted in the contour (Figure 5.7 (I)) and 3D representation plots (Figure 5.7 (II)) blending time 
does not appear to play a significant role in the wetting time of the dosage forms. As blending times 
increase the wetting time of the tablet does not appear to change significantly. However the use of 
CRP does affect the wetting time of the tablets and as the amount of CRP in the formulation increases 
there is a decrease in the wetting time of the tablets. This can be clearly observed in the 3D plot where 
there is a steep decline in the surface plot as the amount of CRP increases in the formulation . In 
contrast the plot remains straight when the blending times are change indicating that this parameter 
has little effect on wetting times.  
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Figure 5.7 Contour plot (I) and 3D representation (II) of the effect of CRP and blending time on the wetting 
time of SC ODT 
Similarly increasing the amount of CMS results in a decrease in the wetting time of the SC ODT and 
blending time has little impact on this performance characteristic (Figure 5.8). 
 
 
Figure 5.8 Contour plot (I) and 3D representation (II) of the effect of CMS and blending time on the wetting 
time of SC ODT 
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5.3.3.3 Content Uniformity 
Following RSM analysis it was found that there was a linear relationship between the API content and 
the blending time and the concentration of any of the disintegrants had an effect on the uniformity of 
content. This relationship between blending time and content uniformity is summarized as Equation 
5.11. 
y=95.7 +0.52A 0.92B+2.55C+ .61D                     
 where,  
  A= Amount of CMS 
  B = Amount of CRP 
  C = Amount  of SSG 
  D = Blending time 
 
The uniform distribution of each of the components of a powder mixture is essential to ensure  that 
there is a uniform subdivision of the individual components of that mixture (173). The uniform 
distribution of the individual components is also critical for the excipients used to produce or 
manufacture a dosage form with the appropriate performance characteristics. For example the non-
uniform distribution of magnesium stearate can lead to over lubrication and potential dissolution rate 
and processability issues (176). 
The data depicted in Figure 5.9 indicate that there is a direct correlation between the blending time 
and the content uniformity of the tablets that were manufactured in these studies. As the blending time 
increases there is an increase in the content uniformity of the tablets manufactured in these studies. 
Efficient mixing of low dose drugs can be challenging due to issues related to segregation, content 
uniformity and physical stability of a low dose solid oral dosage form (221).  
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Figure 5.9 Graphical representation of the linear relationship between blending time and content uniformity of 
SC ODT 
Therefore it is important to establish an appropriate blending time for a manufacturing process, as 
inefficient mixing of a powder blend will result in an uneven distribution of the API and the tablet 
batch will not be uniform with respect to API content. If however the powder blend is mixed for a 
period longer than what is optimal the adhesive tendency of drug particles can increase (222)  which 
can lead to segregation and once again the tablet batch will not be uniform with respect  to API 
content.   
5.3.4 In vitro dissolution 
Unless an API falls into the Biopharmaceutics Classification System (BCS) Class I quadrant which is 
indicative that 80% of the API dissolves in 15 minutes across the pH range or using one of three 
preferred media viz., 0.1M HCl, an acetate buffer of pH 4.5,or a phosphate buffer of 6.8, it is 
necessary to develop a dissolution method that is able to generate a dissolution curve with a 
discernible profile shape (216). Essentially the dissolution of an API should be gradual so that the 
results generated from dissolution testing can be compared at several time points. SC is a BCS Class I 
compound  (52) and dissolution testing was performed using a phosphate buffer of pH 6.8 to mimic 
the pH of the oral cavity. Furthermore since the tablets disintegrate rapidly, plotting dissolution 
profiles for comparison is difficult as the individual profiles tend to be superimposable.  
Consequently the % drug released at 5 minutes (Q5), 10 minutes (Q10) and 15 minutes (Q15) was 
monitored from each batch of tablets manufactured and these data are summarized in Table 5.7. 
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Table 5.7 In vitro dissolution data for CCD experimental batches 
Batch No. Q5 Q10 Q15 
SC 008 83.45±2.32 92.97±3.02 104.56±2.77 
SC 009 80.34±1.78 95.67±1.78 106.79±2.31 
SC 010 85.05±1.48 91.52±1.93 100.77±1.90 
SC 011 79.45±3.45 90.20±2.91 103.77±2.64 
SC 012 78.99±2.81 92.36±2.78 103.56±4.42 
SC 013 84.50±2.75 95.61±2.40 100.68±3.09 
SC 014 82.67±2.39 97.44±1.91 100.92±2.10 
SC 015 86.78±2.11 95.73±30 101.83±1.86 
SC 016 88.03±2.76 90.94±2.62 100.26±2.04 
SC 017 88.92±2.60 96.30±3.40 100.54±2.61 
SC 018 87.26±1.16 95.77±4.89 100.01±4.39 
SC 019 86.51±1.17 99.14±1.07 102.09±3.59 
SC 020 76.56±8.23 97.34±10.21 116.72±8.90 
SC 021 89.06±3.79 97.79±1.49 101.53±2.90 
SC 022 85.23±4.90 91.65±1.07 102.66±0.50 
SC 023 71.52±3.51 88.63±2.86 98.19±0.19 
SC 024 79.99±4.46 84.52±3.46 98.99±0.54 
SC 025 80.11±2.33 95.43±1.91 103.65±2.37 
SC 026 74.10±1.92 84.60±2.13 97.00±6.21 
SC 027 79.78±2.66 93.48±2.89 104.50±2.16 
SC 028 75.99±4.70 84.10±2.13 107.34±6.82 
SC 029 76.62±3.63 100.21±3.35 107.44±6.98 
SC 030 72.62±0.52 99.46±2.51 99.89±5.04 
SC 031 79.62±3.80 99.15±3.66 109.63±2.62 
SC 032 86.45±3.45 97.84±3.45 99.45±2.12 
SC 033 91.43±10.11 99.54±3.48 99.57±7.43 
SC 034 82.58±2.62 95.27±2.77 108.90±3.81 
SC 035 87.31±3.18 94.96±6.64 96.29±4.17 
SC 036 79.91±3.78 89.36±6.26 98.45±6.19 
SC 037 88.43±0.64 93.63±2.00 107.58±2.93 
 
A suitable drug release for tablets that disintegrate rapidly is a quantum of 85% API released in 15 
minutes. It can be concluded therefore that all matches meet the specification (223). 
Since the disintegration time of the tablets is short, model drug release from the respective tablets 
relates exclusively to dissolution rate of the API and not the disintegration of the tablet (224).  
The incorporation of magnesium stearate into a formulation may impart some useful properties for 
ODTs including a resultant decrease in disintegration times (225) or crushing strength. A decrease in 
crushing strength can be attributed to the reduction in interparticulate bonding caused by the 
formation of the lubricant film around the particles of a formulation (226). The lubricant may 
however have a negative impact on drug dissolution and retard the rate at which the drug dissolves. 
Lubricants are, in general, hydrophobic in nature and magnesium stearate, which is an extremely fine 
material, can coat other particles that are present in a powder blend. This renders the particle surface 
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hydrophobic and may result in an increased disintegration time with a resultant decrease in the 
dissolution rate (227). In the context of these studies and evaluation of  in vitro release data it can be 
concluded that the lubricant, does not delay the dissolution of SC from these ODT.    
All manufactured ODT meet the specification for rapidly disintegrating tablets and at least 85% of the 
SC is released in 15 minutes (Q15) and changes in the amount of disintegrant did not appear to affect 
the rate of drug release, to any great extent. However blending time appears to have an effect on the 
quality of the tablets, for example Batch SC020 was blended for only 4 minutes and had non- uniform 
content and erratic drug release as can be seen by the relatively high standard deviation for these 
samples.  
5.3.5 Formulation optimization 
Following an evaluation of the RSM data generated after the analysis of tablets manufactured using a 
CCD approach, a numerical optimization technique was used for the development of an optimized 
formulation that would ensure that responses achieved would meet the relevant specifications of a 
tablet that has a minimal disintegration and wetting time, while at the same time exhibiting content 
uniformity. The constraints were retained and are listed in Table 5.3 together with the designated 
responses. The predicted response values and respective factor compositions are summarized in Table 
5.8. 
Table 5.8 Values for input variables and respective response variables observed 
Factor Composition  Response 
x1 x2 x3 x4 y1 y2 y3 
0.87 1 1 0.48 8 4.14 99.45% 
 
 
Table 5.9 Experimental and predicted response values with percent error for prediction of the 
optimized formula 
Response Experimental value Predicted value Percent prediction 
error 
y1  8.00 7.97 0.38 
y2 4.15±0.10 4.04 2.68 
y3 100 99.45 0.55 
 
The actual responses observed for the optimized formulation are in close agreement with those of the 
predicted responses with the error of prediction of as shown in Table 5.9. The percent prediction error 
is very low for all three responses indicating the accuracy of the model. 
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The physical characteristics of the tablets manufactured using the optimized formulation and 
manufacturing process are summarized in Table 5.10. 
Table 5.10 Physical characteristics of the optimized formulation and in vitro dissolution testing of the 
optimized formulation 
Parameter Results 
Weight (mg) 155.46±5.67 
Thickness (mm) 7.31±0.10 
Diameter (mm) 2.80±0.01 
Crushing strength (N) 18.74±1.81 
Tensile strength (MPa) 0.58±0.05 
Friability (%) 0.63 
Disintegration time (s) 8±0.00 
Wetting time (s) 4.15±0.10 
In vitro dispersion time (s) 35.65±0.15 
Water absorption ratio 147.45±12.40 
Q5 Q10 Q15 
88.74±1.92 96.53±2.30 104.71±1.89 
 
 
Fig 5.10 Dissolution profile of optimized formulation 
The tablets that were produced were white in colour and had a smooth texture with no evidence of 
picking or any cracking. The physicochemical and mechanical parameters that were measured comply 
with the specifications that had been set for these tablets i.e. suitable friability, minimal crushing and 
tensile strength and minimal Dt.  
The in vitro dissolution results for the optimized formulation are also summarized in Table 5.10 and 
reveal that the optimized formulation is an immediate release dosage form and meets the compendial 
limits of at least 85% API release within 15 minutes of commencing testing. 
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5.4 CONCLUSIONS 
The use of Response Surface Methodology can play an important role in the pharmaceutical industry 
for the purposes of formulation, manufacturing process and analytical method optimization. In order 
to generate accurate data using a RSM approach it is important that the experimental procedures are 
performed in a manner such that reproducible and precise results can be generated for each individual 
experimental run.  
The benefits of making use of RSM in formulation optimization is that more than one factor can be 
investigated at a time and therefore is able to generate a large amount of information at the same time 
thereby ensuring a more efficient process with respect to time and cost. There is the added advantage 
that the equations generated for the models that are produced provide a formulation scientist with an 
indication of whether the effect(s) between factors are synergistic or antagonistic in nature. 
The formulation that was developed and reported in Chapter 4 was used for CCD studies and the 
amount of the three disintegrants used in the formula in addition to the blending time were identified 
as the four crucial factors to be investigated to ensure that a tablet with a rapid disintegration time, 
uniformity of content and dosage form integrity was produced.  
All tablets that were produced were assessed in terms of their friability, weight, tensile and crushing 
strength, Dt, wetting time, in vitro dispersion time and water absorption ratio. All tablets that were 
manufactured had no cracks and exhibited satisfactory friability and crushing strength results.  
RSM revealed that neither the blending time nor disintegrant content had a significant effect on the Dt. 
A possible reason for this result is that the critical disintegrant concentration had been reached and 
any further increase in the amount of did not decrease the Dt further.  
The results of RSM analysis reveal that CMS and CRP had a significant effect on the wetting time of 
the tablets whereas SSG and blending time were shown to have little or no significant effect. As the 
concentration of CMS or CRP increased, there was a marked decrease in the wetting time of the 
tablets that is most likely due to the different disintegration mechanisms by which CRP and CMS 
promote disintegration and therefore, the effects are potentiated. A surprising result was that SSG did 
not play a significant role in the wetting time and formulations in which low levels of SSG were used,  
wetting times were optimal and as the levels increased, there was a corresponding increase in the 
wetting time of the tablets. This result can most likely be attributed in part to the mechanism by which 
SSG facilitates disintegration. SSG swells and at concentrations > 8% w/w the material forms a gel 
layer that delays wetting and also disintegration.  
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CCD revealed a linear relationship, shown in Figure 5.9 and Equation 5.11 between blending time and 
content uniformity of the tablets that were manufactured and as the blending time was increased there 
was an improvement in the uniformity of content of the API in the tablets. 
Dissolution studies were performed on the experimental batches manufactured using the CCD 
approach and it was shown that all batches met the specifications for an ODT and 85% of the API was 
release at Q15 for all batches investigated. 
With the aid of mathematical modelling it was established that an optimized SC ODT formulation 
requires 8.13% CMS, 14.85% CRP and 8.8% SSG to ensure rapid disintegration. A blending time of 
7.68 minutes was necessary to ensure that tablets of a suitable quality were produced. The optimized 
tablet was white with a diameter of 7.31 mm and thickness of 2.80 mm with no visible evidence of 
cracking, lamination, picking and/or sticking. The tablets exhibited suitable friability and tensile 
strength characteristics while a disintegration time of only 8s was achieved.  
RSM was successfully used for the development of an optimized ODT containing SC and these have 
potential application for use in paediatric patients. 
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CHAPTER SIX 
 
CONCLUSIONS 
 
SC is a compound that is commonly used for the treatment of erectile dysfunction in adults and has 
become popular for the treatment of Pulmonary Hypertension (PH) in adult and paediatric patients. 
Although the use of SC in paediatric patients has not been approved, controlled clinical studies to 
investigate the use and effect of SC in paediatric patients suffering from PH have been undertaken. 
The results of these studies reveal that there is a significant decrease in vascular resistance when SC is 
administered and the API is generally well tolerated by patients. Dose ranging studies conducted in 
these patients reveal that a dose of 0.5 µg/kg is suitable for the treatment of PH in neonatal and 
paediatric patients.  
Many of the available treatments for PH are not suitable for use in children and despite the fact that 
SC is well tolerated and has reasonable efficacy in this patient group, a major problem is the fact that 
SC is only available in tablet form, for adult use. These dosage forms are not suitable for use in 
paediatric patients who are not able to swallow large dosage units. Therefore the pharmacist is left 
with no other option other than to formulate an extemporaneous product that contains SC derived 
from a raw material source or commercially available dosage forms. These extemporaneous 
suspensions can at times, be harmful as the stability of the formulation in the vehicle that is use is 
often unknown and there is also always the chance of human error in respect of calculating the 
amount of API required for the manufacture of such products. Therefore the formulation and 
manufacture of an ODT may be a viable alternative to the use of extemporaneous preparations SC 
administration. Since these tablets offer an advantage in terms of oral delivery due to rapid 
disintegration they can be administered to paediatric patients with minimal risk of choking.  
An HPLC method for the analysis of SC in dosage forms was developed and validated in terms of the 
ICH guidelines (228). The HPLC separation was developed by investigating the impact of different 
mobile phase compositions and flow rate on retention time, peak sharpness and resolution between the 
analytical response for  SC and the IS, DZ. DZ was selected for use as the IS as it had successfully 
been used in  a previous study (25). The separation was achieved using a Phenomenex® Luna C18 (2) 
5µm, 150 x 4.6mm i.d. maintained at 22 ± 0.5 °C and a mobile phase composition of ACN: water in a 
ratio of 55:45 % v/v. The method was found to be linear and precise over the concentration range of  
0.2-2µg/ml and was shown to be clearly selective for SC when analysing raw material and 
pharmaceutical dosage forms with a clear resolution between SC and the IS peak.  
Stability indicating studies of SC were undertaken in different environments viz. elevated temperature, 
acidic, basic, oxidative and light exposure conditions. SC was shown to be stabile in the presence of 
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elevated temperature, mildly basic and acidic conditions in addition to exposure to light. However, 
considerable degradation of SC was observed when exposed to strongly basic, acidic and oxidative 
conditions. All degradation peaks were well resolved from those of SC and the IS and therefore the 
method can be considered stability indicating.  
System suitability tests viz.  resolution and peak tailing factor determination was also conducted 
throughout the development and validation of an HPLC method to ensure that the results generate 
would be appropriate for these studies. 
Preformulation studies form an initial step in the determination of rational formulation development 
process. The primary goal of preformulation studies is the investigation of important physicochemical 
factors that may affect API purity and the stability in a dosage form.  Prospective excipients and API 
were assessed with respect to particle size, shape and morphology using SEM. The particle size and 
shape of a material are important considerations when attempting to produce a successful tablet 
formulating as these parameters can affect the flow properties of a powder and ultimately the content 
of the resultant tablets. Powders that have particles with a relatively large size generally exhibit better 
flow properties than powders with particles of a smaller diameter. However, combining powders of 
varying particle size may result in particle segregation that may lead to a lack of blend and tablet 
homogeneity. 
SEM imaging revealed that SC was mainly comprised of rod-shaped needle like particles suggesting 
that there may be a possibility of poor flow properties being exhibited during processing. The 
determination of CI, HR and angle of repose confirmed this assumption with values of 34.6, 1.5.1 and 
40.6 for these indices, respectively. However, this was not of great concern in respect of 
manufacturing a tablet formulation of this low-dose API as the poor flow properties of the raw 
material can be masked by use of excipients that exhibit superior flow characteristics.  
Particle flow properties of all raw materials were assessed by establishing the bulk and tapped 
densities and these data were used to calculate CI and HR for these compounds. The angle of repose 
was also measured as an additional approach to ascertain the flow properties of the powders to be 
considered for use and this data was used to confirm the result of studies to establish the HR and CI.  
Potential chemical interactions between the API and excipient were investigated using DSC and IR 
analysis. The API and excipients were analysed alone and as a binary mixture of API and excipient in 
a 1:1 ratio. DSC analysis revealed the possibility of an interaction between SC and magnesium 
stearate or mannitol. However, it was thought that these interactions were primarily a consequence of 
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evaluation at the elevated temperatures at which DSC analysis was conducted  as these interactions 
were not evident  when the samples were analysed using IR at an ambient room temperature of 22°C.  
The direct compression method of tablet manufacture was selected as the most appropriate approach 
to produce the ODT. The direct compression method was selected for use since many commonly used 
excipients have been successfully compressed into tablets using this approach and there is a further 
advantage that fewer manufacturing steps are required, thereby minimizing the potential for 
introducing errors into dosage forms. In addition, as fewer unit operations are required for the 
manufacture of dosage forms, the process times are reduced thereby potentially reducing the cost of 
production. The direct compression method is not without its challenges and care needs to be taken 
when producing a formulation with these excipients as many of these materials are hygroscopic and 
can agglomerate, possibly leading to blend homogeneity issues. To ensure batch to batch uniformity, 
production continuity, and in the absence of an environmentally controlled manufacturing suite, the 
tablets were manufactured between 00h00 am and 06h00 am to minimize the impact of humidity on 
the production process. 
The formulation to be manufactured included three different superdisintegrants, viz., SSG, CMS and 
CRP to maximise the rate of disintegration. Mannitol and MCC were included as diluent and binder 
respectively and MCC also has disintegration properties. Two glidants, viz., talc and CSD were added 
to the formulation to improve flow properties and magnesium stearate was used as a lubricant.  
The initial blending time for manufacture was 10 minutes without the addition of lubricant and then 
for a further three minutes with lubricant. The primary reason for not blending for > 3 minutes with 
the magnesium stearate is due to the fact that excessive blending with this material can reduce the 
crushing strength of the tablets and delay the release of the API in in vitro and in vivo.  Blend 
homogeneity studies were undertaken to ensure that the blending time was suitable for the 
manufacture of this formulation and to establish the optimum  blend time to ensure that blend 
homogeneity is achieved and that particle segregation did not occur. It was established that a blend 
time of 10+3 minutes was suitable and no further changes were made to manufacturing process that 
would be optimised at a later stage.  
Flat faced tablets of 7 mm diameter were compressed using a Manesty®F3 single punch press at a 
compression force of 30N. Increasing the amount of disintegrant in the formulation resulted in an 
increase in the water absorption ratio of the blends and resulted in a decrease in the disintegration, 
wetting and in vitro dispersion times. The tablets produced at this stage of the research process met all 
requirements for an orodispersible tablets and included a low crushing strength, short disintegration 
time whilst maintaining the mechanical strength of the unit to facilitate handling with a friability of < 
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1%. The initial formulations were evaluated and single formulation, Batch SC 007 was selected for 
further optimization using DOE. 
DOE is an efficient statistical approach that has become a popular tool used in the  pharmaceutical 
industry to optimize formulation compositions, analytical methods and manufacturing processes as 
this approach allows for the investigation of several input factors at the same time whilst not using the 
tedious and traditional “ modification of one variable at a time” approach. 
A CCD approach was selected for optimization of the amount of disintegrant to be included and the 
blending time for production. The formulation responses that were monitored were disintegration and 
wetting times in addition to content uniformity. CCD was selected for use as it permits the evaluation 
of input variables at five levels and therefore provides a comprehensive set of data within the design 
space under investigation. Contour and three-dimensional response surface plots together with 
mathematical relationship (equations) were generated and examined to assess the nature of the 
relationship(s) between the levels of input factors used on the measured responses that were 
monitored.  
 
Following evaluation of the plots and equations and with the aid of mathematical modelling it was 
established that an optimized SC formulation required 8.13% w/w CMS, 14.85% w/w CRP and 8.8% 
w/w SSG to facilitate disintegration and a blending time of 7.68 minutes was necessary to ensure high 
quality and robust tablets were produced. The use of this approach to evaluate the data revealed that 
no change in disintegrant concentration or blending time had an effect on the disintegration times of 
the formulations investigated. This is most likely due to the fact that the critical disintegrant 
concentration had been reached and increasing the amount of disintegrant further had no significant 
effect on the disintegration time. It was also established that a change in the amount of CMS and CRP 
altered the wetting time of the tablets significantly, whereas SSG did not affect the wetting time of the 
tablet greatly. This is most likely due to the fact that at high concentrations, SSG swells greatly 
forming a gel-like layer and delaying Dt and wetting time. Finally it was noted that there is a linear 
relationship between blending time and uniformity of content of the dosage forms and therefore an 
optimal blending time was identified.   
 
In vitro dissolution studies were performed to assess the rate at which the API was released from 
these dosage forms. All batches that were manufactured met the compendial standards that 
pertain to orodispersible and 85% of the API was released within 15 minutes of commencing the 
studies.  
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All experimental batches and the optimized batch were subject to quality control testing for 
friability, crushing and tensile strength, disintegration, wetting and in vitro dispersion time in 
addition to water absorption ratio.  The optimized batch of tablets that were produced passed the 
uniformity of weight and friability tests had a crushing strength of 18.74N and a tensile strength 
of 0.58 MPa. The tablets had a disintegration time of 8s and exhibited a high degree of content 
uniformity. The DOE approach was therefore successfully used to optimize a SC formulation for 
the manufacture of an ODT tablet with the potential for paediatric use.   
 
Although a successful ODT containing SC has been formulated, the focus of the research was 
ensuring that the tablet disintegrated rapidly while still retaining suitable mechanical strength. A 
further focus of the project was to ensure that content uniformity of all batches was achieved and 
maintained.  However, additional research is required to ensure the palatability of the tablet. SC has a 
bitter taste even despite the inclusion of mannitol and therefore the excipients that could be included 
into the formulation that would improve palatability and patient adherence must be considered. 
 
Furthermore stability studies will also need to be completed. Stability studies are used to assess 
potential changes in the quality of an API and dosage form under the influence of different 
temperature and humidity conditions. Accelerated studies in addition to long term studies should both 
be undertaken to assess the chemical stability and physical performance of dosage forms over an 
extended period of time.  
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Appendix 1 Batch Record Summaries 
 
Faculty of Pharmacy 
Department of Pharmaceutics 
Grahamstown 6140 
 
Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    15 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 008    
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     17.2°C 
Relative Humidity:    41% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 12.75 8.5 RM000098 
CRP 20.25 13.5 X051707 
SSG 12 8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 76.35 50.9 RM000200 
 
Tablet Parameters 
Weight (mg) 159.54±1.60 
Diameter (mm) 7.33±0.02 
Thickness (mm)  2.89±0.07 
Crushing Strength (N) 18.37±1.32 
Tensile Strength (MPa) 0.55 
Disintegration time (s) 8±1 
Wetting time (s) 4.29±0.02 
In vitro dispersion time (s) 35.92±0.17 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 83.45±2.32 92.97±3.02 104.56±2.77 
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Faculty of Pharmacy 
Department of Pharmaceutics 
Grahamstown 6140 
 
Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    15 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 009    
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     17.2°C 
Relative Humidity:    41% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 14.03 9.35 RM000098 
CRP 18.23 12.15 X051707 
SSG 10.8 7.2 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 78.3 52.2 RM000200 
 
Tablet Parameters 
Weight (mg) 156.67±7.07 
Diameter (mm) 7.32±0.03 
Thickness (mm)  2.85±0.14 
Crushing Strength (N) 18.17±2.49 
Tensile Strength (MPa) 0.55 
Disintegration time (s) 8±1 
Wetting time (s) 4.29±0.06 
In vitro dispersion time (s) 36.68±0.69 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 80.34±1.78 95.67±1.78 106.79±2.31 
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Faculty of Pharmacy 
Department of Pharmaceutics 
Grahamstown 6140 
 
Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    15 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 010   
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     17.2°C 
Relative Humidity:    41% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 14.03 9.35 RM000098 
CRP 22.28 14.85 X051707 
SSG 13.2 8.8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 71.85 47.9 RM000200 
 
Tablet Parameters 
Weight (mg) 154.44±8.81 
Diameter (mm) 7.33±0.02 
Thickness (mm)  2.90±0.10 
Crushing Strength (N) 20.41±3.40 
Tensile Strength (MPa) 0.61 
Disintegration time (s) 8 
Wetting time (s) 3.89±0.19 
In vitro dispersion time (s) 26.76±0.32 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 85.05±1.48 91.52±1.93 100.77±1.90 
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Faculty of Pharmacy 
Department of Pharmaceutics 
Grahamstown 6140 
 
Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    16 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 011  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     15°C 
Relative Humidity:    40% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 11.46 7.65 RM000098 
CRP 22.28 14.85 X051707 
SSG 13.2 8.8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 74.4 49.6 RM000200 
 
Tablet Parameters 
Weight (mg) 153.75±7.44 
Diameter (mm) 7.33±0.02 
Thickness (mm)  3.00±0.00 
Crushing Strength (N) 19.77±2.13 
Tensile Strength (MPa) 0.57 
Disintegration time (s) 8 
Wetting time (s) 4.46±0.23 
In vitro dispersion time (s) 38.60±0.60 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 79.45±3.45 90.20±2.91 103.77±2.64 
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Faculty of Pharmacy 
Department of Pharmaceutics 
Grahamstown 6140 
 
Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    16 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 012  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     15°C 
Relative Humidity:    40% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 11.46 7.65 RM000098 
CRP 18.23 12.15 X051707 
SSG 13.2 8.8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 78.45 52.3 RM000200 
 
Tablet Parameters 
Weight (mg) 154.07±10.73 
Diameter (mm) 7.30±0.01 
Thickness (mm)  2.85±0.15 
Crushing Strength (N) 19.98±3.66 
Tensile Strength (MPa) 0.61 
Disintegration time (s) 8 
Wetting time (s) 4.79±0.18 
In vitro dispersion time (s) 35.79±0.46 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 78.99±2.81 92.36±2.78 103.56±4.42 
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Faculty of Pharmacy 
Department of Pharmaceutics 
Grahamstown 6140 
 
Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    16 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 013  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     15°C 
Relative Humidity:    40% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 11.46 7.65 RM000098 
CRP 22.28 14.85 X051707 
SSG 10.80 7.2 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 76.8 51.2 RM000200 
 
Tablet Parameters 
Weight (mg) 145.83±6.69 
Diameter (mm) 7.32±0.01 
Thickness (mm)  2.85±0.04 
Crushing Strength (N) 17.69±1.94 
Tensile Strength (MPa) 0.54 
Disintegration time (s) 5 
Wetting time (s) 4.44±0.23 
In vitro dispersion time (s) 39.54±0.56 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 84.50±2.75 95.61±2.40 100.68±3.09 
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Faculty of Pharmacy 
Department of Pharmaceutics 
Grahamstown 6140 
 
Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    17 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 014 
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     17.2°C 
Relative Humidity:    44% 
 
     FORMULA 
 
Material Unit Dose  
Mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 12.75 8.5 RM000098 
CRP 16.2 10.8 X051707 
SSG 12 8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 80.40 53.6 RM000200 
 
Tablet Parameters 
Weight (mg) 151.43±9.00 
Diameter (mm) 7.33±0.00 
Thickness (mm)  2.86±0.04 
Crushing Strength (N) 18.55±2.61 
Tensile Strength (MPa) 0.56 
Disintegration time (s) 8 
Wetting time (s) 4.38±0.15 
In vitro dispersion time (s) 36.64±0.55 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 82.67±2.39 97.44±1.91 100.92±2.10 
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Faculty of Pharmacy 
Department of Pharmaceutics 
Grahamstown 6140 
 
Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    17 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 015  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     17.2°C 
Relative Humidity:    44% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 12.75 8.5 RM000098 
CRP 20.25 13.5 X051707 
SSG 12 8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 76.35 50.9 RM000200 
 
Tablet Parameters 
Weight (mg) 158.77±3.50 
Diameter (mm) 7.32±0.01 
Thickness (mm)  2.79±0.10 
Crushing Strength (N) 18.51±1.76 
Tensile Strength (MPa) 0.58 
Disintegration time (s) 5 
Wetting time (s) 4.26±0.24 
In vitro dispersion time (s) 35.41±1.20 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 86.78±2.11 95.73±30 101.83±1.86 
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Faculty of Pharmacy 
Department of Pharmaceutics 
Grahamstown 6140 
 
Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    17 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 016  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     17.2°C 
Relative Humidity:    44% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 12.75 8.5 RM000098 
CRP 20.25 13.5 X051707 
SSG 12 8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 76.35 50.9 RM000200 
 
Tablet Parameters 
Weight (mg) 149.03±7.38 
Diameter (mm) 7.31±0.02 
Thickness (mm)  2.64±0.17 
Crushing Strength (N) 18.98±1.90 
Tensile Strength (MPa) 0.63 
Disintegration time (s) 7 
Wetting time (s) 4.32±0.16 
In vitro dispersion time (s) 35.89±0.17 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 88.03±2.76 90.94±2.62 100.26±2.04 
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Faculty of Pharmacy 
Department of Pharmaceutics 
Grahamstown 6140 
 
Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    18 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 017  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     16.7°C 
Relative Humidity:    45% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 11.48 7.65 RM000098 
CRP 18.23 12.15 X051707 
SSG 12.2 8.8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 78.45 52.3 RM000200 
 
Tablet Parameters 
Weight (mg) 154.74±5.13 
Diameter (mm) 7.25±0.02 
Thickness (mm)  2.86±0.02 
Crushing Strength (N) 18.81±3.25 
Tensile Strength (MPa) 0.58 
Disintegration time (s) 9 
Wetting time (s) 4.64±0.17 
In vitro dispersion time (s) 36.67±0.14 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 88.92±2.60 96.30±3.40 100.54±2.61 
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Faculty of Pharmacy 
Department of Pharmaceutics 
Grahamstown 6140 
 
Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    18 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 018  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     16.7°C 
Relative Humidity:    45% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 10.2 6.8 RM000098 
CRP 20.25 13.5 X051707 
SSG 12 8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 78.9 52.6 RM000200 
 
Tablet Parameters 
Weight (mg) 151.25±8.34 
Diameter (mm) 7.32±0.02 
Thickness (mm)  2.83±0.10 
Crushing Strength (N) 19.88±1.98 
Tensile Strength (MPa) 0.61 
Disintegration time (s) 8 
Wetting time (s) 4.58±0.29 
In vitro dispersion time (s) 37.68±0.45 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 87.26±1.16 95.77±4.89 100.01±4.39 
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Faculty of Pharmacy 
Department of Pharmaceutics 
Grahamstown 6140 
 
Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    18 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 019  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     16.7°C 
Relative Humidity:    45% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 15.3 10.2 RM000098 
CRP 18.23 13.5 X051707 
SSG 12.2 8.0 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 73.8 49.2 RM000200 
 
Tablet Parameters 
Weight (mg) 154.30±4.89 
Diameter (mm) 7.33±0.02 
Thickness (mm)  2.72±0.16 
Crushing Strength (N) 17.41±2.79 
Tensile Strength (MPa) 0.56 
Disintegration time (s) 6 
Wetting time (s) 4.55±0.26 
In vitro dispersion time (s) 36.45±0.17 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 86.51±1.17 99.14±1.07 102.09±3.59 
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Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    19 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 020 
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     17.2°C 
Relative Humidity:    41% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 12.75 8.5 RM000098 
CRP 18.23 13.5 X051707 
SSG 12.2 8.0 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 76.35 50.9 RM000200 
 
Tablet Parameters 
Weight (mg) 150.13±7.39 
Diameter (mm) 7.31±0.01 
Thickness (mm)  2.67±0.19 
Crushing Strength (N) 20.18±3.70 
Tensile Strength (MPa) 0.66 
Disintegration time (s) 7 
Wetting time (s) 4.25±0.26 
In vitro dispersion time (s) 36.23±0.20 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 76.56±8.23 97.34±10.21 116.72±8.90 
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Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    19 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 021  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     17.2°C 
Relative Humidity:    41% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 12.75 8.5 RM000098 
CRP 18.23 13.5 X051707 
SSG 12.2 8.0 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 76.35 50.9 RM000200 
 
Tablet Parameters 
Weight (mg) 158.28±5.03 
Diameter (mm) 7.33±0.01 
Thickness (mm)  2.75±0.11 
Crushing Strength (N) 17.13±1.37 
Tensile Strength (MPa) 0.54 
Disintegration time (s) 6 
Wetting time (s) 4.31±0.10 
In vitro dispersion time (s) 35.98±.0.67 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 89.06±3.79 97.79±1.49 101.53±2.90 
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Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    19 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 022 
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     17.2°C 
Relative Humidity:    41% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 11.48 7.65 RM000098 
CRP 22.28 14.85 X051707 
SSG 13.2 8.8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 74.4 49.6 RM000200 
 
Tablet Parameters 
Weight (mg) 153.65±7.12 
Diameter (mm) 7.32±0.01 
Thickness (mm)  2.79±0.16 
Crushing Strength (N) 19.46±2.11 
Tensile Strength (MPa) 0.61 
Disintegration time (s) 7 
Wetting time (s) 4.15±0.08 
In vitro dispersion time (s) 36.12±0.18 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 85.23±4.90 91.65±1.07 102.66±0.50 
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Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    20 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 023  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     15.8°C 
Relative Humidity:    37% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 14.03 9.35 RM000098 
CRP 18.23 12.15 X051707 
SSG 13.2 8.8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 75.9 50.6 RM000200 
 
Tablet Parameters 
Weight (mg) 156.60±6.75 
Diameter (mm) 7.29±0.03 
Thickness (mm)  2.79±0.13 
Crushing Strength (N) 17.90±4.54 
Tensile Strength (MPa) 0.56 
Disintegration time (s) 8 
Wetting time (s) 4.37±0.23 
In vitro dispersion time (s) 35.42±0.21 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 71.52±3.51 88.63±2.86 98.19±0.19 
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Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    20 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 024  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     15.8°C 
Relative Humidity:    37% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 12.75 8.5 RM000098 
CRP 20.25 13.5 X051707 
SSG 12.2 8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 76.35 50.9 RM000200 
 
Tablet Parameters 
Weight (mg) 149.72±7.46 
Diameter (mm) 7.32±0.02 
Thickness (mm)  2.79±0.17 
Crushing Strength (N) 19.33±2.29 
Tensile Strength (MPa) 0.60 
Disintegration time (s) 7 
Wetting time (s) 4.32±0.20 
In vitro dispersion time (s) 35.78±0.17 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 79.99±4.46 84.52±3.46 98.99±0.54 
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Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    20 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 025  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     15.8°C 
Relative Humidity:    37% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 12.75 8.5 RM000098 
CRP 24.3 16.2 X051707 
SSG 12.2 8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 72.3 48.2 RM000200 
 
Tablet Parameters 
Weight (mg) 155.76±4.23 
Diameter (mm) 7.32±0.02 
Thickness (mm)  2.74±0.07 
Crushing Strength (N) 18.09±2.74 
Tensile Strength (MPa) 0.57 
Disintegration time (s) 7 
Wetting time (s) 4.26±0.14 
In vitro dispersion time (s) 35.69±0.23 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 80.11±2.33 95.43±1.91 103.65±2.37 
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Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    21 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 026 
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     19°C 
Relative Humidity:    41% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 12.75 8.5 RM000098 
CRP 20.25 13.5 X051707 
SSG 12.2 8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 76.35 50.9 RM000200 
 
Tablet Parameters 
Weight (mg) 154.92±8.45 
Diameter (mm) 7.32±0.01 
Thickness (mm)  2.80±0.16 
Crushing Strength (N) 19.34±2.56 
Tensile Strength (MPa) 0.60 
Disintegration time (s) 10 
Wetting time (s) 4.29±0.12 
In vitro dispersion time (s) 35.90±0.15 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 74.10±1.92 84.60±2.13 97.00±6.21 
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Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    21 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 027  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     19°C 
Relative Humidity:    41% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 14.03 9.35 RM000098 
CRP 18.23 12.15 X051707 
SSG 13.2 8.8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 75.9 50.6 RM000200 
 
Tablet Parameters 
Weight (mg) 152.06±7.04 
Diameter (mm) 7.27±0.01 
Thickness (mm)  2.60±0.15 
Crushing Strength (N) 24.71±1.93 
Tensile Strength (MPa) 0.83 
Disintegration time (s) 8 
Wetting time (s) 4.42±0.09 
In vitro dispersion time (s) 35.79±0.19 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 79.78±2.66 93.48±2.89 104.50±2.16 
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Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    21 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 028  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     19°C 
Relative Humidity:    41% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 14.03 9.35 RM000098 
CRP 18.23 12.15 X051707 
SSG 10.8 7.2 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 78.3 52.5 RM000200 
 
Tablet Parameters 
Weight (mg) 156.69±6.99 
Diameter (mm) 7.31±0.02 
Thickness (mm)  2.80±0.22 
Crushing Strength (N) 17.46±2.48 
Tensile Strength (MPa) 0.54 
Disintegration time (s) 9 
Wetting time (s) 4.30±0.24 
In vitro dispersion time (s) 35.92±0.18 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 75.99±4.70 84.10±2.13 107.34±6.82 
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Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    22 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 029  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     20°C 
Relative Humidity:    41% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 11.48 7.65 RM000098 
CRP 18.23 12.15 X051707 
SSG 13.2 8.8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 78.45 52.3 RM000200 
 
Tablet Parameters 
Weight (mg) 147.92±5.49 
Diameter (mm) 7.31±0.03 
Thickness (mm)  2.78±0.18 
Crushing Strength (N) 16.88±4.17 
Tensile Strength (MPa) 0.53 
Disintegration time (s) 8 
Wetting time (s) 4.44±0.22 
In vitro dispersion time (s) 36.20±0.23 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 76.62±3.63 100.21±3.35 107.44±6.98 
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Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    22 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 030  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     20°C 
Relative Humidity:    41% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 12.75 8.5 RM000098 
CRP 20.25 13.5 X051707 
SSG 9.6 6.4 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 76.35 50.9 RM000200 
 
Tablet Parameters 
Weight (mg) 148.05±7.23 
Diameter (mm) 7.30±0.04 
Thickness (mm)  2.72±0.17 
Crushing Strength (N) 19.96±2.51 
Tensile Strength (MPa) 0.64 
Disintegration time (s) 988 
Wetting time (s) 4.42±0.15 
In vitro dispersion time (s) 35.32±0.22 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 72.62±0.52 99.46±2.51 99.89±5.04 
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Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    22 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 031  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     20°C 
Relative Humidity:    41% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 14.03 9.35 RM000098 
CRP 22.28 14.85 X051707 
SSG 10.8 7.2 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 74.25 49.5 RM000200 
 
Tablet Parameters 
Weight (mg) 152.41±8.23 
Diameter (mm) 7.31±0.02 
Thickness (mm)  2.79±0.07 
Crushing Strength (N) 19.64±3.05 
Tensile Strength (MPa) 0.61 
Disintegration time (s) 8 
Wetting time (s) 4.32±0.16 
In vitro dispersion time (s) 35.34±0.40 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 79.62±3.80 99.15±3.66 109.63±2.62 
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Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    23 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 032  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     18.2°C 
Relative Humidity:    44% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 12.75 8.5 RM000098 
CRP 20.25 13.5 X051707 
SSG 12.2 8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 76.35 50.9 RM000200 
 
Tablet Parameters 
Weight (mg) 152.30±5.66 
Diameter (mm) 7.31±0.01 
Thickness (mm)  2.82±0.15 
Crushing Strength (N) 18.76±2.34 
Tensile Strength (MPa) 0.58 
Disintegration time (s) 8 
Wetting time (s) 4.30±0.17 
In vitro dispersion time (s) 35.81±0.12 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 86.45±3.45 97.84±3.45 99.45±2.12 
 
 
 
 
 
178 | P a g e  
 
 
Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    23October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 033  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     18.2°C 
Relative Humidity:    44% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 14.48 7.65 RM000098 
CRP 22.28 14.85 X051707 
SSG 10.8 7.2 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 76.80 51.2 RM000200 
 
Tablet Parameters 
Weight (mg) 150.26±7.19 
Diameter (mm) 7.31±0.02 
Thickness (mm)  2.64±0.17 
Crushing Strength (N) 18.98±1.90 
Tensile Strength (MPa) 0.63 
Disintegration time (s) 10 
Wetting time (s) 4.49±0.16 
In vitro dispersion time (s) 35.40±0.96 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 91.43±10.11 99.54±3.48 99.57±7.43 
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Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    23 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 034  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     18.2°C 
Relative Humidity:    44% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 12.75 8.5 RM000098 
CRP 20.25 13.5 X051707 
SSG 14.4 9.6 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 73.95 49.3 RM000200 
 
Tablet Parameters 
Weight (mg) 152.12±10.91 
Diameter (mm) 7.30±0.01 
Thickness (mm)  2.79±0.15 
Crushing Strength (N) 18.45±3.74 
Tensile Strength (MPa) 0.58 
Disintegration time (s) 8 
Wetting time (s) 4.55±0.22 
In vitro dispersion time (s) 35.76±0.32 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 82.58±2.62 95.27±2.77 108.90±3.81 
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Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    24 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 035  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     17.2°C 
Relative Humidity:    42% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 14.48 7.65 RM000098 
CRP 18.23 12.15 X051707 
SSG 10.8 7.2 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 80.85 53.9 RM000200 
 
Tablet Parameters 
Weight (mg) 149.83±7.33 
Diameter (mm) 7.30±0.01 
Thickness (mm)  2.68±0.28 
Crushing Strength (N) 18.86±3.26 
Tensile Strength (MPa) 0.61 
Disintegration time (s) 9 
Wetting time (s) 4.42±0.23 
In vitro dispersion time (s) 36.62±0.13 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 87.31±3.18 94.96±6.64 96.29±4.17 
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Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    24 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 036  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     17.2°C 
Relative Humidity:    42% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 14.03 9.35 RM000098 
CRP 22.28 14.85 X051707 
SSG 10.8 7.2 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 74.25 49.5 RM000200 
 
Tablet Parameters 
Weight (mg) 155.71±6.73 
Diameter (mm) 7.31±0.01 
Thickness (mm)  2.77±0.22 
Crushing Strength (N) 19.48±3.34 
Tensile Strength (MPa) 0.61 
Disintegration time (s) 8 
Wetting time (s) 4.49±0.19 
In vitro dispersion time (s) 34.85±1.6 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 79.91±3.78 89.36±6.26 98.45±6.19 
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Batch Production Record 
 
Product:      SC ODT 
Date of Manufacture:    24 October 2011 
Formulator:     Bianca Dagnolo 
Batch Number:    SC 037  
Batch Size:     600 tablets 
Target Weight:    150 mg 
Temperature:     17.2°C 
Relative Humidity:    42% 
 
     FORMULA 
 
Material Unit Dose  
mg 
Batch 
G 
Raw Material 
Number 
SC 3 2 RM000109 
MCC 22.5 15 RM 000100 
CMS 14.03 9.35 RM000098 
CRP 22.28 14.85 X051707 
SSG 13.8 8.8 X00074 
Talc 0.15 0.1 5726/04 
Magnesium Stearate 1.5 1 X052015 
Colloidal Silicon Dioxide 1.5 1 X069339 
Mannitol 71.85 47.9 RM000200 
 
Tablet Parameters 
Weight (mg) 156.20±7.19 
Diameter (mm) 7.31±0.02 
Thickness (mm)  2.78±0.23 
Crushing Strength (N) 20.75±3.79 
Tensile Strength (MPa) 0.65 
Disintegration time (s) 8 
Wetting time (s) 4.05±0.09 
In vitro dispersion time (s) 36.68±0.69 
 
In vitro dissolution  
Q5 % 
 
 
 
Q10 % 
 
 
Q15 % 
 88.43±0.64 93.63±2.00 107.58±2.93 
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Appendix 2 
Response Surface Methodology Statistics 
DISINTEGRATION 
Table 7.1 ANOVA for Response Surface Quadratic Model for Disintegration time 
Source  Sum of 
Squares  
df  Mean Square  F Value  P-value  
Model  11.05  14  0.79  0.37  0.9644  
  A-Croscarmellose  2.04 1  2.04  0.96  0.3428  
  B-Crospovidone  1.04  1  1.04  0.49  0.4948  
  C-Sodium starch 
glycolate  
0.042  1  0.042  0.020  0.8906 
  D-Blending time  0.37  1  0.37  0.18  0.6806  
AB 0.063 1 0.063 0.029 0.8662 
AC 0.56 1 0.56 0.26 0.6146 
AD 0.56 1 0.56 0.26 0.6146 
BC 1.56 1 1.56 0.73 0.4050 
BD 0.062 1 0.062 0.029 0.8662 
CD 3.06 1 3.06 1.44 0.2489 
A2 0.027 1 0.027 0.013 0.9122 
B2 0.24 1 0.24 0.11 0.7411 
C2 1.31 1 1.31 0.62 0.4445 
D2 0.24 1 0.24 0.11 0.7411 
 
Table 7.2 ANOVA for Response Surface Linear Model for Disintegration time 
Source  Sum of 
Squares  
df  Mean Square  F Value  P-value  
Model  3.50 4 0.87 0.55 0.6978 
  A-Croscarmellose  2.04 1 2.04 1.29 0.2662 
  B-Crospovidone  1.04 1 1.04 0.66 0.4243 
  C-Sodium starch 
glycolate  
0.042 1 0.042 0.026 0.8722 
  D-Blending time  0.38 1 0.38 0.24 0.6719 
 
184 | P a g e  
 
 
Figure 7.1 Predicted vs. Actual plot for Blending time 
WETTING TIME 
Table 7.3ANOVA for Response Surface Quadratic Model for Wetting time 
 
Source  Sum of 
Squares  
df  Mean 
Square  
F Value  P-value   
Model  0.69  14  0.049  5.02  0.0018  Significant 
  A-Croscarmellose  0.13  1  0.13  13.14  0.005  Significant 
  B-Crospovidone  0.11  1  0.11  11.13  0.0045  Significant 
  C-Sodium starch 
glycolate  
0.013  1  0.013  1.33  0.2668   
  D-Blending time  3.267E-003  1  3.267E-003  0.33  0.5727   
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Figure 7.2 Predicted vs. Actual plot for Wetting time 
 
CONTENT UNIFORMITY 
Table 7.3 ANOVA for Response Surface Linear Model for content uniformity 
Source  Sum of 
Squares  
df  Mean 
Square  
F Value  P-value   
Model  496.69 14  4 3.43 0.0230 Significant 
  A-Croscarmellose  6.48 1   1 0.18 0.6760  
  B-Crospovidone  20.33 1  1 0.56 0.4608  
  C-Sodium starch 
glycolate  
156.32 1  1 4.31 0.0582  
  D-Blending time  313.57 1  1 8.65 0.0069 Significant 
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Figure 7.3 Predicted vs. Actual plot for Blending time 
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